

Mindfulness Meditation for Chronic Pain

A Systematic Review

Margaret A. Maglione, Susanne Hempel, Alicia Ruelaz Maher, Eric Apaydin, Brett Ewing, Lara Hilton, Lea Xenakis, Roberta M. Shanman, Sydne Newberry, Benjamin Colaiaco, Melony E. Sorbero For more information on this publication, visit www.rand.org/t/RR1317

Published by the RAND Corporation, Santa Monica, Calif. © Copyright 2016 RAND Corporation RAND* is a registered trademark.

Limited Print and Electronic Distribution Rights

This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited. Permission is given to duplicate this document for personal use only, as long as it is unaltered and complete. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial use. For information on reprint and linking permissions, please visit www.rand.org/pubs/permissions.html.

The RAND Corporation is a research organization that develops solutions to public policy challenges to help make communities throughout the world safer and more secure, healthier and more prosperous. RAND is nonprofit, nonpartisan, and committed to the public interest.

RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.

Support RAND Make a tax-deductible charitable contribution at www.rand.org/giving/contribute

www.rand.org

Preface

The Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury is interested in determining the efficacy and comparative effectiveness of integrative medicine approaches for several health conditions. This systematic review assesses the safety and efficacy of mindfulness meditation as an intervention to alleviate chronic pain. The review will be of interest to military health policymakers and practitioners, civilian health care providers, and policymakers, payers, and patients.

None of the authors has any conflicts of interest to declare.

This research was sponsored by the Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury and conducted within the Forces and Resources Policy Center of the RAND National Defense Research Institute, a federally funded research and development center sponsored by the Office of the Secretary of Defense, the Joint Staff, the Unified Combatant Commands, the Navy, the Marine Corps, the defense agencies, and the defense Intelligence Community. For more information on the RAND Forces and Resources Policy Center, see http://www.rand.org/nsrd/ndri/centers/frp.html or contact the director (contact information is provided on the web page).

Abstract

This systematic review synthesized evidence on mindfulness meditation interventions for the treatment of chronic pain (PROSPERO 2015:CRD42015025052).

In June 2015, we searched four electronic databases, as well as bibliographies of existing systematic reviews, to identify randomized controlled trials (RCTs) testing the efficacy and safety of mindfulness to treat adults with chronic pain. Two independent reviewers screened identified literature using predetermined eligibility criteria, abstracted study-level information, and assessed the quality of included studies. Outcomes of interest included changes in pain symptoms, use of analgesics, health-related quality of life, and adverse events. Efficacy meta-analyses used the Hartung-Knapp-Sidik-Jonkman method for random-effects models. The quality of evidence was assessed using the GRADE approach.

In total, 28 RCTs met inclusion criteria; three of these RCTs reported on safety. Interventions ranged in length from three to 12 weeks, and the median duration was eight weeks. We found low quality evidence (due to substantial unexplained heterogeneity among studies) that mindfulness meditation is associated with a small decrease in pain compared with control in 24 RCTs (SMD 0.26; CI 0.06, 0.46; 24 RCTs; I² 62%; n=1,456); a sensitivity analysis excluding poor quality studies yielded similar effect estimates. This effect remained up to 12 weeks (SMD 0.27; CI 0.04, 0.50; 24 RCTs; I² 65%), but was not statistically significant for follow-up periods beyond 12 weeks (SMD 0.37; C -0.01, 0.74; I² 75%; 11 RCTs). In subgroup analyses of comparators, mindfulness meditation statistically significantly reduced pain scores compared with treatment as usual (SMD 0.45; CI 0.02, 0.88; 7 RCTs; I² 52%), but not compared with passive controls such as wait lists (SMD 0.28; CI -0.46, 1.02; 8 RCTs; I² 77%) or with education or support groups (SMD 0.19; CI -0.11, 0.49; 8 RCTs; I² 64%). The efficacy of mindfulness meditation, or length or frequency of intervention. No systematic difference in effect on pain between monotherapy and adjunctive therapy was detected in a meta-regression.

Several studies reported non-pain outcomes; mindfulness meditation statistically significantly reduced depression (SMD 0.17; CI 0.03, 0.31; 10 RCTs; I^2 0%), improved mental health-related quality of life (SMD 0.44; CI 0.18, 0.69; 13 RCTs; I^2 51%), and improved physical health-related quality of life (SMD 0.30; CI 0.03, 0.57; 12 RCTs; I^2 55%). Of the three RCTs reporting adverse events, two stated that participants had no adverse events, and one stated that two participants experienced feelings of anxiety and anger toward their pain.

In sum, the review showed that mindfulness meditation improves pain symptoms, depression, and quality of life; however, there was evidence of substantial differences in study outcomes resulting in a low quality of evidence overall. We were unable to determine which patient subgroups or intervention characteristics were associated with greater efficacy, likely due to

small sample sizes and lack of statistical power. Additional trials with adequate power, greater efforts to prevent attrition, monitoring of adherence to meditation practice, active collection of adverse events, and better reporting of methods are suggested.

Table of Contents

Preface	iii
Abstract	v
Figures	ix
Tables	xi
Summary	xiii
Acknowledgments	xix
Abbreviations	xxi
Chapter One: Introduction	
Background and Objective	
Key Questions	
Chapter Two: Methods	
Sources	
Search Strategy	
Eligibility Criteria	5
Inclusion Screening	6
Data Extraction	6
Risk of Bias and Study Quality	7
Data Synthesis	8
Quality of Evidence	8
Summary of Findings	9
Chapter Three: Results	. 11
Results of the Search	11
Description of Included Studies	
Design	
Setting	
Participants	
Interventions	
Comparators	
Study Quality/Risk of Bias for Individual Included Studies	
KQ 1: What Are the Efficacy and Safety of Mindfulness Meditation Interventions, as an Adjunctive	
Monotherapy, for Adults with Chronic Pain Due to Migraine, Headache, Back Pain, Osteoarthr	
or Neuralgic Pain Compared with Treatment as Usual, Waitlists, No Treatment, or Other Active Treatments?	
Chronic Pain Treatment Response Standardized Mean Differences	
Analgesic Use	
Health-Related Quality of Life	
Functional Impairment (Disability Measures)	

Adverse Events Reported in RCTs	
Study Characteristic Moderators and Risk of Bias	
KQ 1a: Does the Effect Vary by the Type of Mindfulness Meditation Intervention?	
Mindfulness-Based Stress Reduction	
Mindfulness-Based Cognitive Therapy	
Other Interventions	
KQ 1b: Does the Effect Vary by Medical Condition Targeted (Migraine, Headache, Back Pa	in,
Osteoarthritis, or Neuralgic Pain)?	
Migraine or Other Headache	
Back Pain	
Fibromyalgia	
KQ 1c: Does the Effect Differ When the Intervention Is Offered as an Adjunctive Therapy R	ather Than
as a Monotherapy?	
KQ 1d: Does the Effect Vary Depending on the Duration and Frequency of Mindfulness Med	ditation
(i.e., Dose Effect)?	
Chapter Four: Discussion	
Summary of Findings	
KQ 1: What Are the Efficacy and Safety of Mindfulness Meditation Interventions, as an A	djunctive
or Monotherapy, for Adults with Chronic Pain Due to Migraine, Headache, Back Pain	,
Osteoarthritis, or Neuralgic Pain Compared with Treatment as Usual, Waitlists, No Tr	eatment,
or Other Active Treatments?	
KQ 1a: Does the Effect Vary by the Type of Mindfulness Meditation Intervention?	
KQ 1b: Does the Effect Vary by Medical Condition Targeted (Migraine, Headache, Back	Pain,
Osteoarthritis, or Neuralgic Pain)?	
KQ 1c: Does the Effect Differ When the Intervention Is Offered as an Adjunctive Therapy	Rather
Than as a Monotherapy?	
KQ 1d: Does the Effect Vary Depending on the Duration and Frequency of Mindfulness M	Aeditation
(i.e., Dose Effect)?	
Other Reviews in this Area	
Strengths and Limitations	
Implications for Future Research and Practice	
Appendix A: Search Strategy	
Appendix B: Excluded Full-Text Articles	
Appendix C: Evidence Table of Included Studies	55
Appendix D: Studies Included in the Most Recent Systematic Review	
References	

Figures

Figure 3.1. Literature Flow Diagram	12
Figure 3.2. Mindfulness Meditation Versus Control, Pain Outcome, Longest Follow-Up	20
Figure 3.3. Mindfulness Meditation Versus Control, Pain Outcome, 0–12 weeks	21
Figure 3.4. Mindfulness Meditation Versus Control, Pain Outcome, >12 Weeks	22
Figure 3.5. Mindfulness Meditation Versus Treatment as Usual	23
Figure 3.6. Mindfulness Meditation Versus Passive Control	24
Figure 3.7. Mindfulness Meditation Versus Education or Support Group	25
Figure 3.8. MBSR Versus Control	28
Figure 3.9. MBCT Versus Control	29
Figure 3.10. Mindfulness Meditation for Migraine or Headache	31
Figure 3.11. Mindfulness Meditation for Back Pain	32
Figure 3.12. Mindfulness Meditation for Fibromyalgia	33

Tables

Table 1.1. Interventions Based on Mindfulness Meditation	2
Table 3.1. Evidence Base for Key Questions	13
Table 3.2. Quality Ratings	17
Table 4.1. Summary of Findings and Quality of Evidence Table	38
Table D.1. Studies Included in the Most Recent Systematic Review	83

Summary

Introduction

Chronic pain, often defined as pain lasting longer than three months or past the normal time for tissue healing, can lead to significant medical, social, and economic consequences; relationship issues; lost productivity; and larger health care costs. The high prevalence and refractory nature of chronic pain and the negative consequences of pain medication dependence drive investigation of innovative treatment modalities. Patients who seek a treatment plan for chronic pain that includes more than just medication are increasingly turning to complementary, alternative, and integrative medicine. One such modality that pain patients are using is mindfulness meditation. Based on ancient Eastern meditation practices, mindfulness is characterized by paying attention to the present moment with openness, curiosity, and acceptance. Previous systematic reviews on mindfulness meditation for chronic pain have been promising, but evidence was of low quality and additional studies have been completed since that time. This systematic review aims to synthesize evidence from trials of mindfulness meditation interventions to provide estimates of its efficacy in treating chronic pain (PROSPERO 2015:CRD42015025052). This report may be used by committees charged with updating U.S. Department of Veterans Affairs and Department of Defense guidelines for treatment of chronic pain.

Key Questions

This review was guided by the following key questions (KQs):

- KQ 1: What are the efficacy and safety of mindfulness meditation interventions, as an adjunctive or monotherapy, for adults with chronic pain due to migraine, headache, back pain, osteoarthritis, or neuralgic pain compared with treatment as usual, waitlists, no treatment, or other active treatments?
 - KQ 1a: Does the effect vary by the type of mindfulness meditation intervention?
 - KQ 1b: Does the effect vary by medical condition targeted (migraine, headache, back pain, osteoarthritis, or neuralgic pain)?
 - KQ 1c: Does the effect differ when the intervention is offered as an adjunctive therapy rather than as a monotherapy?
 - KQ 1d: Does the effect vary depending on the duration and frequency of mindfulness meditation (i.e., dose effect)?

Methods

To answer our key questions, we conducted a systematic search of electronic databases— PubMed, CINAHL (Cumulative Index to Nursing and Allied Health Literature), PsycINFO, and CENTRAL (Cochrane Central Register of Controlled Trials)—as well as bibliographies of existing systematic reviews and included studies, to identify reports of randomized controlled trials (RCTs) testing the efficacy and safety of mindfulness meditation used adjunctively or as monotherapy to treat adults with chronic pain.

Two independent reviewers screened identified literature using predetermined eligibility criteria, abstracted pre-specified study-level information, and assessed the quality of included studies. Outcomes of interest included changes in pain symptomatology, use of analgesics, functional status, health-related quality of life, functional impairment (disability measures), and adverse events.

Meta-analyses for efficacy outcomes were conducted using the Hartung-Knapp-Sidik-Jonkman method for random-effects models to estimate the relative risk (RR), standardized mean differences (SMDs), and 95-percent confidence intervals (CIs). We abstracted any adverse events reported. The quality of evidence was assessed using the Grades of Recommendation, Assessment, Development, and Evaluation (or GRADE) approach.

Results

In total, 28 studies met inclusion criteria. These 28 studies reported on the efficacy of mindfulness meditation, and three addressed safety. Risk of bias in included studies varied: Seven studies obtained a "good" quality rating, ten studies were rated "fair," and 11 were rated "poor" quality.

Key Question 1

We identified 24 RCTs that met the inclusion criteria and reported continuous pain measures on the efficacy of mindfulness meditation for chronic pain. Intervention programs lasted from three to 12 weeks, with a median duration of eight weeks. Results of pooled analysis indicated a significant reduction on pain symptoms (SMD 0.26; CI 0.06, 0.46; 24 RCTs; I² 62.1%). (Four studies were excluded from analyses because they did not report appropriate outcome data for meta-analysis.) A sensitivity analysis excluding poor quality studies yielded similar results (SMD 0.21; CI 0.00, 0.42; 15 RCTs; I² 57.2%). This effect remained up to 12 weeks (SMD 0.27; CI 0.04, 0.50; 24 RCTs; I² 64.6%), but was not significant for follow-up periods beyond 12 weeks (SMD 0.37; C -0.01, 0.74; 11 RCTs, I² 74.7%). The quality of evidence that mindfulness meditation is associated with a decrease in chronic pain compared with control is low overall, and for both short-term and long-term follow-up.

In subgroup analyses of comparators, mindfulness meditation significantly reduced pain scale scores compared with treatment as usual (SMD 0.45; CI 0.02, 0.88; 7 RCTs; I^2 51.5%), but

not compared with passive controls, such as waitlists (SMD 0.28; CI -0.46, 1.02; 8 RCTs; I² 76.5%), or with education or support groups (SMD 0.19; CI -0.11, 0.49; 8 RCTs; I² 63.9%). The quality of evidence is low for comparisons with treatment as usual and passive controls, but is very low for comparisons with education or support groups.

Several studies reported non-pain outcomes. There is high quality evidence that mindfulness meditation to treat chronic pain significantly reduced depressive symptoms (SMD 0.17; CI 0.03, 0.31; 10 RCTs; I² 0%). There is moderate quality evidence that mindfulness meditation for chronic pain improves physical health-related quality of life as measured by the physical health summary measure of the 36-Item Short Form Health Survey (SF-36) (SMD 0.3; CI 0.03, 0.57; 12 RCTs; I² 54.6%) and mental health-related quality of life as assessed by the mental health summary measure of the SF-36 or other instrument that measures such factors as affect, anxiety, vitality, role functioning, and social functioning (SMD 0.44; CI 0.18, 0.69; 13 RCTs; I² 50.6%). When three RCTs were pooled, improvements in disability measures in the mindfulness groups were not significantly different from improvements in the control groups (SMD 0.47; CI -0.18, 1.12; I² 0). Only one study reported on change in analgesic use; this study reported a significant decrease in the mindfulness group compared with control.

Of the three RCTs that reported adverse events, two stated that participants had no adverse events, and one stated that two participants experienced feelings of anxiety and anger toward their pain.

Key Question 1a

We did not identify head-to-head trials comparing different mindfulness interventions. The efficacy of mindfulness meditation did not differ systematically by type of intervention in indirect comparisons across studies. The effect of mindfulness meditation on pain was nonsignificant in the 15 RCTs examining mindfulness-based stress reduction (MBSR) (SMD 0.32; CI –0.06, 0.70; 15 RCTs; I² 69.8%), in the four RCTs examining mindfulness-based cognitive therapy (MBCT) (SMD 0.16; CI –0.45, 0.76; 4 RCTs; I² 63.6%), and in five RCTs examining remote (e.g., Internet, smart phone) interventions (SMD 0.06; CI –0.42, 0.55; 5 RCTs; I² 56.7%). Meta-regression analyses showed that changes in pain outcomes with MBSR (p=0.60), MBCT (p=0.58), and remote mindfulness interventions via Internet or compact disc (p=0.14) were not significantly different from outcomes with other types of mindfulness meditation. The quality of evidence for the absence of differences between intervention types is very low due to the small number of studies per category and the lack of direct comparisons.

Key Question 1b

The effect of mindfulness meditation also did not vary systematically by medical condition. The effect of meditation on pain was not significant for participants with migraine or headache (SMD 0.38; CI –0.41, 1.17; 5 RCTs; I² 80.6%), back pain (SMD –0.04; CI –0.39, 0.32; 4 RCTs; I² 0%), or fibromyalgia (SMD 0.13; CI –0.12, 0.37; 8 RCTs; I² 45.3%). Meta-regression

analyses also showed that changes in pain outcomes for patients with back pain (p=0.28), headache (p=0.69), and fibromyalgia (p=0.24) were not significantly different from outcomes for patients with other types of pain. The quality of evidence is low for migraine and back pain, and moderate for fibromyalgia.

Key Question 1c

The effect of meditation on pain did not differ systematically when offered as a monotherapy compared with as an adjunctive treatment. The effect was not significant for both monotherapy (SMD 0.21; CI -0.02, 0.45; 13 RCTs; I² 55%) and adjunctive treatment (SMD 0.36; CI -0.16, 0.89; 11 RCTs; I² 73.5%). A meta-regression found that pain outcomes did not differ significantly between interventions using mindfulness meditation as monotherapy or adjunctive therapy (p=0.53). The quality of evidence is low for mindfulness meditation as monotherapy and as adjunctive therapy.

Key Question 1d

The efficacy of mindfulness meditation did not differ systematically by frequency or duration of the treatment. In a meta-regression, efficacy did not vary significantly as program duration in weeks increased (p=0.12). The effect was not significant at a dose of less than one hour a week (low frequency; SMD –0.18; CI –0.49, 0.10; 3 RCTs; I² 0%), or at a dose of one to four hours a week (medium frequency; SMD 0.44; CI –0.16, 1.05; 10 RCTs; I² 77.5%). The effect for interventions requiring greater than four hours a week (high frequency) bordered on statistical significance (SMD 0.19; CI 0.00, 0.39; 11 RCTs; I² 4.5%), but the confidence intervals fit within those of the results for interventions requiring one to four hours of participation. A meta-regression found that pain outcomes did not differ significantly between low frequency (p=0.17) or medium frequency (p=0.32) and high frequency interventions. The quality of evidence is low for doses of less than one hour a week and one to four hours a week; the quality of evidence is moderate for more than four hours of participation.

Conclusions

Mindfulness meditation was associated with a small effect of improved pain symptoms compared with control groups in a meta-analysis of 24 RCTs. However, there was evidence of substantial heterogeneity among studies, resulting in a low quality of evidence for this outcome. Mindfulness meditation statistically significantly improved depression, physical health-related quality of life, and mental health-related quality of life; pooled analyses included ten, 12, and 13 studies, respectively. Those analyses detected less heterogeneity, so our confidence in the results is higher; quality of evidence was high for depression and moderate for physical and mental health-related quality of life. Adverse events in the included RCTs were rare and not serious, but the vast majority of studies did not collect adverse event data. As reports of psychosis during meditation have appeared in the medical literature, we strongly suggest that future trials actively collect adverse event data.

Many trials were of poor quality. Due to the low quality of evidence supporting improved pain outcomes, additional trials are needed to increase confidence in this finding. These trials must have adequate power, greater efforts to prevent attrition, and better reporting of methods.

This research is sponsored by the Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury (DCoE). We gratefully acknowledge Kristie Gore for her support and guidance throughout the project. We also would like to thank our project officers and points of contact at DCoE—Chris Crowe, Marina Khusid, and Michael Freed—for their support of our work. In addition, we thank Daniel Cherkin and Thomas Concannon for reviewing the report and offering helpful suggestions. Any errors of fact or interpretation in this report remain the responsibility of the authors.

Abbreviations

BPI	Brief Pain Index
CENTRAL	Cochrane Central Register of Controlled Trials
CI	confidence interval
CINAHL	Cumulative Index to Nursing and Allied Health Literature
GRADE	Grades of Recommendation, Assessment, Development and Evaluation
IBS	irritable bowel syndrome
ITT	intention-to-treat
MBCT	mindfulness-based cognitive therapy
MORE	mindfulness-oriented recovery enhancement
MBSR	mindfulness-based stress reduction
MPQ	McGill Pain Questionnaire
QOL	quality of life
RCT	randomized controlled trial
RR	relative risk
SD	standard deviation
SF-36	36-Item Short Form Health Survey
SMD	standardized mean difference
TAU	treatment as usual
USPSTF	United States Preventive Services Task Force
VAS	visual analog scale

Background and Objective

Chronic pain, often defined as pain lasting longer than three months or past the normal time for tissue healing (Chou et al., 2015), can lead to significant medical, social, and economic consequences; relationship issues; lost productivity; and larger health care costs. Further, chronic pain is frequently accompanied by psychiatric disorders, such as pain medication addiction, depression, and anxiety, that make treatment complicated (Management of Opioid Therapy for Chronic Pain Working Group, 2010). Chronic pain is highly prevalent among service members who served in Operations Enduring Freedom and Iraqi Freedom; 44 percent of those who were deployed in combat deployment report chronic pain, compared with 26 percent of the general public (Toblin et al., 2014). Chronic pain is the most frequent symptom reported in the community and primary care setting, accounting for nearly 20 percent of all ambulatory visits to U.S. Department of Veterans Affairs facilities and is the most common cause of work disability in the military (Management of Opioid Therapy for Chronic Pain Working Group, 2010). In the veteran population, greater than 50 percent of Afghanistan and Iraq veterans report pain as their presenting complaint when signing in for care at a Veterans Health Administration facility. For those with poly-trauma, the prevalence is greater than 90 percent (Management of Opioid Therapy for Chronic Pain Working Group, 2010).

The high prevalence and refractory nature of chronic pain, in conjunction with the negative consequences of pain medication dependence, has led to increased U.S. Department of Defense interest in alternative interventions for chronic pain. Patients who seek a treatment plan that includes adjunctive therapy or alternatives to medication are increasingly turning to complementary and alternative medicine (Chiesa and Serretti, 2011). One such modality that pain patients are using is mindfulness meditation. The Army Surgeon General's Pain Management Task Force recommended that mind-body therapies such as mindfulness meditation be a Tier 1 therapy option (along with acupuncture, yoga, chiropractic care, therapeutic medical massage, and biofeedback) in the interest of providing a holistic, integrative approach to pain management (Office of the Army Surgeon General, 2010). Meditation is the intentional selfregulation of attention from moment to moment (Goleman and Schwartz, 1976). Based on ancient Eastern meditation practices, mindfulness facilitates an attentional stance of detached observation. It is characterized by paying attention to the present moment with openness, curiosity, and acceptance (Kabat-Zinn, Lipworth, and Burney, 1985). Clinical uses of mindfulness include applications in substance abuse (Chiesa and Serretti, 2014), tobacco cessation (de Souza et al., 2015), stress reduction (Goyal et al., 2014), and treatment of chronic pain (Kozasa et al., 2012; Cramer et al., 2012; Reiner, Tibi, and Lipsitz, 2013). The most

commonly used mindfulness meditation interventions are described in Table 1.1. (Mindfulness Awareness Research Center, 2015)

Name Description		
Mindfulness-based stress reduction (MBSR)	In addition to mindfulness meditation, MBSR involves teaching of body scan or yoga to encourage open, nonjudgmental observation and acceptance of painful or unpleasant sensation, negative thoughts, or emotions instead of cognitively appraising them and increasing anticipatory anxiety, avoidance, or other maladaptive patterns.	
Mindfulness-based cognitive therapy (MBCT)	In addition to mindfulness meditation, MBCT encourages acceptant nonjudgmental observation of negative thoughts and emotions instead of their cognitive appraisal triggering ruminative negative thoughts and habitual emotional reactivity.	
Mindfulness-based relapse prevention	In addition to mindfulness meditation, mindfulness-based relapse prevention teaches relapse prevention skills and nonjudgmental, open, and acceptant observation of cravings. It aims to decouple (1) the negative thoughts and emotions that are associated with cravings and (2) relapse.	
Mindfulness training for smoking	In addition to mindfulness meditation, mindfulness training for smoking provides targeted training in how to apply mindfulness to smoking relapse determinants, such as smoking triggers, strong emotions, addictive thoughts, urges, and withdrawal symptoms.	
Mind-body bridging and mindfulness-based therapy for insomnia	indfulness-based therapy therapy for insomnia use behavioral strategies to reduce night wakefulness.	
Mindfulness-oriented recovery enhancement (MORE)	In addition to mindfulness meditation, MORE teaches neutral, open, and acceptant observation of painful sensations. It also incorporates positive psychology and behavioral techniques directed toward neuroscientific underpinnings of addiction.	

Table 1.1. Interventions Based on Mindfulness Meditation

Early studies in pain patients showed promising outcomes on pain symptoms, mood disturbance, anxiety, and depression, as well as pain-related drug utilization (Kabat-Zinn, Lipworth, and Burney, 1985). A 2011 systematic review of ten mindfulness-based interventions for chronic pain patients showed improvements in depressive symptoms and coping, with limited evidence for specific pain effects (Chiesa and Serretti, 2011). That review concluded that further research, using larger, adequately powered studies with robust designs, was warranted. A later review (Lee, Crawford, and Hickey, 2014) funded by the U.S. Army also concluded that additional high-quality research was needed before a recommendation for the use of mindfulness meditation for chronic pain symptoms could be made. Eleven RCTs included in that review investigated the use of mindfulness meditation for chronic pain, fibromyalgia, and musculoskeletal pain. More than half of the studies were poor quality, having high dropout rates, lack of safety reporting, and weak randomization procedures, for example. However, the majority of studies showed promising effects for mindfulness meditation.

The current review was requested by the U.S. Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury. The Centers commissioned the RAND Corporation to develop a series of systematic reviews on complementary and alternative medicine interventions for conditions such as substance abuse, major depressive disorder, and posttraumatic stress disorder. These reviews may be used by committees charged with updating Department of Veterans Affairs and Department of Defense guidelines for treatment of these conditions.

Key Questions

This systematic review identified randomized controlled trials (RCTs) testing the efficacy and safety of mindfulness meditation to treat individuals with chronic pain. The review aimed to answer the following key questions (KQs):

- KQ 1: What are the efficacy and safety of mindfulness meditation interventions, as an adjunctive or monotherapy, for adults with chronic pain due to migraine, headache, back pain, osteoarthritis, or neuralgic pain compared with treatment as usual, waitlists, no treatment, or other active treatments?
 - KQ 1a: Does the effect vary by the type of mindfulness meditation intervention?
 - KQ 1b: Does the effect vary by medical condition targeted (migraine, headache, back pain, osteoarthritis, or neuralgic pain)?
 - KQ 1c: Does the effect differ when the intervention is offered as an adjunctive therapy rather than as a monotherapy?
 - KQ 1d: Does the effect vary depending on the duration and frequency of mindfulness meditation (i.e., dose effect)?

We performed a systematic review to identify RCTs testing the efficacy and safety of mindfulness meditation for chronic pain. The systematic review protocol is registered in PROSPERO, an international registry for systematic reviews.

Sources

We searched the electronic databases PubMed, CINAHL (Cumulative Index to Nursing and Allied Health Literature), PsycINFO, and CENTRAL (Cochrane Central Register of Controlled Trials) for English-language RCTs. In addition to this search and the reference-mining of all included studies identified through it, we reference-mined prior systematic reviews related to this topic and retrieved all studies included therein.

Search Strategy

The search strategy was developed by the chief reference librarian for RAND's Knowledge Services, informed by search results of an environmental scan of the literature at the initiation of this study (as part of unpublished RAND research by Melony Sorbero, Sean Grant, and Susanne Hempel) and existing reviews. The search strings are presented in Appendix A. We searched from the inception of the databases through June 2015.

Eligibility Criteria

The inclusion and exclusion criteria applied to the retrieved publications were developed using the framework of participants, interventions, comparators, outcomes, timing, settings, and study design, or PICOTSS.

- *Participants*: Studies were limited to male and female participants who are 18 years of age or older who report chronic pain. We included studies in which the author defined chronic pain, as well as studies of patients reporting pain for a minimum of three months. Studies not specifying the duration of pain and not referring to chronic pain were excluded.
- *Interventions*: Studies involving mindfulness meditation, either as an adjunctive or monotherapy, were included—for example, MBCT, MBSR, Vipassana, Zazen, Zen, and Shambhala interventions. Studies testing other meditation interventions such as yoga, tai chi, qigong, and transcendental meditation techniques without reference to mindfulness meditation were excluded.
- *Comparators*: Studies that included waitlist control, no treatment, or standard care (e.g., physical activity, pain medications), that compare mindfulness meditation offered as

adjunctive versus monotherapy, and that compare two or more mindfulness meditation interventions were included.

- *Outcomes*: Studies that reported patient pain measures—including pain assessed with a visual analog scale (VAS), the SF-36 pain subscale, the McGill Pain Questionnaire (MPQ), and so on—and studies reporting on change in analgesic use were included.
- *Timing*: Studies could involve any treatment duration and any follow-up time period.
- *Setting*: Studies were not limited by setting.
- *Study design*: Included studies were limited to parallel group, individually-randomized, or cluster-randomized controlled trials.

Inclusion Screening

Two independent reviewers (the project lead, who is an experienced systematic reviewer and former Associate Director of the Southern California Evidence-based Practice Center [EPC], and a RAND research assistant with experience in systematic reviews) independently screened titles and abstracts of retrieved citations following a pilot session to ensure similar interpretation of the inclusion and exclusion criteria.

Citations judged as potentially eligible by one or both reviewers were obtained as full text. The full-text publications were then screened against the specified inclusion criteria by the two independent reviewers; any disagreements were resolved through discussion within the review team. The flow of citations throughout this process was documented in an electronic database, and reasons for exclusion of full-text publications were recorded. A list of excluded publications is shown in Appendix B.

Data Extraction

The two aforementioned reviewers each independently abstracted study-level data in an electronic database. Data collection forms were designed by the project lead, with input from the project team. These two reviewers pilot-tested the data collection forms on a few randomly selected studies, modified the forms, and performed a final pilot of the forms on a random selection of three included studies to ensure agreement of interpretation. EPC biostatisticians abstracted all outcome data to ensure accuracy.

Study-level data were abstracted for the following information:

- *Participants*: gender, age, medical condition(s) and type of pain, baseline pain data, comorbid psychological/behavioral health conditions
- *Interventions*: content of mindfulness meditation sessions, dosage (intensity, frequency, duration), and co-intervention(s)
- *Comparators*: type of comparator
- *Outcomes*: primary endpoint; longest follow-up; measures of pain, use of analgesics, functional status, health-related quality of life, and adverse events for each time point of measurement; domain; method of measurement; metric of data expression (e.g., means, proportions); and corresponding results (e.g., effect estimate, precision)

- *Timing*: time-points of outcome assessment, timing of intervention
- *Setting*: geographic region, clinical setting, interventionist training
- *Study design*: aim of study, definition of chronic pain, inclusion and exclusion criteria, sample size, reported power calculations, items relevant to risk of bias and quality ratings.

If different reports appeared to be from the same study, descriptions of participants were compared to ensure that data from the same study populations entered the analysis only once. For each included study, findings are displayed in an evidence table (see Appendix C) that includes details about the intervention, specific comparisons, and outcomes measured.

Risk of Bias and Study Quality

The two reviewers assessed the risk of bias of included studies using the Cochrane Risk of Bias tool (Higgins and Green, 2011). Specifically, the reviewers assessed risks of bias related to random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and providers (performance bias), blinding of outcome assessors (detection bias), completeness of reporting outcome data (attrition bias), and selective outcome reporting (reporting bias). Involvement of the intervention developers in evaluation of its efficacy was also noted.

Other biases related to the U.S. Preventive Services Task Force's criteria for internal validity of included studies were assessed, namely those related to: equal distribution among groups of potential confounders at baseline; crossovers or contamination between groups; equal, reliable, and valid outcome measurement; clear definitions of interventions; and intention-to-treat (ITT) analysis (U.S. Preventive Services Task Force, 2008; Lewin Group and ECRI Institute, 2014). These criteria were used to rate the quality of evidence of individual included studies using the following guidelines:

- *Good:* Comparable groups are initially assembled and maintained throughout the study with at least 80-percent follow-up; reliable, valid measurement is used and applied equally to all groups; interventions are clearly described; all important outcomes are considered; appropriate attention is given to confounders in analysis; ITT analysis is used.
- *Fair:* One or more of the following issues is found in the study: some, though not major, differences between groups exist at follow-up; measurement instruments are acceptable but not ideal, though are generally applied equally; some but not all important outcomes are considered; some but not all potential confounders are account for in analyses. ITT analysis must be done.
- *Poor:* One or more of the following "fatal flaws" is found in the study: initially assembled groups are not comparable or maintained throughout the study; unreliable or invalid measurements are used or applied unequally across groups; key confounders are given little to no attention in analyses; ITT analysis is not used.

Data Synthesis

The primary aim of this systematic review was to identify whether mindfulness meditation for chronic pain in adults is effective and safe. As such, when sufficient data were available and statistical heterogeneity was below agreed thresholds (Higgins and Green, 2011), we performed meta-analysis to pool efficacy results across included studies for the outcomes of interest, and we present forest plots for these meta-analyses. We used the Hartung-Knapp-Sidik-Jonkman method for random-effects meta-analysis (Hartung, 1999; Hartung and Knapp, 2001; Sidik and Jonkman, 2006) to estimate the relative risk (RR), standardized mean differences (SMDs), and 95-percent confidence intervals (CIs). This approach may be preferred when the number of studies pooled is small and when there is evidence of heterogeneity (IntHout, Ioannidis, and Borm, 2014), and it has been shown that the error rates are more robust than the previously used DerSimonian and Laird method (Sanchez-Meca and Marin-Martinez, 2008). For studies reporting multiple pain outcomes, we used specific pain measures, such as the MPQ for the main meta-analysis rather than the pain subscale of the SF-36, and average or general pain measures rather than situational measures, such as pain right at the time of assessment. Adverse events were classified and grouped according to the Common Terminology Criteria for Adverse Events system. Due to the small number of adverse events reported, quantitative analysis was not conducted.

In addition, we described results of head-to-head comparisons and conducted subgroup analyses and meta-regressions to address secondary questions of this systematic review. Specifically, we examined whether there were differences in effect sizes between different mindfulness meditation interventions; studies conducted in different population groups (e.g., patients with headache, migraine, back pain, or pain due to osteoarthritis); and mindfulness meditation intervention as monotherapy versus an adjunctive therapy. Given the complexity of the topic, subgroup and sensitivity analysis was performed only for those outcomes with sufficient data. For meta-analysis of data with clear outliers, sensitivity analysis was conducted (excluding the outliers), if appropriate (Hamling et al., 2008). We also conducted sensitivity analyses omitting the lower quality studies for major comparisons.

Quality of Evidence

The quality of the body of evidence was assessed for major outcomes using the Grades of Recommendation, Assessment, Development, and Evaluation (or GRADE) approach (Balshem et al., 2011; Lewin Group and ECRI Institute, 2014) in which the body of evidence is assessed based on the following dimensions: study limitations, directness, consistency, precision, and reporting bias (Egger et al., 1997).

The quality of evidence is graded on a four-item scale:

• *High* indicates that the review authors are very confident that the effect estimate lies close to the true effect for a given outcome, as the body of evidence has few or no deficiencies.

As such, the reviewers believe the findings are stable. That is, further research is very unlikely to change confidence in the effect estimate.

- *Moderate* indicates that the review authors are moderately confident that the effect estimate lies close to the true effect for a given outcome, as the body of evidence has some deficiencies. As such, the reviewers believe that the findings are likely to be stable, but further research may change confidence in the effect estimate and may even change the estimate.
- *Low* indicates that the review authors have limited confidence that the effect estimate lies close to the true effect for a given outcome, as the body of evidence has major or numerous (or both) deficiencies. As such, the reviewers believe that additional evidence is needed before concluding either that the findings are stable or that the effect estimate lies close to the true effect.
- *Very low* indicates that the review authors have very little confidence that the effect estimate lies close to the true effect for a given outcome, as the body of evidence has very major deficiencies. As such, the true effect is likely to be substantially different from the estimated effect; thus, any estimate of effect is very uncertain.

Summary of Findings

Review findings are summarized in a table organized by outcomes that reflect the key questions for this systematic review (Table 4.1). This table lists the intervention and comparators evaluated; the outcomes assessed for each type of comparison; the number of studies and number of participants included for each outcome assessment; the direction and magnitude of the effect for each outcome; and the quality of the evidence for each outcome.

For each outcome, results of pooled analyses are described first, followed by narrative descriptions of individual studies not included in the pooled analyses (if any). Findings are first reported for the broad comparison of mindfulness meditation compared with any comparison group. Findings are then reported separately by intervention (e.g., MBSR), population (e.g., patients with headache, back pain, fibromyalgia), therapy characteristic (i.e., monotherapy, adjunctive therapy), and type of comparator. Meta-analyses results are displayed in figures to allow a transparent overview, and results are described in detail in the text.

Results of the Search

We identified 639 citations through searches of electronic databases, plus nine citations by reference-mining previous systematic reviews (see Figure 3.1). Full texts were obtained for 88 citations identified as potentially eligible by two independent reviewers. In total, 60 articles were excluded at the full-text stage because they did not meet eligibility criteria. Ten of these studies were excluded because they were off topic, not reporting on mindfulness or chronic pain. Five were excluded due to intervention, as they did not study mindfulness meditation. Thirteen did not report on pain or analgesic use outcomes. Eleven were not RCTs. Five of the publications were dissertations, nine were conference abstracts, and five reported on studies already in the database and did not present new data. One study could not be obtained to be assessed for eligibility, and one publication was retained for background only. Appendix B lists excluded publications, with reasons for exclusion. Twenty-eight RCTs met inclusion criteria. Details of these studies are displayed in the evidence table in Appendix C.






Table 3.1 displays the number of RCTs that address each key question and subquestion. All 28 studies provided data on the efficacy of mindfulness meditation. Only three RCTs addressed the presence or absence of adverse events.

Key Question		Number of RCTs	
1	What are the efficacy and safety of mindfulness meditation interventions, as an adjunctive or monotherapy, for adults with chronic pain due to migraine, headache, back pain, osteoarthritis, or neuralgic pain compared with treatment as usual, waitlists, no treatment, or other active treatments?	 28 RCTs 8 treatment-as-usual comparator 9 education/support group comparator 1 stress management comparator 1 cognitive behavioral therapy comparator 1 massage comparator 1 multidisciplinary pain intervention comparator 1 muscle relaxation/stretching comparator 1 nutritional information/food diary comparator Note: Some trials have two comparison arms. 3 RCTs report on adverse events. 	
1a	Does the effect vary by the type of mindfulness meditation intervention?	16 MBSR 3 MBCT 1 MORE 1 mindfulness-based pain management 1 mindful socioemotional regulation 6 other mindfulness meditation programs	
1b	Does the effect vary by medical condition targeted (migraine, headache, back pain, osteoarthritis, or neuralgic pain)?	8 fibromyalgia 6 migraine or other headache 4 back pain 2 osteoarthritis 3 rheumatoid arthritis 1 cancer 3 irritable bowel syndrome 6 other conditions 4 unspecified conditions Note: Categories are not mutually exclusive.	
1c	Does the effect differ when the intervention is offered as an adjunctive therapy rather than as a monotherapy?	13 monotherapy 13 adjunctive therapy 2 unclear	
1d	Does the effect vary depending on the duration and frequency of mindfulness meditation (i.e., dose effect)?	2 low frequency (<1 hour per week) 9 medium frequency (1–4 hours per week) 10 high frequency (>4 hours per week) 7 unclear frequency	

Table 3.1. Evidence Base for Key Questions

For KQ 1a on whether the effect of mindfulness meditation varies by intervention type, we identified 16 studies examining MBSR, three studies examining MBCT, one study examining MORE, one study of mindfulness-based pain management, one study of mindful socioemotional regulation, and six studies examining other mindfulness meditation programs.

For KQ 1b on whether the effect of mindfulness meditation varies by type of condition treated, we found eight studies examining fibromyalgia, six studies examining migraine or

headache, four studies examining back pain, two studies examining osteoarthritis, three studies examining rheumatoid arthritis, one study examining cancer, three studies examining irritable bowel syndrome (IBS), six studies examining other conditions, and four studies examining unspecified conditions. (Categories are not mutually exclusive; some studies did not limit enrollment to a particular medical condition or source of pain.)

For KQ 1c on whether mindfulness meditation is more effective as monotherapy than as an adjunctive treatment, we found 13 studies examining meditation as monotherapy, 13 examining it as adjunctive therapy, and two that were unclear.

For KQ 1d on whether the effect of mindfulness meditation varied by the frequency and duration of the intervention, we found that the duration varied from three to 12 weeks (median eight weeks) and that the frequency (defined as the total time spent in group sessions, remote sessions, and "homework") varied from less than one hour a week in two studies to more than four hours a week in ten studies. Two studies examine programs estimated at less than one hour per week (i.e., low frequency), nine studies examined programs estimated at one to four hours per week (i.e., high frequency), and seven studies were unclear.

Description of Included Studies

Design

One RCT (Zautra et al., 2008) randomized clusters of participants, while the rest randomized individual participants. Overall, studies assigned 2,179 participants; sample sizes ranged from 19 to 195. Eight studies did not report any information about a power calculation, 11 studies reported an a priori power calculation with targeted sample size achieved, and two studies were unclear in the reporting of a power calculation. Seven studies noted there was insufficient power; the authors considered these pilot studies.

Setting

Fourteen studies were conducted in either the United States or Canada, eight took place in Europe, two in Asia, two in the Middle East, one in Australia, and one in New Zealand.

The mindfulness intervention was delivered remotely (e.g., via telephone, Internet, or mobile app) in six of the studies. Two of the studies delivered the mindfulness intervention in an outpatient pain clinic, and three of the studies delivered it in another outpatient setting; in 17 studies, it was unclear where the intervention was delivered.

Participants

The mean age of participants ranged from 34.6 (standard deviation [SD] 9.4) to 74.6 (SD 10.8) years. Twenty-one studies included both male and female participants, five studies

included only female participants, and two studies did not provide information on gender. The proportion of males ranged from 0.7 percent (one patient) to 56 percent.

Medical conditions reported included fibromyalgia in eight studies and back pain in four studies. (Categories are not mutually exclusive; some studies included patients with different conditions.) Osteoarthritis was reported in two studies and rheumatoid arthritis in three. Migraine headache was reported in two studies and another type of headache in four studies. Three studies reported IBS. Six studies reported other causes of pain, and four studies did not specify a medical condition or source of chronic pain.

Interventions

The total length of the intervention program ranged from three to 12 weeks. The majority of intervention programs (21 studies) were eight weeks in length. Sixteen studies utilized MBSR, three used MBCT, and one used MORE. Eight of the studies used another mindfulness intervention, such as a compact disc of guided meditation, daily mindfulness meditation piece from MBSR, and mindful socioemotional regulation.

We identified 13 RCTs that provided the mindfulness intervention as monotherapy and 13 that utilized a mindfulness intervention as adjunctive therapy, specifying that all participants received this in addition to other treatment, such as medication. Two of the studies were unclear about whether the mindfulness intervention was monotherapy or adjunctive therapy.

Comparators

Eight RCTs used treatment as usual as comparators; eight used passive comparators, such as a waitlist; and nine used education or support groups as comparators. Beyond these common comparators, one study each used stress management, cognitive behavioral therapy, massage, a multidisciplinary pain intervention, relaxation/stretching, and nutritional information/food diaries as comparators. (Several studies had two comparison arms, so numbers do not add to 28.)

Study Quality/Risk of Bias for Individual Included Studies

The risk of bias and study quality for each included study is displayed in Table 3.2. Seven studies obtained a "good" quality rating (Fjorback et al., 2013; Fogarty et al., 2015; Ljotsson, Falk, et al., 2010; Ljotsson, Hedman, et al., 2011; Parra-Delgado and Latorre-Postigo, 2013; Wong et al., 2011; Zautra et al., 2008). Ten studies were judged to be of fair quality, primarily due to being unclear in some aspects of the methods (Cash et al., 2015; Davis and Zautra, 2013; Day et al., 2014; Dowd et al., 2015; Garland et al., 2014; Gaylord et al., 2011; la Cour and Petersen, 2015; Morone, Greco, and Weiner, 2008; Schmidt et al., 2011; Wells et al., 2014). Eleven studies were judged to be poor; eight of these were primarily due to issues with completeness of reporting outcome data, such as inadequate or missing ITT analysis or less than 80-percent follow-up (Astin et al., 2003; Brown and Jones, 2013; Cathcart et al., 2014; Esmer et

al., 2010; Meize-Grochowski et al., 2015; Morone et al., 2009; Omidi and Zargar, 2014; Plews-Ogan et al., 2005). Three studies were judged poor primarily due to unclear methods (Rahmani and Talepasand, 2015; Teixeira, 2010; Wong, 2009).

Random sequence generation. Ten studies had unclear selection bias because they did not report their random sequence generation method; 18 other studies reported adequate random sequence generation methods (e.g., computerized random generator) so were at low risk for selection bias.

Allocation concealment. Thirteen studies had unclear selection bias because they did not report their allocation concealment method, whereas 14 studies did give a method of allocation concealment, and one other study presented a method of allocation concealment that was at high risk of being inadequate.

Blinding of participants and providers. All but two studies were rated high risk on this domain, as it is almost impossible to blind participants to meditation interventions. One study had low risk of bias because the authors used sham meditation as the control. The remaining study had unclear selection bias because the authors did not report the method of ensuring blinding.

Blinding of outcome assessors. Ten studies had unclear risk of detection bias because they did not report whether outcome assessors were blind to participant intervention conditions. Six studies had low risk of bias, because the authors explicitly indicated that the outcome assessors were blind to intervention assignment, and 12 studies had high risk of bias, indicating assessors were not blinded.

Outcome data. Twenty studies had low risk of attrition bias; seven had high risk due to attrition of more than 20 percent at follow up, and one study was unclear.

Selective outcome reporting. Two of the studies had high risk of reporting bias. Nine studies had low risk of reporting bias because the authors cited a protocol for the study. Seventeen studies had unclear risk of bias because it was not possible to determine whether all outcomes collected were reported.

Other. Four of the studies were identified as having an unequal distribution among groups of potential confounders at baseline, five studies were found to be unclear in this regard, and 19 studies reported no significant differences in baseline characteristics. None of the studies was a crossover trial, and therefore appropriate washout was not applicable. Only one study was judged to have any problems with having equal, reliable, and valid outcome measurement. One study was found to have issues with clear definitions of the interventions. Seven studies were identified as having problems with appropriate ITT analysis for outcomes with missing data, one study was unclear, and the remaining studies had no indication of problems with ITT analysis.

Table 3.2. Quality Ratings

								c	Other Biases			
Study ID	Random Sequence Generation (selection bias)	Allocation Concealment (selection bias)	Blinding of Participants and Personnel (performance bias)	Blinding of Outcome Assessors (detection bias)	Completeness of Reporting Outcome Data (attrition bias)	Selective Outcome Reporting (reporting bias	Unequal Distribution Among Groups of Potential Confounders at Baseline	Crossovers or Contamination Between Groups	Equal, Reliable, and Valid Outcome Measurement	Clear Definitions of Interventions	ITT Analysis	USPSTF Quality Rating
Astin et al., 2003	Low risk	Low risk	High risk	Unclear risk	High risk	Unclear risk	No	No	Yes	Yes	No	Poor
Brown and Jones, 2013	Unclear risk	Unclear risk	High risk	Unclear risk	High risk	Unclear risk	Unclear	No	No	Yes	No	Poor
Cash et al., 2015	Low risk	Unclear risk	High risk	Unclear risk	Low risk	Low risk	No	No	Yes	Yes	Yes	Fair
Cathcart et al., 2014	Unclear risk	Low risk	High risk	Low risk	Low risk	Low risk	No	No	Yes	Yes	No	Poor
Davis and Zautra, 2013	Low risk	Low risk	High risk	High risk	Low risk	Low risk	No	No	Yes	Yes	Yes	Fair
Day et al., 2014	Low risk	High risk	High risk	High risk	Low risk	Unclear risk	No	No	Yes	Yes	Yes	Fair
Dowd et al., 2015	Low risk	Low risk	High risk	High risk	Low risk	Unclear risk	No	No	Yes	Yes	Yes	Fair
Esmer et al., 2010	Unclear risk	Unclear risk	High risk	High risk	High risk	Unclear risk	No	No	Yes	Yes	Yes	Poor
Fjorback et al., 2013	Low risk	Low risk	High risk	Unclear risk	Low risk	Unclear risk	No	No	Yes	Yes	Yes	Good
Fogarty et al., 2015	Unclear risk	Unclear risk	High risk	Low risk	Low risk	Unclear risk	No	No	Yes	Yes	Yes	Good
Garland et al., 2014	Low risk	Low risk	High risk	Low risk	Low risk	Unclear risk	No	No	Yes	Yes	Yes	Fair
Gaylord et al., 2011	Low risk	Low risk	High risk	Low risk	Low risk	Low risk	No	No	Yes	Yes	Yes	Fair
la Cour and Petersen, 2015	Low risk	Low risk	High risk	High risk	Low risk	Unclear risk	Yes	No	Yes	Yes	Yes	Fair
Ljotsson, Falk, et al., 2010	Low risk	Low risk	High risk	High risk	Low risk	Unclear risk	Unclear	No	Yes	Yes	Yes	Good
Ljotsson, Hedman, et al., 2011	Low risk	Low risk	High risk	High risk	Low risk	High risk	No	No	Yes	Yes	Yes	Good

								C	Other Biases			
Study ID	Random Sequence Generation (selection bias)	Allocation Concealment (selection bias)	Blinding of Participants and Personnel (performance bias)	Blinding of Outcome Assessors (detection bias)	Completeness of Reporting Outcome Data (attrition bias)	Selective Outcome Reporting (reporting bias	Unequal Distribution Among Groups of Potential Confounders at Baseline	Crossovers or Contamination Between Groups	Equal, Reliable, and Valid Outcome Measurement	Clear Definitions of Interventions	ITT Analysis	USPSTF Quality Rating
Meize- Grochowski et al., 2015	Unclear risk	Unclear risk	High risk	High risk	High risk	Unclear risk	Unclear	No	Yes	Yes	No	Poor
Morone, Greco, and Weiner, 2008	Low risk	Low risk	High risk	Unclear risk	Low risk	Unclear risk	No	No	Yes	Yes	Yes	Fair
Morone et al., 2009	Low risk	Low risk	High risk	Low risk	High risk	Unclear risk	Yes	No	Yes	Yes	No	Poor
Omidi and Zargar, 2014	Unclear risk	Unclear risk	Unclear risk	Unclear risk	High risk	Low risk	Yes	No	Yes	Yes	No	Poor
Parra-Delgado and Latorre- Postigo, 2013	Low risk	Unclear risk	High risk	Unclear risk	Low risk	Low risk	No	No	Yes	Yes	Yes	Good
Plews-Ogan et al., 2005	Low risk	Unclear risk	High risk	High risk	High risk	Unclear risk	No	No	Yes	Yes	No	Poor
Rahmani and Talepasand, 2015	Unclear risk	Unclear risk	High risk	Unclear risk	Low risk	Low risk	Yes	No	Yes	Yes	Yes	Poor
Schmidt et al., 2011	Unclear risk	Unclear risk	Low risk	Low risk	Low risk	High risk	No	No	Yes	Yes	Yes	Fair
Teixeira, 2010	Unclear risk	Unclear risk	High risk	Unclear risk	Low risk	Low risk	Unclear	No	Yes	Yes	Yes	Poor
Wells et al., 2014	Low risk	Low risk	High risk	Unclear risk	Low risk	Low risk	Unclear	No	Yes	No	Yes	Fair
Wong, 2009	Unclear risk	Unclear risk	High risk	High risk	Unclear risk	Unclear risk	No	No	Yes	Yes	Unclear	Poor
Wong et al., 2011	Low risk	Low risk	High risk	High risk	Low risk	Unclear risk	No	No	Yes	Yes	Yes	Good
Zautra et al., 2008	Low risk	Unclear risk	High risk	High risk	Low risk	Unclear risk	No	No	Yes	Yes	Yes	Good

KQ 1: What Are the Efficacy and Safety of Mindfulness Meditation Interventions, as an Adjunctive or Monotherapy, for Adults with Chronic Pain Due to Migraine, Headache, Back Pain, Osteoarthritis, or Neuralgic Pain Compared with Treatment as Usual, Waitlists, No Treatment, or Other Active Treatments?

Chronic Pain Treatment Response Standardized Mean Differences

Twenty-four RCTs reported continuous outcome data on scales assessing chronic pain in each study arm. Pain scales and comparators varied from study to study (Astin et al., 2000; Brown and Jones, 2013; Cash et al., 2015; Cathcart et al., 2014; Davis and Zautra, 2013; Day et al., 2014; Dowd et al., 2015; Esmer et al., 2010; Garland et al., 2014; la Cour and Petersen, 2015; Meize-Grochowski et al., 2015; Morone, Greco, and Weiner, 2008; Morone et al., 2009; Omidi and Zargar, 2014; Plews-Ogan et al., 2005; Schmidt et al., 2011; Teixeira, 2010; Wells et al., 2014; Zautra et al., 2008; Parra-Delgado and Latorre-Postigo, 2013; Rahmani and Talepasand, 2015; Fjorback et al., 2013; Gaylord et al., 2011; Ljotsson, Falk, et al., 2010). The median follow-up time was 12 weeks, with a range of four to 60 weeks. Although 15 studies indicated that mindfulness reduced pain, many did not report a statistically significant effect, and confidence intervals varied widely between studies (see Figure 3.2). However, the pooled analysis indicates a statistically significant effect of mindfulness meditation (SMD 0.26; CI 0.06, 0.46; 24 RCTs; I² 62.1%). Substantial heterogeneity was detected. Begg's and Egger's tests for publication bias were nonsignificant.

The difference in the pooled and individual results could also indicate that the majority of studies were underpowered. This possibility is buttressed by the fact that most of the 24 RCTs either reported being underpowered or did not report power. To investigate the effect of methodological quality on these results, we conducted a sensitivity analysis excluding all poor quality studies (not displayed). The results were very similar to our main pooled analysis (SMD 0.21; CI 0.00, 0.42; 15 RCTs; I^2 57.2%).

Author, year	Overall Pain - Longest Follow Up	SMD [95% CI]
Astin, 2003	F==-1	-0.04 [-0.52 , 0.45]
Brown, 2013	⊢ ∔∎I	0.24 [-0.51 , 0.98]
Cash, 2015	⊢∔→	0.00 [-0.42, 0.41]
Cathcart, 2014		0.08 [-0.52 , 0.69]
Davis, 2013	⊢∎∔	-0.24 [-0.69 , 0.20]
Day, 2014	⊢	-0.01 [-0.66 , 0.65]
Dowd, 2015	⊢‡ →	0.00 [-0.36 , 0.35]
Esmer, 2010	⊢┼╼──┥	0.30 [-0.50 , 1.10]
Fjorback, 2013	⊢∎⊢	-0.10 [-0.51 , 0.31]
Garland, 2014		0.76 [0.38 , 1.14]
Gaylord, 2011	<u>}∎</u> i	0.53 [0.06 , 0.99]
le Cour, 2015	⊨∎÷⊣	-0.16 [-0.53 , 0.22]
Ljotsson, 2010	⊢ ∎→	0.64 [0.19 , 1.08]
Meize-Grochowski, 2015		-0.31 [-1.07 , 0.45]
Morone, 2008		0.23 [-0.42 , 0.88]
Morone, 2009	⊢	-0.04 [-0.70 , 0.63]
Omidi, 2014	⊢ ∎→I	1.23 [0.68 , 1.78]
Parra-Delgado, 2013		0.44 [-0.27 , 1.15]
Plews-Ogan MBSR v. TAU, 2005		0.02 [-1.04 , 1.07]
Rahmani, 2015	· · · · · · · · · · · · · · · · · · ·	1.85 [0.89 , 2.80]
Schmidt, MM v. waitlist, 2011	⊢;∎	0.17 [-0.20 , 0.55]
Teixeira, 2010	⊢ i•i	0.14 [-0.74 , 1.01]
Wells, 2014	· · · · · · · · · · · · · · · · · · ·	1.50 [0.48 , 2.51]
Zautra - MM v. Educ, 2008	H-	0.22 [-0.20 , 0.63]
RE Model	\$	0.28 [0.08 , 0.48]
I-squared=62.1%		Total N = 1456
	-2.00 0.00 1.00 2.00 3.00 4.00	5.00
	Favors Control Favors Inter	vention

Figure 3.2. Mindfulness Meditation Versus Control, Pain Outcome, Longest Follow-Up

Overall Pain - Longest Follow Up

20

Short Term

To determine the difference between the short- and long-term effects of mindfulness meditation, we split the above analysis into short-term (0–12 weeks) and long-term (>12 weeks) follow-up. The median short-term follow-up time was eight weeks (range 4–12 weeks). Figure 3.3 shows a positive effect of meditation on pain from 0–12 weeks in 17 studies (Brown and Jones, 2013; Cash et al., 2015; Cathcart et al., 2014; Esmer et al., 2010; Garland et al., 2014; Morone, Greco, and Weiner, 2008; Omidi and Zargar, 2014; Plews-Ogan et al., 2005; Schmidt et al., 2011; Teixeira, 2010; Wells et al., 2014; Zautra et al., 2008; Parra-Delgado and Latorre-Postigo, 2013; Rahmani and Talepasand, 2015; Fjorback et al., 2013; Gaylord et al., 2011; Ljotsson, Falk, et al., 2010), which was statistically significant in five studies (Garland et al., 2014; Omidi and Zargar, 2014; Rahmani and Talepasand, 2015; Gaylord et al., 2015; Gaylord et al., 2011). The pooled analysis of all 24 RCTs showed a significant positive effect (SMD 0.27;

CI 0.04, 0.50; 24 RCTs; I^2 64.6%). Substantial heterogeneity was detected. Egger's test indicated possible publication bias, while Begg's test did not. However, using the trim and fill method to correct for this bias yielded an estimate identical to the original pooled result The effect was very similar when nine poor quality studies were excluded from analysis (SMD 0.2; CI 0.03, 0.38; not displayed); heterogeneity was moderate (I^2 43.8%).

Author, year	Pain - 0-12 Weeks Follow-Up	SMD (95% CI)
Astin, 2003 Brown, 2013 Cash, 2015 Cathcart, 2014 Davis, 2013 Day, 2014 Dowd, 2015 Esmer, 2010 Fjorback, 2013 Garland, 2014 Gaylord, 2011 le Cour, 2015 Ljotsson, 2010 Meize-Grochowski, 2015 Morone, 2008 Morone, 2009 Omidi, 2014 Parra-Delgado, 2013 Plews-Ogan MBSR v. TAU, 2005		-0.05 [-0.54 , 0.43] 0.24 [-0.51 , 0.98] 0.32 [-0.10 , 0.74] 0.08 [-0.52 , 0.69] -0.24 [-0.69 , 0.20] -0.01 [-0.66 , 0.65] -0.19 [-0.54 , 0.17] 0.30 [-0.50 , 1.10] 0.15 [-0.23 , 0.53] 0.57 [0.19 , 0.94] 0.54 [0.08 , 1.00] -0.16 [-0.53 , 0.22] 0.64 [0.19 , 1.08] -0.31 [-1.07 , 0.45] 0.23 [-0.42 , 0.88] -0.01 [-0.68 , 0.65] 1.21 [0.66 , 1.76] 0.19 [-0.51 , 0.90] 0.02 [-1.04 , 1.07]
Rahmani, 2015 Schmidt, MM v. waitlist, 2011 Teixeira, 2010 Wells, 2014 Zautra - MM v. Educ, 2008		3.24 [2.02 , 4.48] 0.22 [-0.16 , 0.60] 0.14 [-0.74 , 1.01] 0.99 [0.04 , 1.95] 0.22 [-0.20 , 0.63]
RE Model I-squared=64.6%	-2.00 0.00 1.00 2.00 3.00 4.00	0.27 [0.04 , 0.50] Total N = 1456 5.00
	Favors Control Favors Interv	vention

Figure 3.3. Mindfulness Meditation Versus Control, Pain Outcome, 0–12 weeks

Long Term

Eleven RCTs followed study participants more than 12 weeks (median: 20 weeks; range: 16–60 weeks) (Astin et al., 2003; Cash et al., 2015; Dowd et al., 2015; Garland et al., 2014; Morone et al., 2009; Omidi and Zargar, 2014; Schmidt et al., 2011; Parra-Delgado and Latorre-Postigo, 2013; Rahmani and Talepasand, 2015; Fjorback et al., 2013; Gaylord et al., 2011). Figure 3.4 shows that there is an effect of meditation on pain for participants in six of these studies but not

overall (SMD 0.37; C -0.01, 0.74; 11 RCTs, I² 74.7%) (Garland et al., 2014; Omidi and Zargar, 2014; Schmidt et al., 2011; Parra-Delgado and Latorre-Postigo, 2013; Rahmani and Talepasand, 2015; Gaylord et al., 2011). Substantial heterogeneity was detected. Publication bias was not detected. Removing poor quality studies (not shown) yielded a slightly smaller nonsignificant effect (SMD 0.24; CI -0.07, 0.55; 7 RCTs, I² 59.8%). It is important to note that no interventions were more than 12 weeks in length, so these findings reflect outcomes collected after the interventions ended. Few studies collected information on continued practice of mindfulness meditation.




Figure 3.4. Mindfulness Meditation Versus Control, Pain Outcome, >12 Weeks

Comparators

Studies examined three major comparators: treatment as usual (TAU), passive control, and education or support groups. Seven RCTs compared the effect of mindfulness meditation to TAU (Brown and Jones, 2013; Esmer et al., 2010; Omidi and Zargar, 2014; Plews-Ogan et al., 2005; Wells et al., 2014; Parra-Delgado and Latorre-Postigo, 2013; Fjorback et al., 2013) (see

Figure 3.5). Two of the seven studies reported significant effects and the pooled effect was significant overall (SMD 0.45; CI 0.02, 0.88; 7 RCTs; I^2 51.5%) (Omidi and Zargar, 2014; Wells et al., 2014). Heterogeneity among studies was moderate. Begg's and Egger's tests were nonsignificant for publication bias. The size of the effect decreased and became nonsignificant when poor quality studies were removed from analysis (SMD 0.29; CI –0.62, 1.21; 3 RCTs; I^2 23.1%). A meta-regression found that treatment effects did not differ significantly when TAU was used as a comparator versus all other comparators.




Figure 3.5. Mindfulness Meditation Versus Treatment as Usual

Among the eight RCTs that compared mindfulness meditation to a passive control (either intervention or a waitlist for the primary intervention) (Cash et al., 2015; Cathcart et al., 2014; Day et al., 2014; la Cour and Petersen, 2015; Meize-Grochowski et al., 2015; Morone, Greco, and Weiner, 2008; Schmidt et al., 2011; Rahmani and Talepasand, 2015), one showed a significant effect of meditation on pain (Rahmani and Talepasand, 2015). The pooled effect (displayed in Figure 3.6) was not significant (SMD 0.28; CI –0.46, 1.02; 8 RCTs; I² 76.5%);

considerable heterogeneity was detected. Nonsignificance persisted when poor quality studies were dropped from analysis (SMD 0.11; CI -0.10, 0.32; 6 RCTs; I² 0%; not displayed).

Author, year	Pain - Passive, 0-12 Weeks F	Follow-Up SMD (95% CI)
Cash, 2015	⋫₩→	0.32 [-0.10 , 0.74]
Cathcart, 2014	⊢ ∎-1	0.08 [-0.52 , 0.69]
Day, 2014	L.	-0.01 [-0.66 , 0.65]
le Cour, 2015	F a ri	-0.16 [-0.53 , 0.22]
Meize-Grochowski, 2015	⊢ ∎∔1	-0.31 [-1.07 , 0.45]
Morone, 2008	F=-1	0.23 [-0.42 , 0.88]
Rahmani, 2015	,	- 3.24 [2.02 , 4.46]
Schmidt, MM v. waitlist, 2011	L B -1	0.22 [-0.16 , 0.60]
RE Model		0.28 [-0.46 , 1.02] Total N = 475
	-2.00 0.00 2.0	0 4.00
	Favors Control	Favors Intervention

Figure 3.6. Mindfulness Meditation Versus Passive Control

Eight RCTs examined the effect of mindfulness meditation on pain compared with education or support groups (Astin et al., 2003; Davis and Zautra, 2013; Garland et al., 2014; Dowd et al., 2015; Morone et al., 2009; Gaylord et al., 2011; Ljotsson, Falk, et al., 2010; Zautra et al., 2008) (see Figure 3.7). The effect of meditation was significant in three of these studies, and not significant when studies were pooled (SMD 0.19; CI –0.11, 0.49; 8 RCTs; I^2 63.9%) (Garland et al., 2014; Gaylord et al., 2011; Ljotsson, Falk, et al., 2010). Substantial heterogeneity was detected. The nonsignificant effect remained largely unchanged when poor quality studies were removed from analysis (SMD 0.25; CI –0.16, 0.66; 6 RCTs; I^2 71.9%; not displayed).




Figure 3.7. Mindfulness Meditation Versus Education or Support Group

Pain - Education, 0-12 Weeks Follow-Up

Four studies examined the effect of mindfulness meditation on pain versus a comparator other than those listed above. Mindfulness meditation improved self-reported pain more than cognitive behavioral therapy (SMD 0.56; CI 0.16, 0.96) (Zautra et al., 2008) but not more than a nutritional program (SMD 0.08; CI –0.30, 0.45) (Teixeira, 2010). MBSR had no significant effect on pain unpleasantness compared with massage (SMD –0.30; CI –1.34, 0.74) (Plews-Ogan et al., 2005) or on Pain Perception Scale affective component scores compared with relaxation training (SMD 0.08; CI –0.30, .45) (Schmidt et al., 2011).

Effect sizes could not be calculated for four studies because authors reported limited information or nonstandard outcomes. In one study, MBSR had no significant effect on pain intensity versus a multidisciplinary pain intervention at six months postintervention, but in another study, MBSR significantly reduced pain after the same amount of time. In the third, Internet-based cognitive behavioral therapy with a mindfulness component significantly increased relief from IBS-related pain and discomfort at six months. The last study reported a decrease in pain intensity for those participating in MBSR at both eight weeks and six months, although no numeric data were reported (Wong et al., 2011; Fogarty et al., 2015; Ljotsson, Hedman, et al., 2011; Wong, 2009).

Analgesic Use

Only one study reported use of analgesics as an outcome (Esmer et al., 2010). Esmer and colleagues studied 25 patients with chronic pain due to failed back surgery syndrome. Fifteen of the participants received the MBSR intervention and ten participants were controls, receiving no treatment. Each group kept a log of analgesic medication use, which was scored on a scale of 0 to 4 points (0: no analgesic use; 1: less than daily nonopioid analgesic use; 2: daily nonopioid analgesic use; 3: less than daily opioid analgesic use; and 4: daily opioid medications). At 12-week follow-up, the analgesic medication logs of those in the intervention group documented a decrease in analgesic use compared with those in the control group (-1.5 (SD 1.8) versus 0.4 (SD 1.1), p=<.001).

Health-Related Quality of Life

Ten RCTs measured depression outcomes (Astin et al., 2003; Gaylord et al., 2011; la Cour and Petersen, 2015; Ljotsson, Falk, et al., 2010; Ljotsson, Hedman, et al., 2011; Meize-Grochowski et al., 2015; Parra-Delgado and Latorre-Postigo, 2013; Schmidt et al., 2011; Wells et al., 2014; Zautra et al., 2008). Overall, meditation significantly reduced depression (SMD 0.17; CI 0.03, 0.31; 10 RCTs; I² 0%). No heterogeneity was detected. Five (Brown and Jones, 2013; la Cour and Petersen, 2015; Ljotsson, Falk, et al., 2010; Ljotsson, Hedman, et al., 2011; Rahmani and Talepasand, 2015) of the 13 studies reporting mental health-related quality of life reported a significant effect, and this effect is significant in the pooled analysis (SMD 0.44; CI 0.18, 0.69; 13 RCTs; I² 50.6%) (Brown and Jones, 2013; Fjorback et al., 2013; Gaylord et al., 2011; la Cour and Petersen, 2015; Ljotsson, Falk, et al., 2010; Ljotsson, Hedman, et al., 2011; Meize-Grochowski et al., 2015; Morone, Greco and Weiner, 2008; Plews-Ogan et al., 2005; Rahmani and Talepasand, 2015; Schmidt et al., 2011; Teixeira, 2010; Wells et al., 2014).¹ Twelve studies measured physical health-related quality of life (Brown and Jones, 2013; Fjorback et al., 2013; Gaylord et al., 2011; la Cour and Petersen, 2015; Ljotsson, Falk, et al., 2010; Ljotsson, Hedman, et al., 2011; Meize-Grochowski et al., 2015; Morone, Greco, and Weiner, 2008; Rahmani and Talepasand, 2015; Schmidt et al., 2011; Teixeira, 2010; Wells et al., 2014), and four of these studies used a remote intervention (Ljotsson, Falk, et al., 2010; Ljotsson, Hedman, et al., 2011; Meize-Grochowski et al., 2015; Teixeira, 2010).² Three (Liotsson, Falk. et

¹ Mental health-related quality of life is assessed by the mental health summary measure of the SF-36 or other instrument that measures such factors as affect, anxiety, vitality, ability to emotionally function in self-identified roles, and social functioning.

² Physical health-related quality of life is assessed by the physical health summary measure of the SF-36, which captures physical functioning, ability to physically function in self-identified roles, general health, and pain.

al., 2010; Ljotsson, Hedman, et al., 2011; Rahmani and Talepasand, 2015) of the 12 and all of those using a remote intervention report a significant positive effect of meditation on physical health-related quality of life. Pooled analyses showed a significant effect for all studies that reported a physical health-related quality of life (SMD 0.3; CI 0.03, 0.57; 12 RCTs; I² 54.6%) and in those with a remote intervention (SMD 0.61; CI 0.06, 1.15; 4 RCTs; I² 36.6%). The quality of life analyses detected moderate heterogeneity.

Functional Impairment (Disability Measures)

Three studies reported poolable disability scores. Esmer and colleagues (2010) and Morone, Greco, and Weiner (2008) reported Roland-Morris Disability Questionnaire scores, while Ljotsson, Falk, and colleagues (2010) reported the Sheehan Disability Scale. Improvements in these scores in the mindfulness groups were not significantly different from improvements in the control groups (SMD 0.47; CI -0.18, 1.12; I² 0%). No heterogeneity was detected.

Adverse Events Reported in RCTs

Only three of the included RCTs reported on adverse events. Of these three, two stated that no adverse events occurred (Morone, Greco, and Weiner, 2008; Morone et al., 2009), and one described that two participants experienced temporary strong feelings of anger toward their pain condition and two of the participants experienced greater anxiety (la Cour and Petersen, 2015).

Study Characteristic Moderators and Risk of Bias

Several meta-regressions were run to determine if changes in pain outcomes systematically differed by several subcategories. Changes in pain outcomes in good (p=0.72) and fair (p=0.32) quality studies were not significantly different from changes in poor quality studies.

KQ 1a: Does the Effect Vary by the Type of Mindfulness Meditation Intervention?

Mindfulness-Based Stress Reduction

Fifteen RCTs examined the effect of MBSR on a continuous chronic pain measure (Astin et al., 2003; Cash et al., 2015; Esmer et al., 2010; la Cour and Petersen, 2015; Meize-Grochowski et al., 2015; Morone, Greco, and Weiner, 2008; Morone et al., 2009; Omidi and Zargar, 2014; Plews-Ogan et al., 2005; Schmidt et al., 2011; Teixeira, 2010; Wells et al., 2014; Zautra et al., 2008; Rahmani and Talepasand, 2015; Fjorback et al., 2013) (see Figure 3.8). Eleven of these studies (Cash et al., 2015; Esmer et al., 2010; Morone, Greco, and Weiner, 2008; Omidi and Zargar, 2014; Plews-Ogan et al., 2005; Schmidt et al., 2010; Morone, Greco, and Weiner, 2008; Omidi and Zargar, 2014; Plews-Ogan et al., 2005; Schmidt et al., 2011; Teixeira, 2010; Wells et al., 2014; Zautra et al., 2014; Plews-Ogan et al., 2005; Schmidt et al., 2011; Teixeira, 2010; Wells et al., 2014; Zautra et al., 2014; Plews-Ogan et al., 2005; Schmidt et al., 2011; Teixeira, 2010; Wells et al., 2014; Zautra et al., 2014; Plews-Ogan et al., 2005; Schmidt et al., 2011; Teixeira, 2010; Wells et al., 2014; Zautra et al., 2008; Rahmani and Talepasand, 2015; Fjorback et al., 2013) reported a positive effect after treatment was applied for up to 12 weeks, three of which were statistically significant

(Omidi and Zargar, 2014; Rahmani and Talepasand, 2015; Wells et al., 2014). This effect was nonsignificant in the pooled analysis (SMD 0.32; CI -0.06, 0.70; 15 RCTs; I² 69.8%). Substantial heterogeneity was detected. After removing eight poor quality studies from analysis, the effect decreased and remained nonsignificant (SMD 0.18; CI -0.04, 0.39; 7 RCTs; I² 6%). A meta-regression showed that changes in pain outcomes with MBSR were not significantly different than with other types of mindfulness meditation (p=0.60).

Author, year	Pain - MBSR, 0-12 Weeks Folk	ом-Up вмр (эзчь сі)
Astin, 2003	⊢ ∎ ⊣	-0.05 [-0.54 , 0.43]
Cash, 2015	i ∎ -i	0.32 [-0.10 , 0.74]
Esmer, 2010	r =	0.30 [-0.50 , 1.10]
Fjorback, 2013	H H -1	0.15 [-0.23 , 0.53]
le Cour, 2015	H ar i	-0.16 [-0.53 , 0.22]
Meize-Grochowski, 2015	⊢ ∎1	-0.31 [-1.07 , 0.45]
Morone, 2008	⊢╼	0.23 [-0.42 , 0.88]
Morone, 2009	F	-0.01 [-0.68 , 0.65]
Omidi, 2014	⊢ ∎→1	1.21 [0.66 , 1.76]
Plews-Ogan MBSR v. TAU, 2005	▶ →	0.02 [-1.04 , 1.07]
Rahmani, 2015	⊢ ⊢	- 3.24 [2.02 , 4.46]
Schmidt, MM v. waitlist, 2011	i,∎-i	0.22 [-0.16 , 0.60]
Teixeira, 2010	⊢ <u></u>	0.14 [-0.74 , 1.01]
Wells, 2014	·	0.99 [0.04 , 1.95]
Zautra - MM v. Educ, 2008	H B -1	0.22 [-0.20 , 0.63]
RE Model	\$	0.32 [-0.06 , 0.70]
I-squared=69.8%		Total N = 845
	-2.00 0.00 2.00	4.00
	Favors Control	Favors Intervention

Figure 3.8. MBSR Versus Control

Mindfulness-Based Cognitive Therapy

Only four RCTs explored the relationship between MBCT and chronic pain (Day et al., 2014; Dowd et al., 2015; Parra-Delgado and Latorre-Postigo, 2013; Ljotsson, Falk, et al., 2010) (see Figure 3.9). One of these four (Ljotsson, Falk, et al., 2010) showed that MBCT significantly reduced pain within 12 weeks, but this effect was nonsignificant in the pooled analysis (SMD

0.16; CI -0.45, 0.76; 4 RCTs; I² 63.6%). Substantial heterogeneity was detected. There were no poor quality studies to exclude in this subgroup analysis. A meta-regression did not detect systematic differences between MBSR and other types of mindfulness meditation (p=0.58).




Figure 3.9. MBCT Versus Control

Other Interventions

The remaining studies addressed MORE, mindfulness-based pain management, mindful socioemotional regulation, or other unique interventions. Five RCTs delivered mindfulness meditation interventions remotely—via either Internet-based programs or materials instructing participants to conduct mindfulness exercises at home (Davis and Zautra, 2013; Dowd et al., 2015; Meize-Grochowski et al., 2015; Teixeira, 2010; Ljotsson, Falk, et al., 2010). Within 12 weeks, pain was significantly reduced in only one of these five programs, and the effect of the programs in the pooled analysis was close to zero and not statistically significant (SMD 0.01; CI -0.50, 0.52; 5 RCTs; I² 62.9%) (Ljotsson, Falk, et al., 2010). Removing poor quality studies

from analysis increased the estimate of the effect but did not change its nonsignificance (SMD 0.06; CI -1.15, 1.27; 3 RCTs; I² 80%). A meta-regression showed that changes in pain outcomes with remote treatment did not differ significantly from in-person mindfulness meditation (p=0.14).

We did not identify any head-to-head trials comparing different meditation interventions.

KQ 1b: Does the Effect Vary by Medical Condition Targeted (Migraine, Headache, Back Pain, Osteoarthritis, or Neuralgic Pain)?

Migraine or Other Headache

Five RCTs reported continuous outcomes measuring the effect of mindfulness meditation on participants with chronic pain from migraine or headache (Cathcart et al., 2014; Day et al., 2014; Dowd et al., 2015; Omidi and Zargar, 2014; Wells et al., 2014) (see Figure 3.10). Two of these studies (Omidi and Zargar, 2014; Wells et al., 2014) showed a significant positive effect after up to 12 weeks of intervention, but these results were not significant in the pooled analysis (SMD 0.38; CI –0.41, 1.17; 5 RCTs; I² 80.6%). Considerable heterogeneity was detected. Removing one poor quality study reduced the estimated effect but did not make it significant (SMD 0.08; CI –0.61, 0.77; 4 RCTs; I² 43.5%). Results from a meta-regression confirmed that participants with chronic migraines or headaches did not benefit from mindfulness meditation more than those with other conditions (p=0.52).




Figure 3.10. Mindfulness Meditation for Migraine or Headache

Pain - Migraine/Headache, 0-12 Weeks Follow-Up

Back Pain

Four RCTs investigated the effect of mindfulness meditation on participants with chronic back pain (Dowd et al., 2015; Esmer et al., 2010; Morone et al., 2009; Morone, Greco, and Weiner, 2008) (see Figure 3.11). Two of these four studies showed a positive effect after up to 12 weeks of intervention, neither of which was statistically significant (Esmer et al., 2010; Morone, Greco, and Weiner, 2008). The pooled analysis did show a very small effect favoring the comparator, which was not statistically significant (SMD -0.04; CI -0.39, 0.32; 4 RCTs; I² 0%). No heterogeneity was detected. A pooled analysis without poor quality studies showed roughly the same effect with a larger confidence interval (SMD -0.07; CI -2.46, 2.32; 2 RCTs; I² 19.1%). Participants suffering from back pain did not differentially benefit from mindfulness meditation, according to results from a meta-regression (p=0.41).




Figure 3.11. Mindfulness Meditation for Back Pain

Fibromyalgia

Eight RCTs examined the effect of mindfulness meditation on chronic pain due to fibromyalgia (Astin et al., 2003; Brown and Jones, 2013; Cash et al., 2015; Davis and Zautra, 2013; Dowd et al., 2015; Garland et al., 2014; Parra-Delgado and Latorre-Postigo, 2013; Schmidt et al., 2011) (see Figure 3.12). In five of these eight, meditation reduced pain (Brown and Jones, 2013; Cash et al., 2015; Garland et al., 2014; Parra-Delgado and Latorre-Postigo, 2013; Schmidt et al., 2011), but the results were statistically significant in one study (Garland et al., 2014). The effect was not significant in the pooled analysis (SMD 0.13; CI –0.12, 0.37; 8 RCTs; I² 45.3%). Even with the removal of two poor quality studies, this effect remained nonsignificant (SMD 0.14; CI –0.19, 0.48; 6 RCTs; I² 58.8%). A meta-regression revealed that participants with fibromyalgia did not receive more benefit from mindfulness meditation than participants with other conditions (p=0.29).




Figure 3.12. Mindfulness Meditation for Fibromyalgia

Pain - Fibromyalgia, 0-12 Weeks Follow-Up

KQ 1c: Does the Effect Differ When the Intervention Is Offered as an Adjunctive Therapy Rather Than as a Monotherapy?

Mindfulness meditation was adjunctive to treatment as usual in 13 RCTs (Day et al., 2014; Esmer et al., 2010; Garland et al., 2014; la Cour and Petersen, 2015; Meize-Grochowski et al., 2015; Morone et al., 2009; Wells et al., 2014; Parra-Delgado and Latorre-Postigo, 2013; Rahmani and Talepasand, 2015; Fjorback et al., 2013; Gaylord et al., 2011; Wong et al., 2011; and Fogarty et al., 2015). In one study, meditation was combined with group conscious yoga (Rahmani and Talepasand, 2015). In 13 studies, meditation was given as a monotherapy (Astin et al., 2003; Brown and Jones, 2013; Cash et al., 2015; Cathcart et al., 2014; Dowd et al., 2015; Davis and Zautra, 2013; Morone, Greco, and Weiner, 2008; Omidi and Zargar, 2014; Plews-Ogan et al., 2005; Schmidt et al., 2011; Teixeira, 2010; Zautra et al., 2008; Ljotsson, Falk, et al., 2010). In two studies, the treatment status was unclear (Zautra et al., 2008; Ljotsson, Hedman, et al., 2011). While the efficacy of meditation may vary by its combination with other interventions, no systematic difference in effect between monotherapy and adjunctive therapy was detected in a meta-regression (p=0.53).

KQ 1d: Does the Effect Vary Depending on the Duration and Frequency of Mindfulness Meditation (i.e., Dose Effect)?

The efficacy of meditation did not significantly vary by length or frequency of the intervention.

Interventions ranged in length from three to 12 weeks (median eight weeks). In a metaregression, efficacy did not vary significantly as program duration in weeks increased (p=0.12).

In subgroup analyses, the effect was not significant when participation in mindfulness intervention (including homework) was less than one hour per week (SMD -0.18; CI -0.49, 0.10; 3 RCTs; I² 0%) (Dowd et al., 2015; Davis and Zautra, 2013; Teixeira, 2010), or one to four hours per week (SMD 0.44; CI -0.16, 1.05; 10 RCTs; I² 77.5%) (Astin et al., 2003; Brown and Jones, 2013; Garland et al., 2014; Meize-Grochowski et al., 2015; Omidi and Zargar, 2014; Plews-Ogan et al., 2005; Zautra et al., 2008; Parra-Delgado and Latorre-Postigo, 2013; Rahmani and Talepasand, 2015; Fjorback et al., 2013). The effect for programs involving greater than four hours per week (high frequency) bordered on statistical significance (SMD 0.19; CI 0.00, 0.39; 11 RCTs; I² 4.5%), but the confidence intervals were within those for programs requiring one to four hours (medium frequency) of participation (Cash et al., 2015; Cathcart et al., 2014; Day et al., 2014; Esmer et al., 2010; la Cour and Petersen, 2015; Morone, Greco, and Weiner, 2008; Morone et al., 2009; Schmidt et al., 2011; Wells et al., 2014; Gaylord et al., 2011). In a meta-regression, participation of one to four hours per week (p=0.32) or less than one hour per week. (p=0.17) was not significantly less effective than participation of more than four hours per week.

Summary of Findings

In this chapter, we first summarize the findings in response to each key question and subquestion, along with the quality of the evidence (see Table 4.1). We briefly discuss the findings in the context of prior systematic reviews. We then describe the limitations of the body of literature and provide suggestions for further research based on those limitations.

In total, 28 studies met inclusion criteria. All reported on the efficacy of mindfulness meditation, and three addressed safety. Risk of bias in included studies varied; seven studies obtained a "good" quality rating, ten studies were rated "fair," and 11 were rated "poor" quality.

KQ 1: What Are the Efficacy and Safety of Mindfulness Meditation Interventions, as an Adjunctive or Monotherapy, for Adults with Chronic Pain Due to Migraine, Headache, Back Pain, Osteoarthritis, or Neuralgic Pain Compared with Treatment as Usual, Waitlists, No Treatment, or Other Active Treatments?

We identified 24 RCTs that met the inclusion criteria and reported continuous pain measures on the efficacy of mindfulness meditation for chronic pain (SMD 0.26; CI 0.06, 0.46; 24 RCTs; I^2 62.1%). (Four studies were excluded from analyses because they did not report appropriate outcome data for meta-analysis.) Study quality was mixed. A sensitivity analysis excluding poor quality studies yielded similar results (SMD 0.21; CI 0.00, 0.42; 15 RCTs; I^2 57.2%). This effect remained up to 12 weeks postintervention (SMD 0.27; CI 0.04, 0.50; 24 RCTs; I^2 64.6%), but dropped out of significance for follow-up periods beyond 12 weeks (SMD 0.37; C -0.01, 0.74; 11 RCTs, I^2 74.7%). These analyses detected substantial heterogeneity. The quality of evidence that mindfulness meditation is associated with a decrease in chronic pain compared with control is low overall and for short-term follow-up because of the quality of the included studies and heterogeneity. The quality of evidence for long-term follow-up is low because of the quality of the included studies, heterogeneity, and imprecision of results.

In subgroup analyses of comparators, mindfulness meditation significantly reduced pain scale scores compared with TAU (SMD 0.45; CI 0.02, 0.88; 7 RCTs; I^2 51.5%), but not compared with passive controls (SMD 0.28; CI –0.46, 1.02; 8 RCTs; I^2 76.5%) or with education or support groups (SMD 0.19; CI –0.11, 0.49; 8 RCTs; I^2 63.9%). The quality of evidence is low for the first two comparisons and very low for the third because of the quality of the included studies, heterogeneity, and imprecision of results.

A number of the studies reported non-pain outcomes. Ten studies assessed the effect of mindfulness meditation on depression in chronic pain studies; pooled analyses showed that mindfulness meditation significantly reduced depression (SMD 0.17; CI 0.03, 0.31; 10 RCTs; I²

0%). The quality of evidence is high. Twelve studies assessed physical health-related quality of life (SMD 0.3; CI 0.03, 0.57; 12 RCTs; I^2 54.6%), and 13 assessed mental health-related quality of life (SMD 0.44; CI 0.18, 0.69; 13 RCTs; I^2 50.6%). The quality of evidence regarding the efficacy of mindfulness meditation for quality of life is moderate because of imprecise results. Three studies reported poolable disability measures; improvements in the mindfulness groups were not significantly different from improvements in the control groups (SMD 0.47; CI –0.18, 1.12; I^2 0). Only one study assessed the effect of meditation on the reduction of analgesic use; effects were significant in favor of the mindfulness intervention (p<0.001).

Of the three RCTs reporting adverse events, two stated that participants had no adverse events, and one stated that two participants experienced feelings of anxiety and anger toward their pain. The quality of evidence for adverse events is very low, as the vast majority of the 28 included RCTs did not collect adverse events data.

KQ 1a: Does the Effect Vary by the Type of Mindfulness Meditation Intervention?

The effect of meditation on pain was nonsignificant in pooled analysis of 15 RCTs examining MBSR (SMD 0.32; CI –0.06, 0.70; 15 RCTs; I² 69.8%); the quality of evidence is low because of the poor quality of the studies and imprecision of the results. Four RCTs examined MBCT (SMD 0.16; CI –0.45, 0.76; 4 RCTs; I² 63.6%) and five examined remote (e.g., Internet, smart phone) interventions (SMD 0.01; CI –0.50, 0.52; 5 RCTs; I² 62.9%). The quality of evidence for both comparisons is low because of inconsistency and imprecision of study results. Meta-regression did not indicate that the efficacy of mindfulness meditation differs significantly by type of intervention.

KQ 1b: Does the Effect Vary by Medical Condition Targeted (Migraine, Headache, Back Pain, Osteoarthritis, or Neuralgic Pain)?

Five studies assessed the effect of mindfulness meditation for chronic pain caused by migraine or headache. Pooled analyses showed no significant effect (SMD 0.38; CI –0.41, 1.17; 5 RCTs; I² 80.6%). The quality of evidence is low because of inconsistent and imprecise results.

Four studies assessed the effect of mindfulness meditation for chronic back pain, and pooled analysis showed no significant effect (SMD -0.04; CI -0.39, 0.32; 4 RCTs; I² 0%). The quality of evidence is low for no effect because of the quality of the individual studies. Eight studies assessed the effect of mindfulness meditation on chronic pain due to fibromyalgia, and pooled analysis showed no significant effect (SMD 0.13; CI -0.12, 0.37; 8 RCTs; I² 45.3%). The quality of evidence is moderate because of the heterogeneity of the results. Meta-regressions showed that the effect of mindfulness meditation did not vary by medical condition.

KQ 1c: Does the Effect Differ When the Intervention Is Offered as an Adjunctive Therapy Rather Than as a Monotherapy?

Thirteen studies assessed the effect of mindfulness meditation for chronic pain as monotherapy. The effect was not significant (SMD 0.21; CI –0.02, 0.45; 13 RCTs; I² 55%) and the quality of evidence is low because of the heterogeneity of the results. Eleven studies assessed the effect of mindfulness meditation as an adjunctive therapy. The effect on chronic pain was not significant (SMD 0.36; CI –0.16, 0.89; 11 RCTs; I² 73.5%) and the quality of evidence is low because of heterogeneity and imprecision of results. A meta-regression showed that effect of meditation on pain did not differ significantly when offered as a monotherapy compared with as an adjunctive treatment.

KQ 1d: Does the Effect Vary Depending on the Duration and Frequency of Mindfulness Meditation (i.e., Dose Effect)?

Meta-regression indicated that the efficacy of mindfulness meditation did not differ significantly by frequency or duration of the treatment. The effect was not significant at a dose of less than one hour per week (SMD -0.18; CI -0.49, 0.10; 3 RCTs; I² 0%) or at a dose of one to four hours per week (SMD 0.44; CI -0.16, 1.05; 10 RCTs; I² 77.5%). The quality of the evidence for these two categories of frequency of practice was low, because of the quality of the individual studies and imprecision. The effect for programs requiring greater than four hours per week bordered on statistical significance (SMD 0.19; CI 0.00, 0.39; 11 RCTs; I² 4.5%), but the confidence intervals fit within those of the results for programs requiring one to four hours of participation. The quality of the evidence for the high frequency of participation was moderate because of the quality of the individual studies.

Table 4.1. Summ	nary of Findings	and Quality o	f Evidence Table
-----------------	------------------	---------------	------------------

Outcome	Study Design (number of RCTs and participants	Findings (direction and magnitude of effect)	Study Limitations (study quality; risk of bias)	Inconsistency	Indirectness	Imprecision	GRADE of Evidence for Outcome
KQ 1		· · · · · ·		<u> </u>			•
Longest follow-up	24 RCTs, 1,456 participants	SMD 0.26 (CI 0.06, 0.46), favors mindfulness meditation	Majority good or fair quality; effect similar when poor quality RCTs excluded	Inconsistent; substantial heterogeneity	Direct	Precise	Low
0–12 weeks follow-up	24 RCTs, 1,456 participants	SMD 0.27 (Cl 0.04, 0.50), favors mindfulness meditation	Majority good or fair quality; effect similar when poor quality RCTs excluded; possible publication bias	Inconsistent; substantial heterogeneity	Direct	Precise	Low
>12 weeks follow-up	11 RCTs, 848 participants	SMD 0.37 (CI −0.01, 0.74), n.s.	Majority good or fair quality; effect similar when poor quality RCTs excluded	Inconsistent; substantial heterogeneity	Direct	Imprecise	Low
Mindfulness meditation versus TAU, 0–12 weeks	7 RCTs, 296 participants	SMD 0.45 (Cl 0.02, 0.88), favors mindfulness meditation	Majority poor quality	Consistent; moderate heterogeneity	Direct	Imprecise	Low
Mindfulness meditation versus passive comparator, 0–12 weeks		SMD 0.28 (CI −0.46, 1.02), n.s.	Majority fair quality; no good quality; effect similar when poor quality RCTs excluded	Consistent regarding significant no effect; substantial heterogeneity	Direct	Imprecise	Low for no effect
Mindfulness meditation versus education or support groups, 0–12 weeks	8 RCTs, 665 participants	SMD 0.19 (CI −0.11, 0.49), n.s.	Majority good or fair quality; effect similar when poor quality RCTs excluded	Inconsistent; substantial heterogeneity	Direct	Imprecise	Very low for no effect
MBSR versus massage	1 RCT, 23 participants	SMD -0.30 (CI -1.34, 0.74), n.s.	Poor quality	No replication	Direct	Imprecise	Very low for no effect
MBSR versus relaxation training	1 RCT, 168 participants	SMD 0.08 (CI −0.30, 0.45), n.s.	Fair quality	No replication	Direct	Imprecise	Very low for no effect
Mindfulness meditation versus cognitive-based therapy	1 RCT, 137 participants	SMD 0.56 (CI 0.16, 0.96), favors mindfulness meditation	Good quality	No replication	Direct	Imprecise	Very low

Outcome	Study Design (number of RCTs and participants	Findings (direction and magnitude of effect)	Study Limitations (study quality; risk of bias)	Inconsistency	Indirectness	Imprecision	GRADE of Evidence for Outcome
Mindfulness meditation	1 RCT,	SMD 0.08 (CI -0.30,	Poor quality	No replication	Direct	Imprecise	Very low for
versus nutritional program Depression	20 participants 10 RCTs, 801 participants	045), n.s. SMD 0.17 (CI 0.03, 0.31), favors mindfulness meditation	Majority good or fair quality; effect similar when poor quality RCTs excluded	Consistent; no heterogeneity	Direct	Precise	no effect High
Physical health-related quality of life	12 RCTs, 841 participants	SMD 0.30 (CI 0.03, 0.57), favors mindfulness meditation	Majority good or fair quality; effect similar when poor quality RCTs excluded	Consistent; moderate heterogeneity	Direct	Imprecise	Moderate
Mental health-related quality of life	13 RCTs, 855 participants	SMD 0.44 (Cl 0.18, 0.69), favors mindfulness meditation	Majority good or fair quality; effect similar when poor quality RCTs excluded	Consistent; moderate heterogeneity	Direct	Imprecise	Moderate
Functional impairment/disability measures	3 RCTs, 143 participants	SMD 0.47 (CI −0.18, 1.12), n.s.	1 poor, 1 fair, 1 good quality RCT	Inconsistent, no heterogeneity	Direct	Imprecise	Very low
KQ 1a							•
MBSR, pain 0–12 weeks	15 RCTs, 845 participants	SMD 0.32 (CI -0.06, 0.70), n.s.	Majority poor quality	Consistent; substantial heterogeneity	Direct	Imprecise	Low for no effect
MBCT, pain 0–12 weeks	4 RCTs, 272 participants	SMD 0.16 (CI −0.45, 0.76), n.s.	All good or fair quality	Inconsistent; substantial heterogeneity	Direct	Imprecise	Low for no effect
Meta-regression result, intervention type and pain outcome	24 RCTs, 1,456 participants	Meta-regression did not suggest differences among intervention types (MBSR p=0.60; MBCT p=0.58; remote versus other interventions p=0.14)	Mixed quality	Not applicable	Indirect	Not applicable	Very low
KQ 1b							
Migraine/headache	5 RCTs, 281 participants	SMD 0.38 (CI -0.42, 1.17), n.s.	Majority fair quality; no good quality; effect consistent when poor quality RCTs excluded	Inconsistent; considerable heterogeneity	Direct	Imprecise	Low for no effect

Outcome	Study Design (number of RCTs and participants	Findings (direction and magnitude of effect)	Study Limitations (study quality; risk of bias)	Inconsistency	Indirectness	Imprecision	GRADE of Evidence for Outcome
Back pain	4 RCTs, 221 participants	SMD -0.04 (CI -0.39, 0.32), n.s. SMD 0.07 (CI -0.15, 0.29), n.s.	Equally fair and poor quality; no good quality; consistent when poor quality RCTs excluded	Consistent; no heterogeneity	Direct	Precise	Low for no effect
Fibromyalgia	8 RCTs, 642 participants	SMD 0.13 (CI -0.12, 0.37), n.s.	Majority good or fair quality; consistent when poor quality RCTs excluded	Consistent; moderate heterogeneity	Direct	Precise	Moderate for no effect
Meta-regression result, source of pain and pain outcome	24 RCTs, 1,456 participants	Meta-regressions did not suggest differences between headache and other conditions (p=0.52), back pain and other conditions (p=0.41), and fibromyalgia and other conditions (p=0.29)	Mixed quality	Not applicable	Indirect	Not applicable	Very low
KQ 1c			•				
Meta-regression result, monotherapy or adjunctive therapy, pain outcome	24 RCTs, 1,456 participants	Meta-regression did not suggest differences between monotherapy and adjunctive therapy (p=0.53)	Mixed quality	Not applicable	Indirect	Not applicable	Very low
KQ 1d	1	T	1	-1	r	1	1
Meta-regression result, duration of treatment and pain outcome	24 RCTs, 1,456 participants	Meta-regression did not suggest differences by duration (p=0.12)		Not applicable	Indirect	Not applicable	Very low
Meta-regression result, frequency of participation and pain outcome	24 RCTs, 1,456 participants	Meta-regression did not suggest differences by frequency (p=0.17)	Mixed quality	Not applicable	Indirect	Not applicable	Very low

NOTE: n.s. = not significant.

Other Reviews in this Area

Numerous systematic reviews on the effects of mindfulness meditation have been published in recent years. Of those that report pain outcomes, several have focused on specific types of pain, such as low back pain (Cramer et al., 2012), fibromyalgia (Lauche et al., 2013), or somatization disorder (Lakhan and Schofield, 2013). Others were not limited to RCTs (Merkes, 2010; Reiner, Tibi, and Lipsitz, 2013). This section focuses on the most recent comprehensive reviews of controlled trials of mindfulness interventions for chronic pain regardless of etiology (Bawa et al., 2015; Chiesa and Serretti, 2011). Despite identifying more than twice as many RCTs as each previous systematic review on this topic, our findings are quite similar.

Chiesa and Serretti (2011) reviewed MBSR and similar mindfulness interventions for chronic pain and depressive symptoms in ten studies (six RCTs, four controlled studies) on fibromyalgia; musculoskeletal pain, such as low back pain; and rheumatoid arthritis. Results demonstrated that interventions could have nonspecific effects related to expectation of a benefit or group support for pain and depressive symptoms, while only limited evidence suggested specific effects of such interventions. Chiesa and Serretti concluded that there is not yet sufficient evidence to determine the magnitude of the effects of mindfulness-based interventions for patients with chronic pain because of methodological issues. In the current review, we included four of the ten studies from Chiesa's review (Astin et al., 2003; Morone, Greco, and Weiner, 2008; Plews-Ogan et al., 2005; Zautra et al., 2008). Four studies were excluded because of no randomization, and two excluded because they did not report pain outcomes.

Lee, Crawford, and Hickey (2014) reviewed MBSR and related mindfulness interventions for back pain, fibromyalgia, musculoskeletal pain, diabetic neuropathy, and unspecified chronic pain in 11 RCTs of mixed methodological quality. The authors report a moderate level of confidence for a small effect of meditation on chronic pain from the five included studies that reported effect sizes. However, they concluded that higher-quality research is necessary to estimate an effect with more confidence. In the current review, we included eight of these 11 studies (Morone, Greco, and Weiner, 2008; Morone et al., 2009; Wong et al., 2011; Wong, 2009; Schmidt et al., 2011; Esmer et al., 2010; Plews-Ogan et al., 2005; Teixeira, 2010). Three studies were excluded for interventions that did not meet our definition of mindfulness meditation; these studied affective self-awareness, the Alexander technique, and loving-kindness meditation.

Bawa and colleagues (Bawa et al., 2015), the most recent review on MBSR and MBCT for chronic pain, included 11 controlled trials of mixed methodological quality on fibromyalgia, rheumatoid arthritis, chronic musculoskeletal pain, failed back surgery syndrome, and mixed etiology. Meta-analysis results yielded small effect sizes for pain, health-related quality of life (physical and mental), and functional status, while affective outcomes, such as pain acceptance, yielded larger effect sizes. The authors concluded that there is limited evidence for efficacy of mindfulness-based interventions for patients with chronic pain and that better-quality studies are required. Of the 11 studies in the Bawa review, we included eight in the current review (Astin et

al., 2003; Brown and Jones, 2013; Esmer et al., 2010; Morone et al., 2009; Plews-Ogan et al., 2005; Schmidt et al., 2011; Wong et al., 2011; Zautra et al., 2008). Two RCTs were excluded because they did not collect outcomes on pain, and another study was excluded due to lack of randomization. Appendix D displays references for the studies included by Bawa, along with their inclusion and exclusion status in the current review.

Two of these prior systematic reviews (Chiesa and Serretti, 2011; Bawa et al., 2015) did not mention adverse events; the third (Lee, Crawford, and Hickey, 2014) noted that two included trials reported that no adverse events occurred.

Our review yielded similar results in that we found low quality evidence that mindfulness meditation is associated with a decrease in chronic pain compared with control. Intervention participants reported significantly lower pain scale scores in the 24 RCTs that reported continuous outcomes; a sensitivity analysis excluding poor quality studies yielded similar results. This effect remained up to 12 weeks postintervention but was no longer statistically significant for follow-up periods beyond 12 weeks. Further, the efficacy of mindfulness meditation did not differ significantly by type of intervention (MBSR, MBCT, other). In subgroup analyses of comparators, mindfulness meditation significantly reduced pain scale scores compared with TAU, but not compared with passive controls or with education or support groups. In terms of non-pain outcomes, mindfulness meditation significantly improved depression, physical health-related quality of life, and mental health-related quality of life.

Strengths and Limitations

This review has several methodological strengths: an a priori research design, duplicate study selection and data abstraction of study information, a comprehensive search of electronic databases, risk of bias assessments, and comprehensive quality of evidence assessments used to formulate review conclusions. One limitation is that we did not contact individual study authors; results reported in the review are based on published data. We excluded the nine conference abstracts identified, because abstracts do not contain enough data to evaluate study quality. In addition, we included only studies published in English.

The included studies had many limitations. Eleven of the 28 studies were rated as poor quality, primarily due to lack of ITT analysis, poor follow-up, or poor reporting of methods. Although mindfulness meditation showed significant improvements in pain compared with control in a meta-analysis of 24 studies, the treatment effect estimate showed significant heterogeneity. In subgroup analyses, mindfulness meditation significantly reduced pain scale scores compared with treatment as usual, but not compared with passive controls or with education or support groups. Additional sensitivity analyses and meta-regression did not identify systematic sources of differences between studies. Because of the small number of trials included in the subgroup analyses, as well as the small sample sizes and heterogeneity of these trials, it is not surprising that the meta-analyses and meta-regressions are often nonsignificant. The authors

of seven studies reported inadequate statistical power to detect differences in pain outcomes between mindfulness meditation and the comparator; those authors considered these pilot studies. Eight other studies did not report a power calculation. Sample sizes were small; 12 studies randomized fewer than 50 participants.

Only one RCT attributed adverse events to mindfulness meditation (two participants experienced greater anxiety, and two experienced strong feelings of anger toward their pain condition). However, only three of the 28 included RCTs mentioned whether adverse event data were collected. Thus, quality of evidence for adverse events reported in RCTs is very low.

Implications for Future Research and Practice

Similar to previous reviews in this area, we conclude that the weaknesses in the body of evidence prevent any strong conclusions about mindfulness meditation for chronic pain. The available evidence did not yield consistent effects for pain outcomes, and few studies were available for many specific causes of pain or forms of mindfulness meditation other than MBSR. Quality of evidence for the efficacy of mindfulness interventions in reducing chronic pain is low. There was higher quality evidence of the efficacy of mindfulness meditation on quality of life outcomes (both physical and mental health, as well as depression). This review is consistent with previous reviews concluding that more well-designed, rigorous, and large RCTs are needed in order to develop an evidence base that can more decisively provide estimates of the efficacy of mindfulness meditation for chronic pain.

Very few RCTs collected information on adverse events. Given published reports of adverse events during meditation, including psychosis (Kuijpers et al., 2007), we strongly suggest that future trials actively collect adverse event data. In addition, a systematic review of observational studies and case reports would shed additional light on adverse events during mindfulness meditation.

Committees charged with updating the Department of Veterans Affairs and Department of Defense clinical practice guidelines for treating chronic pain may use this report as a source of evidence on mindfulness meditation. Unfortunately, we identified no RCTs that focused on active military or veteran populations; future RCTs incorporating military-related eligibility criteria could provide evidence more applicable to pain resulting from military service and evidence for use by decisionmakers in military and veteran health systems.

Further research examining the effect of mindfulness meditation on chronic pain also should focus on better understanding whether there is a minimum frequency or duration of meditation practice for it to be effective. Future trials should monitor adherence (meditation practice) both during the intervention program and after the program ends if long-term results are to be assessed.

TIME PERIOD COVERED:

Since inception to June 2015

SEARCH STRATEGY:

"Mindfulness" [Mesh]) OR "Meditation" [Mesh] OR mindfulness* or mindfulness-based or mbsr or mbct or m-bct or meditation or meditat* OR Vipassana or satipatthāna OR anapanasati OR Zen OR Pranayama OR Sudarshan OR Kriya OR zazen OR shambhala OR buddhis* AND

Pain[MH] OR pain*[tiab] OR headache disorders[mh] OR headache* or head ache* or headache* or migraine* OR cephalalgi* OR neuralgi* OR osteoarthritis OR arthrosis OR backache* OR back ache* OR back-ache* OR Neuralgia OR neuropathic pain OR neuropathy OR radiculopathy OR, complex regional pain syndrome* OR CPRS OR causalgia OR herpetic neuralgia OR sciatic* OR cervicalgi*

AND

systematic[sb] OR systematic review* OR random* OR rct* OR randomized controlled trial*[pt] OR "Randomized Controlled Trial" [Publication Type] OR "Randomized Controlled Trials as Topic"[Mesh] OR meta-analy* OR metaanaly* OR meta analy*

LANGUAGE:

English

Reason Excluded: Background

Blodt, S., D. Pach, S. Roll, and C. M. Witt, "Effectiveness of App-Based Relaxation for Patients with Chronic Low Back Pain (Relaxback) and Chronic Neck Pain (Relaxneck): Study Protocol for Two Randomized Pragmatic Trials," *Trials*, Vol. 15, 2014, p. 490.

Reason Excluded: Off Topic (Not Mindfulness or Chronic Pain)

- Arefnasab, Z., M. Ghanei, A. A. Noorbala, A. Alipour, F. Babamahmoodi, A. Babamahmoodi, and M. Salehi, "Effect of Mindfulness Based Stress Reduction on Quality of Life (SF-36) and Spirometry Parameters, in Chemically Pulmonary Injured Veterans," *Iranian Journal of Public Health*, Vol. 42, No. 9, September 2013, pp. 1026–1033.
- Dion, L. J., D. J. Engen, V. Lemaine, D. K. Lawson, C. G. Brock, B. S. Thomley, S. S. Cha, A. Sood, B. A. Bauer, and D. L. Wahner-Roedler, "Massage Therapy Alone and in Combination with Meditation for Breast Cancer Patients Undergoing Autologous Tissue Reconstruction: A Randomized Pilot Study," *Complementary Therapies in Clinical Practice*, May 12, 2015.
- Fernros, Lotta, Anna-Karin Furhoff, and Per E. Wändell, "Improving Quality of Life Using Compound Mind-Body Therapies: Evaluation of a Course Intervention with Body Movement and Breath Therapy, Guided Imagery, Chakra Experiencing and Mindfulness Meditation," *Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation*, Vol. 17, No. 3, April 2008, pp. 367–376.
- Grossman, P., L. Kappos, H. Gensicke, M. D'Souza, D. C. Mohr, I. K. Penner, and C. Steiner, "MS Quality of Life, Depression, and Fatigue Improve After Mindfulness Training: A Randomized Trial," *Neurology*, Vol. 75, No. 13, September 28, 2010, pp. 1141–1149.
- Hosseinzadeh Asl, N. R., and F. Hosseinalipour, "Effectiveness of Mindfulness-Based Stress Reduction Intervention for Health-Related Quality of Life in Drug-Dependent Males," *Iranian Red Crescent Medical Journal*, Vol. 16, No. 9, September, 2014, p. e12608.
- Hucker, A., and M. P. McCabe, "Incorporating Mindfulness and Chat Groups into an Online Cognitive Behavioral Therapy for Mixed Female Sexual Problems," *Journal of Sex Research*, April 17, 2014, pp. 1–13.
- Lengacher, C. A., V. Johnson-Mallard, J. Post-White, M. S. Moscoso, P. B. Jacobsen, T. W. Klein, R. H. Widen, S. G. Fitzgerald, M. M. Shelton, M. Barta, M. Goodman, C. E. Cox, and K. E. Kip, "Randomized Controlled Trial of Mindfulness-Based Stress Reduction (MBSR)

for Survivors of Breast Cancer," *Psycho-Oncology*, Vol. 18, No. 12, December 2009, pp. 1261–1272.

- Mills, N., and J. Allen, "Mindfulness of Movement as a Coping Strategy in Multiple Sclerosis: A Pilot Study," *General Hospital Psychiatry*, Vol. 22, No. 6, November–December 2000, pp. 425–431.
- Pickut, B., and S. Vanneste, "Mindfulness Training Among Individuals with Parkinson's Disease: Neurobehavioral Effects," Vol. 2015, 2015, p. 816404.
- Price, C. J., B. McBride, L. Hyerle, and D. R. Kivlahan, "Mindful Awareness in Body-Oriented Therapy for Female Veterans with Post-Traumatic Stress Disorder Taking Prescription Analgesics for Chronic Pain: A Feasibility Study," *Alternative Therapies in Health and Medicine*, Vol. 13, No. 6, November–December 2007, pp. 32–40.

Reason Excluded: Outcome (Not Pain or Analgesic Use)

- Astin, J. A., "Stress Reduction Through Mindfulness Meditation: Effects on Psychological Symptomatology, Sense of Control, and Spiritual Experiences," *Psychotherapy and Psychosomatics*, Vol. 66, No. 2, 1997, pp. 97–106.
- Berrill, J. W., M. Sadlier, K. Hood, and J. T. Green, "Mindfulness-Based Therapy for Inflammatory Bowel Disease Patients with Functional Abdominal Symptoms or High Perceived Stress Levels," *Journal of Crohn's and Colitis*, Vol. 8, No. 9, September 2014, pp. 945–955.
- Bogosian, A., P. Chadwick, S. Windgassen, S. Norton, P. McCrone, I. Mosweu, E. Silber, and R. Moss-Morris, "Distress Improves After Mindfulness Training for Progressive MS: A Pilot Randomised Trial," *Multiple Sclerosis*, March 12, 2015.
- Clark, Paul G., Geronima Cortese-Jimenez, and Eric Cohen, "Effects of Reiki, Yoga, or Meditation on the Physical and Psychological Symptoms of Chemotherapy-Induced Peripheral Neuropathy: A Randomized Pilot Study," *Journal of Evidence-Based Complementary & Alternative Medicine*, Vol. 17, No. 3, October 2012, pp. 161–171.
- Duncan, L. G., J. T. Moskowitz, T. B. Neilands, S. E. Dilworth, F. M. Hecht, and M. O. Johnson, "Mindfulness-Based Stress Reduction for HIV Treatment Side Effects: A Randomized, Wait-List Controlled Trial," *Journal of Pain and Symptom Management*, Vol. 43, No. 2, 2012.
- Feuille, M., and K. Pargament, "Pain, Mindfulness, and Spirituality: A Randomized Controlled Trial Comparing Effects of Mindfulness and Relaxation on Pain-Related Outcomes in Migraineurs," *Journal of Health Psychology*, November 7, 2013.
- Fjorback, L. O., T. Carstensen, M. Arendt, E. Ornbol, H. Walach, E. Rehfeld, and P. Fink, "Mindfulness Therapy for Somatization Disorder and Functional Somatic Syndromes:

Analysis of Economic Consequences Alongside a Randomized Trial," *Journal of Psychosomatic Research*, Vol. 74, No. 1, January 2013, pp. 41–48.

- Garland, E. L., and M. O. Howard, "Mindfulness-Oriented Recovery Enhancement Reduces Pain Attentional Bias in Chronic Pain Patients," *Psychotherapy and Psychosomatics*, Vol. 82, No. 5, 2013, pp. 311–318.
- Ljotsson, B., G. Andersson, E. Andersson, E. Hedman, P. Lindfors, S. Andreewitch, C. Ruck, and N. Lindefors, "Acceptability, Effectiveness, and Cost-Effectiveness of Internet-Based Exposure Treatment for Irritable Bowel Syndrome in a Clinical Sample: A Randomized Controlled Trial," *BMC Gastroenterology*, Vol. 11, 2011, p. 110.
- McMillan, T. M., Ian H. Robertson, D. Brock, and L. Chorlton, "Brief Mindfulness Training for Attentional Problems After Traumatic Brain Injury: A Randomised Control Treatment Trial," *Neuropsychological Rehabilitation*, Vol. 12, No. 2, May 2002, pp. 117–125.
- Sagula, D. A., "Varying Treatment Duration in a Mindfulness Meditation Stress Reduction Program for Chronic Pain Patients," *Michigan State University*, Vol. 131, 1999.
- Wolever, R. Q., K. J. Bobinet, K. McCabe, E. R. Mackenzie, E. Fekete, C. A. Kusnick, and M. Baime, "Effective and Viable Mind-Body Stress Reduction in the Workplace: A Randomized Controlled Trial," *Journal of Occupational Health Psychology*, Vol. 17, No. 2, April 2012, pp. 246–258.
- Zernicke, K. A., T. S. Campbell, P. K. Blustein, T. S. Fung, J. A. Johnson, S. L. Bacon, and L. E. Carlson, "Mindfulness-Based Stress Reduction for the Treatment of Irritable Bowel Syndrome Symptoms: A Randomized Wait-List Controlled Trial," *International Journal of Behavioral Medicine*, Vol. 20, No. 3, September 2013, pp. 385–396.

Reason Excluded: Design (Not RCT)

- Brotto, Lori A., Rosemary Basson, Kelly B. Smith, Miriam Driscoll, and Leslie Sadownik, "Mindfulness-Based Group Therapy for Women with Provoked Vestibulodynia," *Mindfulness*, Vol. 6, No. 3, June 2015, pp. 417–432.
- Cusens, Bryany, Geoffrey B. Duggan, Kirsty Thorne, and Vidyamala Burch, "Evaluation of the Breathworks Mindfulness-Based Pain Management Programme: Effects on Well-Being and Multiple Measures of Mindfulness," *Clinical Psychology & Psychotherapy*, Vol. 17, No. 1, January–February 2010, pp. 63–78.
- Fjorback, L. O., "Mindfulness and Bodily Distress," *Danish Medical Journal*, Vol. 59, No. 11, November 2012, p. B4547.

- Gardner-Nix, Jacqueline, Stéphanie Backman, Julianna Barbati, and Jessica Grummitt, "Evaluating Distance Education of a Mindfulness-Based Meditation Programme for Chronic Pain Management," *Journal of Telemedicine and Telecare*, Vol. 14, No. 2, 2008, pp. 88–92.
- Gardner-Nix, Jacqueline, Julianna Barbati, Jessica Grummitt, Sara Pukal, and Rosa Raponi Newton, "Exploring the Effectiveness of a Mindfulness-Based Chronic Pain Management Course Delivered Simultaneously to On-Site and Off-Site Patients Using Telemedicine," *Mindfulness*, Vol. 5, No. 3, June 2014, pp. 223–231.
- Grossman, P., U. Tiefenthaler-Gilmer, A. Raysz, and U. Kesper, "Mindfulness Training as an Intervention for Fibromyalgia: Evidence of Postintervention and 3-Year Follow-Up Benefits in Well-Being," *Psychotherapy and Psychosomatics*, Vol. 76, No. 4, 2007, pp. 226–233.
- Heeren, Alexandre, Sandrine Deplus, Virginie Peschard, François Nef, Ilios Kotsou, Christophe Dierickx, Laurie Mondillon, Donald J. Robinaugh, and Pierre Philippot, "Does Change in Self-Reported Mindfulness Mediate the Clinical Benefits of Mindfulness Training? A Controlled Study Using the French Translation of the Five Facet Mindfulness Questionnaire," *Mindfulness*, Vol. 6, No. 3, June 2015, pp. 553–559.
- Igna, Raluca, Simona Ștefan, Ioan Onac, Ioana Onac, Rodica-Ana Ungur, and Aurora Szentagotai Tatar, "Mindfulness-Based Cognitive-Behavior Therapy (MCBT Versus Virtual Reality (VR) Enhanced CBT, Versus Treatment as Usual for Chronic Back Pain: A Clinical Trial," *Journal of Evidence-Based Psychotherapies*, Vol. 14, No. 2, September 2014, pp. 229–247.
- Jones, Kim Dupree, "A Mindful Future for Fibromyalgia? A Comment on Davis and Zautra," *Annals of Behavioral Medicine*, Vol. 46, No. 3, December 2013, 2013, pp. 253–255.
- Mawani, Al-Noor, "Reducing Chronic Pain Using Mindfulness Meditation: An Exploration of the Role of Spirituality," *Dissertation Abstracts International: Section B: The Sciences and Engineering*, Vol. 72, No. 4-B, 2011, p. 2442.
- Moura, Vera Lucia, Keturah R. Faurot, Susan A. Gaylord, J. Douglas Mann, Morgan Sill, Chanee Lynch, and Michael Y. Lee, "Mind-Body Interventions for Treatment of Phantom Limb Pain in Persons with Amputation," *American Journal of Physical Medicine and Rehabilitation*, Vol. 91, No. 8, 2012, pp. 701–714.

Reason Excluded: Reports on Study Already in Database

Cathcart, Stuart, Vanessa Barone, Maarten Immink, and Michael Proeve, "Mindfulness Training Does Not Reduce Generalized Hyperalgesia in Chronic Tension-Type Headache," *Journal of Pain Management*, Vol. 6, No. 3, July–September 2013, pp. 217–221.

- Davis, M. C., A. J. Zautra, L. D. Wolf, H. Tennen, and E. W. Yeung, "Mindfulness and Cognitive-Behavioral Interventions for Chronic Pain: Differential Effects on Daily Pain Reactivity and Stress Reactivity," *Journal of Consulting and Clinical Psychology*, Vol. 83, No. 1, February 2015, pp. 24–35.
- Garland, E. L., S. A. Gaylord, O. Palsson, K. Faurot, J. Douglas Mann, and W. E. Whitehead, "Therapeutic Mechanisms of a Mindfulness-Based Treatment for IBS: Effects on Visceral Sensitivity, Catastrophizing, and Affective Processing of Pain Sensations," *Journal of Behavioral Medicine*, Vol. 35, No. 6, December 2012, pp. 591–602.
- Garland, E. L., E. Thomas, and M. O. Howard, "Mindfulness-Oriented Recovery Enhancement Ameliorates the Impact of Pain on Self-Reported Psychological and Physical Function Among Opioid-Using Chronic Pain Patients," *Journal of Pain and Symptom Management*, Vol. 48, No. 6, December 2014, pp. 1091–1099.
- Garland, Eric L., Brett Froeliger, and Matthew O. Howard, "Effects of Mindfulness-Oriented Recovery Enhancement on Reward Responsiveness and Opioid Cue-Reactivity," *Psychopharmacology*, Vol. 231, No. 16, August 2014, pp. 3229–3238.

Reason Excluded: Conference Abstract

- Cour, P., M. C. Pedersen, and J. Hojsted, "Mindfulness and Chronic Pain: A Randomized, Controlled Study of Effect and Feasibility," *European Journal of Pain Supplements*, Vol. 5, No. 1, 2011.
- Fjorback, L., A. Schroder, E. Ornbol, E. Rehfeld, M. Arendt, and P. Fink, "Mindfulness Therapy for Bodily Distress Syndrome: A Randomized Controlled Trial," *Journal of Psychosomatic Research*, Vol. 70, No. 6, 2011.
- Heffner, K. L., N. L. Talbot, M. S. Krasner, and J. A. Moynihan, "Pain in Older Men Is Associated with Interleukin (IL)-6 Change Across Time Following a Mindfulness-Based Stress Reduction Intervention [Conference Abstract]," *Brain, Behavior, and Immunity* [Abstracts from the 18th Annual Meeting of the Psychoneuroimmunology Research Society— Psychoneuroimmunology Mechanisms of Disease: From Pathophysiology to Prevention and Treatment, PNIRS; 8–11 Jun 2011; Chicago, Illinois United States], 2011.
- Johns, S. A., L. F. Brown, K. Beck-Coon, P. O. Monahan, Y. Tong, K. Schmidt, and K. Kroenke, "Mindfulness-Based Stress Reduction for Breast Cancer Survivors with Fatigue and Related Symptoms: Outcomes from a Randomized Controlled Trial," *Psycho-Oncology*, Vol. 23, 2014.
- Meize-Grochowski, R., A. Prasad, C. Murray-Krezan, R. Schrader, M. DuVal, B. Smith, and C. Herman, "Mindfulness Meditation in Community Dwelling Older Adults with Postherpetic Neuralgia," *BMC Complementary and Alternative Medicine*, Vol. 12, 2012.

- Meize-Grochowski, Robin, "Meditation in Older Adults with Postherpetic Neuralgia," *Communicating Nursing Research*, Vol. 44, 2011, p. 404.
- Shennan, J., P. Thomas, W. Tuck, H. Conaglen, and J. Bell, "Mindfulness-Based Stress Reduction Programme for Chronic Pain: A Pilot Study [Abstract]," *New Zealand Medical Journal*, Vol. 122, No. 1292, 2009.
- Wells, R. E., R. Burch, R. Paulsen, P. Wayne, C. Aschenbrenner, T. T. Houle, J. C. Senach, and E. Loder, "Meditation for Migraines: A Pilot Randomized Controlled Trial," *Cephalalgia*, Vol. 33, 2013.
- Wright, C., J. Carson, K. Carson, R. Bennett, S. Mist, and K. Jones, "Yoga of Awareness: A Randomized Trial in Fibromyalgia: Post Intervention and 3 Month Follow Up Results," *BMC Complementary and Alternative Medicine*, Vol. 12, 2012.

Reason Excluded: Dissertation

- Day, Melissa A., "Mindfulness-Based Cognitive Therapy for the Treatment of Chronic Headache Pain," *Dissertation Abstracts International: Section B: The Sciences and Engineering*, Vol. 75, No. 1-B(E), 2014.
- Martin, Kathryn Leigh, "The Influence of Pain Avoidance on the Experience of Mindfulness Training," *Dissertation Abstracts International: Section B: The Sciences and Engineering*, Vol. 74, No. 1-B(E), 2013.
- Matchim, Yaowarat, "A Qualitative and Quantitative Study Examining Effects of Mindfulness-Based Stress Reduction (MBSR) on Physical and Psychological Well-Being Among Breast Cancer Survivors," *Dissertation Abstracts International: Section B: The Sciences and Engineering*, Vol. 73, No. 3-B, 2012, p. 1486.
- Nash-McFeron, Diane E., "Mindfulness in the Treatment of Chronic Headache Pain," *Dissertation Abstracts International: Section B: The Sciences and Engineering*, Vol. 67, No. 5-B, 2006, p. 2841.
- Nassif, Thomas Harttung, "Examining the Effectiveness of Mindfulness Meditation for Chronic Pain Management in Combat Veterans with Traumatic Brain Injury," *Dissertation Abstracts International: Section B: The Sciences and Engineering*, Vol. 75, No. 3-B(E), 2014.
- Rosdahl, D. R. L., "The Effect of Mindfulness Meditation on Tension Headaches and Secretory Immunoglobulin A in Saliva," *University of Arizona*, Vol. 399, 2003.
- Wong, Chi Ming, "Four-Step Mindfulness-Based Therapy for Chronic Pain: A Pilot Randomized Controlled Trial," *Dissertation Abstracts International: Section B: The Sciences and Engineering*, Vol. 72, No. 1-B, 2011, p. 562.

Reason Excluded: Intervention (Not Mindfulness Meditation)

- Sendhilkumar, R., A. Gupta, R. Nagarathna, and A. B. Taly, "Effect of Pranayama and Meditation as an Add-On Therapy in Rehabilitation of Patients with Guillain-Barre Syndrome: A Randomized Control Pilot Study," *Disability and Rehabilitation*, Vol. 35, No. 1, January 2013, pp. 57–62.
- Ussher, M., A. Spatz, C. Copland, A. Nicolaou, A. Cargill, N. Amini-Tabrizi, and L. M. McCracken, "Immediate Effects of a Brief Mindfulness-Based Body Scan on Patients with Chronic Pain," *Journal of Behavioral Medicine*, Vol. 37, No. 1, February 2014, pp. 127–134.
- Wachholtz, A. B., C. D. Malone, and K. I. Pargament, "Effect of Different Meditation Types on Migraine Headache Medication Use," *Behavioral Medicine*, April 11, 2015.
- Zangi, H. A., P. Mowinckel, A. Finset, L. R. Eriksson, T. O. Hoystad, A. K. Lunde, and K. B. Hagen, "A Mindfulness-Based Group Intervention to Reduce Psychological Distress and Fatigue in Patients with Inflammatory Rheumatic Joint Diseases: A Randomised Controlled Trial," *Annals of the Rheumatic Diseases*, Vol. 71, No. 6, June 2012, pp. 911–917.

Study Details	Participants	Intervention	Outcomes
Reference: Astin et al., 2003	Number of Patients: 128	Content of Intervention: Treatment was a combination of	Pain Measures:
		MBSR and Qigong. Each session focused first on the	SF-36 pain score, 14 weeks:
Location: United States or Canada	Medical Condition/Type of Pain: Fibromyalgia	mindfulness meditation aspects of MBSR and then the	SMD 0.02 (CI -0.47, 0.5)
		physical postures, breathing techniques, and focused	SF-36 pain score, 24 weeks:
Purpose: To test the short- and	Definition of Chronic Pain: 3 months minimum or	attention aspects of Qigong.	SMD -0.04 (CI -0.52, 0.45)
long-term benefits of an 8-week	"past normal time for tissue healing"		SF-36 pain score, 8 weeks:
mind-body intervention that		Setting: Unclear	SMD -0.05 (CI -0.54, 0.43)
combined training in mindfulness	Baseline Pain Score: SF-36 pain score		D . M
meditation with Qigong movement	Intervention Group: 32.3 (SD 14.4); Control Group:	Dosage, Duration: 1–4 hours spent in session, homework,	Depression Measures:
therapy for individuals with	31.4 (SD 16.7)	and other each week, for 8 weeks	BDI: SMD 0.15 (CI -0.35, 0.64)
fibromyalgia syndrome			
	Mean Age: 47.7 (SD 10.6)	Co-interventions: NA	Analgesic Use: No
Quality Rating: Poor	Gender (% Male): 0.7	Comparator: Education or support group	Adverse Events: No mention
		Comparator: Education or support group	Adverse Events. No mention
	Inclusion Criteria: Clinical diagnosis of fibromyalgia	Primary Endpoint: SF-36 pain score	
	syndrome by patient's own health care provider;		
	fulfillment of American College of Rheumatology	Power Calculation: Power insufficient (post hoc test by	
	classification criteria for fibromyalgia syndrome	authors)	
	verified by rheumatologic examination—widespread		
	pain (axial plus upper and lower segment plus left	Follow-Up Time: 24 weeks	
	and right side pain for 3 months, and tenderness at		
	11 of the 18 specific tender point sites; age between		
	18 and 70 years; able to read and speak English		
	fluently; able to attend group intervention session if		
	assigned to that group; and able to give informed		
	consent.		
	Exclusion Criteria: Pregnancy, substance abuse,		
	major psychiatric disorder (that would prevent		
	compliance), involvement in impending litigation or		
	judgment for disability workers' compensation, or		
	uncontrolled hypertension, diabetes, congestive		
	heart failure, or other severe chronic medical		
	conditions judged by the clinician to place the patient		
	at risk of possible severe consequences of his or her		
	disease.		

Study Details	Participants	Intervention	Outcomes
Reference: Brown and Jones,	Number of Patients: 40	Content of Intervention: The program teaches not to try to	Pain Measures:
2013		do anything about the underlying unpleasant sensation of	Laser Pain Unpleasantness:
	Medical Condition/Type of Pain: Fibromyalgia,	pain, but to train in mindfulness to lessen the reactive	SMD 0.24 (CI -0.51, 0.98)
Location: Europe	rheumatoid arthritis, other musculoskeletal	cycle that leads to physical and emotional stress. This is	
		done by teaching breath awareness, body awareness,	Analgesic Use: No
Purpose: To investigate whether	Definition of Chronic Pain: No definition	gentle movement, and how to manage pain, illness, and	
improvement in mental health		fatigue in daily life, as well as cultivating kindliness and	Mental Health-Related Quality
might require (1) reduction in the	Baseline Pain Score: Laser Pain Unpleasantness	compassion toward oneself and others.	of Life (QoL) Measure:
sensory pain experience and brain	Intervention Group: 5.4 (SD 2); Control Group: 5.9		SF-36 Mental Health:
correlates of that experience,	(SD 1.3)	Setting: Unclear	SMD 1.16 (CI 0.36, 1.96)
and/or (2) improved perceptions of			
the controllability of pain and	Mean Age Intervention: 48 (SD 10); Control: 45	Dosage, Duration: 1–4 hours spent in session, homework,	Physical Health-Related QoL
corresponding brain activity	(SD 12)	and other each week, for 8 weeks	Measure:
related to cognitive control and			SF-36 Physical Health:
emotional regulation	Gender (% Male): 25.5	Co-interventions: NA	SMD -0.42 (CI -1.17, 0.33)
Quality Rating: Poor	Inclusion Criteria: Right-handed patients with any	Comparator: TAU or standard of care	Adverse Events: No mention
	type of musculoskeletal pain.		
		Primary Endpoint: Laser Pain Unpleasantness	
	Exclusion Criteria: History of neurological,		
	psychiatric, or cardiovascular disease.	Power Calculation: Power insufficient (post hoc test by authors)	
		,	
		Follow-Up Time: 24 weeks	

Study Details	Participants	Intervention	Outcomes
Reference: Cash et al., 2015	Number of Patients: 91	Content of Intervention: Both formal and informal	Pain Measures:
		mindfulness practices were introduced, including	VAS, 16 weeks: SMD 0
Location: United States or Canada	Medical Condition/Type of Pain: Fibromyalgia	instruction/discussion, an attention-focusing technique	(CI -0.42, 0.41)
		(body scan, directing attention throughout the body in a	VAS, 8 weeks: SMD 0.32
Purpose: Randomized prospective	Definition of Chronic Pain: 3 months minimum or	relaxed, supine state), sitting meditation (systematically	(CI -0.1, 0.74)
trial of MBSR among female	"past normal time for tissue healing"	directing attention to breath and immediate sensory and	
fibromyalgia patients		cognitive experiences), and a series of simple yoga	Analgesic Use: No
	Baseline Pain Score: VAS	positions taught as a means of encouraging relaxed and	
Quality Rating: Fair	Intervention Group: 68.1 (SD 25.4); Control Group: 69.2 (SD 19.6)	focused movement	Adverse Events: No mention
		Setting: Unclear	
	Mean Age: Not reported		
		Dosage, Duration: >4 hours spent in session, homework,	
	Gender (% Male): 0	and other each week, for 8 weeks	
	Inclusion Criteria: Female fibromyalgia sufferers	Co-interventions: NA	
	aged 18 years and older who were able to attend a		
	weekly group and had a physician-verified diagnosis.	Comparator: Passive (e.g., waitlist, no treatment)	
	Exclusion Criteria: Severe mental illness.	Primary Endpoint: VAS	
		Power Calculation: Yes (sufficient power)	
		Follow-Up Time: 8 weeks	

Study Details	Participants	Intervention	Outcomes
Reference: Cathcart et al., 2014	Number of Patients: 58	Content of Intervention: The mindfulness-based therapy	Pain Measures:
		intervention, based on MBSR and MBCT, was conducted	Headache Intensity: SMD 0.08
Location: Australia	Medical Condition/Type of Pain: Other headache	over a 3-week period involving twice-weekly group	(CI -0.52, 0.69)
		classes and daily practice. The program, which included a	
Purpose: To conduct a pilot study	Definition of Chronic Pain: Other definition	particular focus on management of headache pain and	Analgesic Use: No
into the efficacy of brief		related psychosocial sequelae and of stress as a	
mindfulness-based therapy for	Baseline Pain Score: Headache Intensity	contributing factor to headache, was developed by some	Adverse Events: No mention
chronic tension-type headache	Intervention Group: 2.26 (SD 0.62); Control Group:	of the authors, who are psychologists with formal training	
Quality Dations Fair	2.51 (SD 0.82)	in mindfulness therapy (e.g., completion of MBSR and	
Quality Rating: Fair	Maan Anal Intervention: 45 70 (CD 42 40); Control:	MBCT training courses, and clinical experience in the	
	Mean Age: Intervention: 45.78 (SD 13.10); Control:	delivery of these), and extensive teaching, practice, and	
	45.26 (SD 14.18)	research experience in mindfulness-based meditation	
	Gender (% Male): 37.25	(e.g., university lecturing and research, clinical practice instruction).	
	Gender (70 Male). 57.25		
	Inclusion Criteria: Satisfying International Headache	Setting: Unclear	
	Society-II criteria for chronic tension-type headache,	Setting. Sheed	
	aged 18–65 years, not currently receiving (or having	Dosage, Duration: >4 hours spent in session, homework,	
	received in the past 12 months) intervention for	and other each week, for 3 weeks	
	headache, no psychiatric or major medical condition	,,,,	
	currently or in the past 12 months, and no other	Co-interventions: NA	
	headache, pain symptoms, or diagnoses in addition		
	to chronic tension-type headache, including	Comparator: Passive (e.g., waitlist, no treatment)	
	suspected or probable medication overuse		
	headache (i.e., medication use ten or more days per	Primary Endpoint: Headache Intensity	
	month, for three or more months).		
		Power Calculation: No	
	Exclusion Criteria: NA		
		Follow-Up Time: 8 weeks	

Study Details	Participants	Intervention	Outcomes
Reference: Davis and Zautra,	Number of Patients: 79	Content of Intervention: Mindful socioemotional	Pain Measures:
2013		regulation. Training focused on (1) the regulation of	Pain: SMD -0.24 (CI -0.69,
	Medical Condition/Type of Pain: Fibromyalgia	emotions via enhancing awareness and acceptance of	0.2)
Location: United States or Canada		the full range of emotion experiences via mindfulness	
	Definition of Chronic Pain: No definition	meditation, and (2) the use of mindful awareness skills to	Analgesic Use: No
Purpose: To compare the effects		make choices that build stronger social bonds, enhancing	
of a 12-module online intervention	Baseline Pain Score: Pain	a sense of belonging and increasing enjoyment of social	Adverse Events: No mention
targeting socioemotional	Intervention Group: 59.89 (SD 22.11); Control	relations.	
regulation via mindful	Group: 55.03 (SD 24.65)		
awareness/acceptance (mindful		Setting: Remote (e.g., telephone Internet app)	
socioemotional regulation) with	Mean Age: 46.14; range: 22–81		
those of an attention-control		Dosage, Duration: 1 hour or less spent in session,	
treatment and healthy lifestyle tips	Gender (% Male): 2	homework, and other each week, for 6 weeks	
Quality Rating: Fair	Inclusion Criteria: Being over 18 years of age, being	Co-interventions: NA	
	able to understand written and spoken English, reporting having received a diagnosis of fibromyalgia	Comparator: Health tips via the Internet	
	syndrome from a physician, and having daily access to the Internet.	Primary Endpoint: Pain	
	Exclusion Criteria: History of more than five past episodes of depression.	Power Calculation: Yes (sufficient power)	
		Follow-Up Time: 6 weeks	

Study Details	Participants	Intervention	Outcomes
Reference: Day et al., 2014	ParticipantsNumber of Patients: 36Medical Condition/Type of Pain: Migraine, other headacheDefinition of Chronic Pain: 3 months minimum or "past normal time for tissue healing"Baseline Pain Score: Brief Pain Index (BPI) Intensity Intervention Group: 3.59 (SD 1.74); Control Group: 3.37 (SD 2.03)Mean Age: 41.7 (SD 12.0)	Content of Intervention: The 8-week MBCT for headache pain manual was adapted from an existing 8-week MBCT for depression protocol. The adapted manual, developed by Day and Thorn, incorporated knowledge about the specific issues of relevance and importance to a headache pain population. The treatment development phase included piloting the manual and treatment approach within a group of patients with heterogeneous chronic pain conditions. Setting: Outpatient pain clinic Dosage, Duration: >4 hours spent in session, homework,	Outcomes Pain Measures: BPI Intensity: SMD -0.01 (CI -0.66, 0.65) Analgesic Use: No Adverse Events: No mention
	Gender (% Male): 11.1 Inclusion Criteria: 19 years of age or older; at least three pain days per month (for the past 3 months or longer) due to a primary headache pain type (i.e., migraine, tension-type headache, cluster, or other) as defined by the International Headache Society; headache pain was the primary source of pain; if currently using psychotropic or headache medications, use of these medications must have begun at least 4 weeks before baseline assessment; and reading ability was sufficient to comprehend self-monitoring forms.	 Dosage, Duration: 24 hours spent in session, nonework, and other each week, for 8 weeks Co-interventions: TAU or standard of care Comparator: Passive (e.g., waitlist, no treatment) Primary Endpoint: BPI Intensity Power Calculation: Power insufficient (post hoc test by authors) Follow-Up Time: 8 weeks 	
	Exclusion Criteria: Human immunodeficiency virus– related pain and cancer pain, because these are associated with malignant disease; history of seizure or facial neuralgia, as these conditions might preclude the accurate diagnosis of headache; significant cognitive impairment, evidenced by a positive screen on the Mini-cog21; current participation in other psychological treatments for any pain condition; and schizophrenia, bipolar affective disorder, seizure disorder not adequately controlled by medication, or current substance abuse.		

Participants	Intervention	Outcomes
Number of Patients: 124	Content of Intervention: Computerized MBCT intervention	Pain Measures:
Medical Condition/Turce of Dainy Other headeaba		Average Pain, 6 weeks: SMD 0
		(CI −0.36, 0.35) Average Pain, 30 weeks: SMD
	and behavioral change component	-0.19 (CI -0.54, 0.17)
	Setting: Remote (e.g., telephone internet app)	
Definition of Chronic Pain: Other definition		Analgesic Use: No
•	homework, and other each week, for 6 weeks	Adverse Events: No mention
	Co-interventions: NA	
Mean Age: 44.53 (SD 12.25)	Comparator: Psychoeducation program	
$O_{\rm res}$ days (9) Marta): $O_{\rm r}$	Drinsen - Endersiet, Assesse Drin	
Gender (% Male): 9.7	Primary Endpoint: Average Pain	
Inclusion Criteria: Self-reported chronic pain	Power Calculation: Yes (sufficient power)	
Exclusion Criteria: Had <6 months of pain: reported	Follow-Up Time: 30 weeks	
experiencing chronic pain due to cancer; reported		
possible symptoms of psychosis (Health Problems		
	Number of Patients: 124 Medical Condition/Type of Pain: Other headache, back pain, osteoarthritis, fibromyalgia, unspecified, nerve damage/pain, neuropathy Definition of Chronic Pain: Other definition Baseline Pain Score: Average Pain Intervention Group: 5.57 (SD 1.89); Control Group: 5.86 (SD 1.89) Mean Age: 44.53 (SD 12.25) Gender (% Male): 9.7 Inclusion Criteria: Self-reported chronic pain Exclusion Criteria: Had <6 months of pain; reported experiencing chronic pain due to cancer; reported	Number of Patients: 124Content of Intervention: Computerized MBCT interventionMedical Condition/Type of Pain: Other headache, back pain, osteoarthritis, fibromyalgia, unspecified, nerve damage/pain, neuropathyContent of Intervention: Computerized MBCT intervention included audio-recorded meditation, psychoeducation component, a mindfulness practice focus, and a cognitive and behavioral change componentDefinition of Chronic Pain: Other definition Baseline Pain Score: Average Pain Intervention Group: 5.57 (SD 1.89); Control Group: 5.86 (SD 1.89)Setting: Remote (e.g., telephone internet app)Dosage, Duration: 1 hour or less spent in session, homework, and other each week, for 6 weeksMean Age: 44.53 (SD 12.25)Co-interventions: NAMean Age: 44.53 (SD 12.25)Comparator: Psychoeducation programGender (% Male): 9.7Primary Endpoint: Average Pain Primary Endpoint: Average PainInclusion Criteria: Had <6 months of pain; reported possible symptoms of psychosis (Health Problems Questionnaire); were under the age of 18 years; and were unable to complete the required questionnaires due to insufficient English language or cognitiveFollow-Up Time: 30 weeks

Study Details	Participants	Intervention	Outcomes
Reference: Esmer et al., 2010	Number of Patients: 40	Content of Intervention: MBSR course educated	Pain Measures:
		participants on the physiology of stress and stress	VAS: SMD 0.3 (CI -0.5, 1.1)
Location: United States or Canada	Medical Condition/Type of Pain: Back pain, leg pain	hardiness, and provided participants with coping	
		strategies for pain by developing and refining the capacity	Analgesic Use: Yes:
Purpose: To evaluate short-term	Definition of Chronic Pain: No definition	to be mindful. Participants were encouraged to be present	analgesic medication log on a
efficacy of MBSR therapy for		with their experience of pain and stress, in particular. The	4-point scale: 0=no meds,
improving quality of life in adults	Baseline Pain Score: VAS	intervention helped students to resist their experience of	4=daily narcotic meds;
with failed back surgery syndrome	Intervention Group: 23.2 (SD 5); Control Group: 24.3	pain less and thereby reduce the suffering caused by their	statistically significant reduction
	(SD 7.8)	resistance. Participants were taught to perform daily	in analgesic use at 12-week
Quality Rating: Poor		mindfulness practices: gentle yoga, walking, and seated	follow up
	Mean Age: Intervention: 55.2 (SD 11.2); Control:	meditation.	
	54.9 (SD 9.5)		Adverse Events: No mention
		Setting: Unclear	
	Gender (% Male): 56		
		Dosage, Duration: >4 hours spent in session, homework,	
	Inclusion Criteria: Persistent leg pain, back pain, or	and other each week, for 8 weeks	
	both despite a history of lumbosacral spinal surgery		
	within the previous 2 years.	Co-interventions: Traditional care as prescribed by their	
		medical care providers	
	Exclusion Criteria: Pregnancy, cognitive impairment,		
	relapsed chemical dependency, and lack of effective	Comparator: Traditional care as prescribed by their	
	transportation.	medical care providers	
		Primary Endpoint: VAS	
		Power Calculation: No	
		Follow Lin Time: 12 weeks	
		Follow-Up Time: 12 weeks	

Study Details	Participants	Intervention	Outcomes
Reference: Fjorback et al., 2013	Number of Patients: 120	Content of Intervention: Based on Kabat-Zinn (2005) MBSR manual. The intervention included	Pain Measures: SF-36 Bodily Pain ,12 weeks:
Location: Europe	Medical Condition/Type of Pain: Bodily distress	psychoeducation, symptom registration, and a model for	SMD 0.15 (CI -0.23, 0.53)
Purpose: To conduct a feasibility	syndrome, a somatization disorder	graded exercise from the STreSS-1 manual.	SF-36 Bodily Pain, 36 weeks: SMD 0.23 (CI -0.18, 0.63)
and efficacy trial of mindfulness therapy in somatization disorder	Definition of Chronic Pain: No definition	Setting: Other outpatient	SF-36 Bodily Pain, 60 weeks: SMD −0.1 (CI −0.51, 0.31)
and functional somatic syndromes, such as fibromyalgia,	Baseline Pain Score: SF-36 Bodily Pain Intervention Group: 27.2 (SD 23.1); Control Group:	Dosage, Duration: 1–4 hours spent in session, homework, and other each week, for 8 weeks	Analgesic Use: No
IBS, and chronic fatigue syndrome, defined as bodily distrong syndrome	29.8 (SD 21.3)	Co-interventions: TAU or standard of care; patients	Mental Health-Related QoL Measure:
distress syndrome Quality Rating: Good	Mean Age: Mindfulness: 38 (SD 9); Enhanced TAU: 40 (SD 8)	received proper diagnoses, psychoeducation, and treatment advice on medicine and graded exercise	SF-36 Mental Composite: SMD -0.04 (CI -0.42, 0.34)
Quality Nating. 6000	Gender (% Male): 20	Comparator: "Enhanced TAU," enhanced by a face-to-	
	Inclusion Criteria: Chronic (i.e., at least 2 years) of	face meeting with a psychiatrist	Physical Health-Related QoL Measure:
	the multi-organ type bodily distress syndrome, which requires functional somatic symptoms from at least	Primary Endpoint: SF-36 Bodily Pain	SF-36 Physical Composite: SMD 0.22 (CI -0.16, 0.61)
	three out of four bodily systems—the cardiopulmonary, gastrointestinal, musculoskeletal,	Power Calculation: Yes (sufficient power)	Adverse Events: No mention
	or general symptoms; moderate to severe	Follow-Up Time: 60 weeks	
	impairment in daily living; age 20 to 50 years; absence of severe psychiatric morbidity (i.e.,		
	psychotic and bipolar disorders). The patients with comorbid depression and anxiety, and with comorbid		
	medical conditions (e.g., asthma, diabetes) were included if symptoms attributed to these conditions		
	could be clearly differentiated from symptoms due to bodily distress syndrome.		
	Exclusion Criteria: Current alcohol or drug abuse; pregnancy; not fluent in the Danish language (operationalized as non-Scandinavian origin); no informed consent.		

Study Details	Participants	Intervention	Outcomes
Reference: Fogarty et al., 2015	Number of Patients: 51	Content of Intervention: Standardized 8-week program	Pain: Significant reduction
		developed by the University of Massachusetts Medical	reported; no usable data
Location: New Zealand	Medical Condition/Type of Pain: Rheumatoid arthritis	School	
			Analgesic Use: No
Purpose: To examine the effects	Definition of Chronic Pain: No definition	Setting: Unclear	
of a standardized MBSR			Adverse Events: No mention
intervention on rheumatoid arthritis disease activity	Mean Age: Intervention: 52 (SD 12); Control: 55 (SD 13)	Dosage, Duration: Dosage is unclear, for 8 weeks	
-		Co-interventions: TAU or standard of care:	
Quality Rating: Good	Gender (% Male): 12	acetaminophen, rheumatic painkiller, and opioids	
	Inclusion Criteria: Rheumatoid arthritis, according to the 1987 American College of Rheumatology classification criteria.	Comparator: Passive (e.g., waitlist, no treatment), TAU or standard of care: acetaminophen, rheumatic painkiller, and opioids	
	Exclusion Criteria: Prior meditation experience.	Primary Endpoint: Arthritis activity	
		Power Calculation: No	

Study Details	Participants	Intervention	Outcomes
Reference: Garland et al., 2014	Number of Patients: 115	Content of Intervention: MORE unites complementary	Pain Measures:
		aspects of mindfulness training, third-wave cognitive-	BPI Severity, 20 weeks: SMD
Location: United States or Canada	Medical Condition/Type of Pain: Osteoarthritis,	behavioral therapy, and principles from positive	0.76 (CI 0.38, 1.14)
	fibromyalgia	psychology into an integrative intervention strategy.	BPI Severity, 8 weeks: SMD
Purpose: To conduct an early-		Techniques drawn from these therapeutic approaches	0.57 (CI 0.19, 0.94)
stage RCT of MORE, a	Definition of Chronic Pain: Other definition	were integrated into a manualized 8-session group	
multimodal intervention designed		intervention designed to address the multiplicity of	Analgesic Use: No;
to simultaneously target	Baseline Pain Score: BPI Severity	pathogenic factors involved in chronic pain and long-term	reports on prescription opioid
mechanisms underpinning chronic	Intervention Group: 5.44 (SD 1.4); Control Group:	opioid use. MORE sessions involved mindfulness training	misuse post-treatment
pain and opioid misuse	5.49 (SD 1.54)	to target automatic habit behavior and foster	
		nonreactivity, positive reappraisal training to regulate	Adverse Events: No mention
Quality Rating: Fair	Mean Age: 48 (SD 14)	negative emotions and foster a sense of meaningfulness	
		in life, and training in savoring pleasant events and	
	Gender (% Male): 32	emotions to ameliorate deficits in natural reward	
		processing and positive affectivity.	
	Inclusion Criteria: Reported recurrent pain (i.e., pain		
	on more days than not) stemming from chronic	Setting: Unclear	
	benign (i.e., non-cancer-related) pain conditions,		
	arthritis or fibromyalgia and had been prescribed and	Dosage, Duration: 1–4 hours spent in session, homework,	
	taken opioids for analgesia daily or nearly every day	and other each week, for 8 weeks	
	(≥5 days per week) for at least the past 90 days.		
		Co-interventions: TAU or standard of care: medical care,	
	Exclusion Criteria: Actively suicidal or psychotic via	prescription pain medications	
	assessment on Mini-International Neuropsychiatric		
	Interview 6.0.	Comparator: Support groups	
		Primary Endpoint: BPI Severity	
		Power Calculation: Yes (sufficient power)	
		Follow-Up Time: 20 weeks	

Study Details	Participants	Intervention	Outcomes
Reference: Gaylord et al., 2011	Number of Patients: 75	Content of Intervention: The mindfulness-based stress	Pain Measures:
		and pain management program was based on the MBSR	Pain Severity, 20 weeks: SMD
Location: United States or Canada	Medical Condition/Type of Pain: IBS	program developed by Jon Kabat-Zinn and Saki Santorelli	
Dumperer Televisiens the feasibility	Definition of Observic Deirs No. definition	at the University of Massachusetts. The basic course was	Pain Severity, 8 weeks: SMD
Purpose: To explore the feasibility	Definition of Chronic Pain: No definition	adapted to an IBS population by emphasizing the	0.54 (CI 0.08, 1)
and efficacy of a group program of mindfulness training, a cognitive-	Baseline Pain Score: Pain Severity	relevance of mindfulness in coping with IBS-related symptoms and perceptions.	Depression Measures:
behavioral technique, for women	Intervention Group: 54.54 (SD 22.82); Control	symptoms and perceptions.	Brief Symptom Inventory-18
with irritable bowel syndrome	Group: 53.35 (SD 28.12)	Setting: Unclear	depression: SMD 0.03
	Group: 50.00 (OB 20.12)	Setting. Sheed	(CI -0.42, 0.49)
Quality Rating: Fair	Mean Age: Mindfulness Group: 44.72 (SD 12.55);	Dosage, Duration: >4 hours spent in session, homework,	(01 0.12, 0.10)
et all the second s	Control Group: 40.89 (SD 14.68)	and other each week, for 8 weeks	Analgesic Use: No
		,,,,	
	Gender (% Male): 0	Co-interventions: TAU or standard of care; subjects	General QoL Measure:
		continued with their usual medical care throughout the	IBS Quality of Life: SMD 0.25
	Inclusion Criteria: IBS diagnosis according to Rome	study	(CI -0.21, 0.7)
	Il criteria and physician diagnosis; female; age 18-		
	75 years; ability to understand English; willingness to		Adverse Events: No mention
	document bowel symptoms and medication use	with their usual medical care throughout the study);	
	regularly and complete the assessments; and	social-support group intervention	
	willingness to attend eight weekly sessions, plus one	Drimony Endnainty Dain Soverity	
	additional half-day session of either mindfulness training or support group.	Primary Endpoint: Pain Severity	
		Power Calculation: No	
	Exclusion Criteria: Diagnosis of mental illness with		
	psychosis; a history of inpatient admission for	Follow-Up Time: 20 weeks	
	psychiatric disorder within the past 2 years; a history		
	or current diagnosis of inflammatory bowel disease		
	or gastrointestinal malignancy; active liver or		
	pancreatic disease; uncontrolled lactose intolerance;		
	celiac disease; a history of abdominal trauma or		
	surgery involving gastrointestinal resection; or		
	pregnancy.		

Study Details	Participants	Intervention	Outcomes
Reference: la Cour and Petersen,	Number of Patients: 109	Content of Intervention: MBSR standard program	Pain Measures:
2015		modified for chronic pain patients	BPI average score: SMD -0.16
	Medical Condition/Type of Pain: Unspecified, varied		(CI -0.53, 0.22)
Location: Europe		Setting: Outpatient pain clinic	
	Definition of Chronic Pain: No definition		Depression Measures:
Purpose: To investigate the		Dosage, Duration: >4 hours spent in session, homework,	Hospital Anxiety and
effects on pain, physical function,	Baseline Pain Score: BPI average score	and other each week, for 8 weeks	Depression Scale, depression:
mental function, pain acceptance,	Intervention Group: 19 (SD 6.6); Control Group: 19.2		SMD 0.37 (CI -0.01, 0.75)
and health-related quality of life of	(SD 5.2)	Co-interventions: TAU or standard of care	
mindfulness meditation via MBSR			Analgesic Use: No
on nonspecific chronic pain as	Mean Age: Intervention: 46.52 (SD 12.42); Control:	Comparator: Passive (e.g., waitlist, no treatment), TAU or	
compared with a waitlist control	48.84 (SD 12.20)	standard of care	Mental Health-Related QoL
group			Measure:
	Gender (% Male): 15	Primary Endpoint: BPI	SF36 Mental Composite:
Quality Rating: Fair			SMD 0.53 (CI 0.15, 0.91)
	Inclusion Criteria: Chronic pain diagnosis by trained	Power Calculation: Yes (sufficient power)	
	physicians who specialized in treating pain; all pain		Physical Health-Related QoL
	conditions and physical abilities were included.	Follow-Up Time: 8 weeks	Measure:
			SF-36 Physical Composite:
	Exclusion Criteria: Unstable clinical situations, such		SMD 0 (CI -0.38, 0.38)
	as pharmaceutical treatments that continued to		
	change, and patients with obvious mental		Adverse Events: Yes;
	disabilities, such as severe cognitive problems or		two participants experienced
	emotional turmoil; very poor Danish language skills.		temporary strong feelings of
			anger toward their pain
			condition, and two patients
			experienced greater anxiety

Study Details	Participants	Intervention	Outcomes
Reference: Ljotsson, Falk, et al.,	Number of Patients: 85	Content of Intervention: Text-based (online) self-help	Pain Measures:
2010		manual divided into five steps: Step 1. A rationale for the	Total Pain: SMD 0.64 (CI 0.19,
	Medical Condition/Type of Pain: IBS	treatment and instructions on mindfulness. The	1.08)
Location: Europe		mindfulness instructions included exercises to be	
	Definition of Chronic Pain: No definition	practiced daily, aimed at bringing the participant into	Depression Measures:
Purpose: To investigate if		immediate awareness of current gastrointestinal	Montgomery–Åsberg
cognitive behavior therapy based	Baseline Pain Score: Total Pain	symptoms, thoughts, feelings, and behavioral impulses.	Depression Rating Scale–Self-
on exposure and mindfulness	Intervention Group: 2.6 (SD 1.7); Control Group: 2.4	Steps 2–4. A presentation of a psychological model of	Report: SMD 0.43 (CI -0.02,
exercises delivered via the	(SD 1.5)	IBS and continued mindfulness exercises. Step 5. Three	0.87)
Internet would be effective in		categories of exposure exercises: (a) exercises that	
treating participants with IBS	Mean Age: 34.6 (SD 9.4)	provoke symptoms, such as certain foods, physical	Analgesic Use: No
		activity, and stressful situations; (b) abolishment of	
Quality Rating: Good	Gender (% Male): 15	behaviors that serve to control symptoms, such as	General QoL Measure:
		distraction, excessive toilet visits, eating certain foods,	IBS Quality of Life: SMD 0.95
	Inclusion Criteria: A previous diagnosis of IBS given	resting, and taking unprescribed medications; (c)	(CI 0.49, 1.41)
	by a physician, and currently fulfilling the Rome III	exposure to situations where symptoms were unwanted,	
	criteria for IBS.	such as attending a meeting when experiencing	Adverse Events: No mention
		abdominal pain or riding the bus with fear of losing control	
	Exclusion Criteria: Patients with symptoms that in a	of the bowels. The steps were to be done in order, about	
	live care setting would have rendered a somatic	one per week, and homework exercises and a symptom	
	investigation to rule out organic disease; symptom	diary were to be completed. Participants were also	
	debut after age 50; blood in stool without satisfactory	encouraged to contact a therapy student, online.	
	medical explanation (such as known hemorrhoids);		
	diarrhea predominant IBS with no colonoscopy	Setting: Remote (e.g., telephone Internet app)	
	performed; rapid weight loss that could not be linked		
	to change in diet; night symptoms that persistently	Dosage, Duration: Dosage is unclear, for 10 weeks	
	caused sleeplessness; less than 2 years of IBS-	boodgo, buration. boodgo to anoloal, for no wooko	
	symptoms; any presence of current or previous	Co-interventions: NA	
	inflammatory bowel disease; lactose or gluten		
	intolerance where proper adjustments in diet had not	Comparator: Passive (e.g., waitlist, no treatment); also,	
	been made; suicide ideation based on Montgomery	participants randomized to waiting list were therefore	
	Åsberg Depression Rating Scale Self-report; severe	given access to an online discussion forum (separate	
	depressive symptoms (total score 30) based on	from the one used by the treatment intervention) where	
	Montgomery Åsberg Depression Rating Scale Self-	suggestions about general discussions regarding IBS	
	report; substance dependence according to Alcohol	were given each week	
	Use Disorders Identification Test or Drug Use		
	Disorders Identification Test; psychosis; manic	Primary Endpoint: Total Pain	
	episode; or anorexia according to the Mini-		
	International Neuropsychiatric Interview.	Power Calculation: Yes (sufficient power)	
	memational neuropsychiatric interview.		
		Follow-Up Time: 10 weeks	

Study Details	Participants	Intervention	Outcomes
Reference: Ljotsson, Hedman, et	Number of Patients: 195	Content of Intervention: Text-based (online) self-help	Pain: Increased relief from IBS
al., 2011		manual divided into five steps. Step 1. A rationale for the	pain and discomfort significant
	Medical Condition/Type of Pain: IBS	treatment and instructions on mindfulness. The	
Location: Europe	Definition of Obvenia Dains No definition	mindfulness instructions included exercises to be	Depression Measures:
Durnasa, Ta asmasra Internat	Definition of Chronic Pain: No definition	practiced daily, aimed at bringing the participant into	HADS depression: SMD 0
Purpose: To compare Internet- based cognitive behavioral	Mean Age: 38.9 (SD 11.1)	immediate awareness of current gastrointestinal symptoms, thoughts, feelings, and behavioral impulses.	(CI -0.28, 0.28)
therapy with Internet-delivered	Medil Age. 56.9 (5D 11.1)	Steps 2–4. A presentation of a psychological model of	Analgesic Use: No
stress management for IBS to	Gender (% Male): 21	IBS and continued mindfulness exercises. Step 5. Three	Analgesie 036. No
assess whether the effects of		categories of exposure exercises: (a) exercises that	General QoL Measure:
such therapy are specific and not	Inclusion Criteria: A previous diagnosis of IBS given	provoke symptoms, such as certain foods, physical	IBS Quality of Life: SMD 0.51
attributable to credibility or	by a physician; fulfillment of the Rome III criteria for	activity, and stressful situations; (b) abolishment of	(CI 0.22, 0.8)
expectation of improvement	IBS; symptom history of at least 2 years.	behaviors that serve to control symptoms, such as	
		distraction, excessive toilet visits, eating certain foods,	Adverse Events: No mention
Quality Rating: Good	Exclusion Criteria: Symptom onset after age 50,	resting, and taking unprescribed medications; (c)	
	blood in stool without satisfactory medical	exposure to situations where symptoms were unwanted,	
	explanation (such as known hemorrhoids); diarrhea	such as attending a meeting when experiencing	
	predominant IBS with no colonoscopy performed,	abdominal pain or riding the bus with fear of losing control	
	rapid weight loss that could not be linked to change	of the bowels. The steps were to be done in order, about	
	in diet, and nocturnal symptoms that persistently	one per week, and homework exercises and a symptom	
	caused sleeplessness. In addition to the alarm symptoms, the following criteria were cause for	diary were to be completed. Participants were also encouraged to contact a therapy student, online.	
	exclusion: <2 years of IBS symptoms (regardless of	encouraged to contact a therapy student, online.	
	when diagnosis had been given), any presence of	Setting: Remote (e.g., telephone Internet app)	
	current or previous inflammatory bowel disease,	Setting. Remote (e.g., telephone internet app)	
	lactose or gluten intolerance where proper dietary	Dosage, Duration: Dosage is unclear, for 10 weeks	
	changes had not been made, and severe alcohol		
	dependence, depression, or suicidal ideation.	Co-interventions: NA	
		Comparator: Internet stress management	
		Primary Endpoint: Relief from IBS symptoms	
		Power Calculation: Yes (sufficient power)	
		Follow-Up Time: 24 weeks	

Study Details	Participants	Intervention	Outcomes
Reference: Meize-Grochowski et	Number of Patients: 31	Content of Intervention: MBSR: 1 hour instruction	Pain Measures:
al., 2015		focusing breathing while seated comfortably, daily	Short-Form MPQ – total pain
	Medical Condition/Type of Pain: Postherpetic	meditation using a compact disc, phone call reminders,	score, 2 weeks: SMD -0.48
Location: United States or Canada	neuralgia	and daily journal	(CI -1.25, 0.28)
			Short-Form MPQ – total pain
Purpose: To examine daily meditation versus usual care in a	Definition of Chronic Pain: No definition	Setting: Remote (e.g., telephone Internet app)	score, 8 weeks: SMD -0.31 (CI -1.07, 0.45)
diverse sample of older adults	Baseline Pain Score: Short-Form MPQ – total pain	Dosage, Duration: 1-4 hours spent in session, homework,	
with postherpetic neuralgia	score	and other each week, for 6 weeks	Depression Measures:
	Intervention Group: 3.5 (SD 2.2); Control Group: 2.4		Center for Epidemiologic
Quality Rating: Poor	(SD 1.5)	Co-interventions: TAU or standard of care	Studies Depression Scale
			score: SMD -0.32 (CI -1.08,
	Mean Age: 72 (SD 9.6)	Comparator: TAU or standard of care	0.44)
	Gender (% Male): 44.4	Primary Endpoint: SF MPQ	Analgesic Use: No
	Inclusion Criteria: 50 years of age or older, able to	Power Calculation: Power insufficient (post hoc test by	Mental Health-Related QoL
	read and write English, and self-reported persistent	authors)	Measure:
	pain after the shingles rash had resolved.		Emotional Well-Being:
		Follow-Up Time: 8 weeks	SMD 0.07 (CI -0.69, 0.82)
	Exclusion Criteria: Consistent use of meditation in		
	the previous year; medical instability from severe		Physical Health-Related QoL
	heart disease, lung disease, or diabetes mellitus;		Measure:
	multiple recent falls; pain caused by an acute injury		Average Physical Subscales:
	in the previous month; unable to stand		SMD -0.02 (CI -0.77, 0.74)
	independently; and underlying serious illness, such		
	as unexplained weight loss, fever, or pain from		Adverse Events: No mention
	cancer.		

Study Details	Participants	Intervention	Outcomes
Reference: Morone et al., 2009	Number of Patients: 40	Content of Intervention: Partial MBSR: The methods used	Pain Measures:
		were (1) the body scan, where in a lying position, the	Short-Form MPQ – total pain
Location: United States or Canada	Medical Condition/Type of Pain: Back pain	participant is guided to place attention nonjudgmentally	score, 24 weeks: SMD -0.04
Dumpered Te determine the immedia	Definition of Obversio Deirs 2 months minimum on	on each area of the body, from the toes to the top of the	(CI -0.7, 0.63)
Purpose: To determine the impact of an 8-week mindfulness	Definition of Chronic Pain: 3 months minimum or	head; (2) sitting practice, where the participant is guided to focus attention on breathing while sitting on a chair;	Short-Form MPQ – total pain
meditation program on disability,	"past normal time for tissue healing"	and (3) walking meditation, where the participant is	score, 8 weeks: SMD -0.01 (CI -0.68, 0.65)
psychological function, and pain	Baseline Pain Score: Short-Form MPQ – total pain	guided in mindful slow walking with focused attention on	-0.08, 0.03)
severity in community-dwelling	score	body sensation and/or breathing	Analgesic Use: No
older adults with chronic low back	Intervention Group: 15.6 (SD 7.52); Control Group:	body sensation and/or breatining	Analgesie 03e. No
pain, and test the education	16.1 (SD 7.52)	Setting: Unclear	Adverse Events: None reported
control program for feasibility			· · · · · · · · · · · · · · · · · · ·
·······	Mean Age: Intervention: 78 (SD 7.1); Control: 73	Dosage, Duration: >4 hours spent in session, homework,	
Quality Rating: Poor	(SD 6.2)	and other each week, for 8 weeks	
	Gender (% Male): 37	Co-interventions: Over the counter medication (ibuprofen,	
		Tylenol, acetaminophen, etc.), opioids, other prescription	
		medications	
	3 months' duration and of at least moderate intensity		
	according to a vertical verbal descriptor scale (pain	Comparator: Over the counter medication (ibuprofen,	
	thermometer), age ≥65 years, and intact cognition	Tylenol, acetaminophen, etc.), opioids, other prescription	
	(Mini-Mental Status Exam ≥24).	medications, health education program	
	Exclusion Criteria: Non-English speaking, previous	Primary Endpoint: SF MPQ – total pain score	
	participation in a mindfulness meditation program,		
	serious hearing or vision impairment that would	Power Calculation: Unclear (cannot tell for outcomes of	
	preclude responding to questionnaires or	interest)	
	participating in the meditation program, medical		
	instability from heart or lung disease, multiple recent	Follow-Up Time: 24 weeks	
	falls or inability to stand independently, pain caused		
	by an acute injury in the previous 3 months, and		
	underlying red flags of serious underlying illness,		
	such as recent unexplained weight loss, fever, or		
	sudden worsening of back pain.		

Study Details	Participants	Intervention	Outcomes
Reference: Morone, Greco, and	Number of Patients: 37	Content of Intervention: Partial MBSR: The techniques	Pain Measures:
Weiner, 2008		used were: (1) the body scan, where in a lying position,	Short-Form MPQ: SMD 0.23
	Medical Condition/Type of Pain: Back pain	the participant is guided to place attention	(CI -0.42, 0.88)
Location: United States or Canada		nonjudgmentally on each area of the body, from the toes	
	Definition of Chronic Pain: 3 months minimum or	to the top of the head; (2) sitting practice, which is	Analgesic Use: No
Purpose: To assess the feasibility	"past normal time for tissue healing"	focused attention on breathing while sitting on a chair or	
of recruitment and adherence to		on a meditation cushion on the floor; and (3) walking	Mental Health-Related QoL
an eight-session mindfulness	Baseline Pain Score: Short-Form MPQ	meditation, which is mindful slow walking with focused	Measure:
meditation program for	Intervention Group: 15.5 (SD 10); Control Group:	attention on body sensation and/or breathing	SF-36 Mental Composite:
community-dwelling older adults	15.2 (SD 7)		SMD 0.22 (CI -0.43, 0.86)
with chronic low back pain, and		Setting: Unclear	
develop initial estimates of	Mean Age: Intervention: 74.1(SD 6.1); Controls: 75.6		Physical Health-Related QoL
treatment effects	(SD 5.0)	Dosage, Duration: >4 hours spent in session, homework,	Measure:
		and other each week, for 8 weeks	SF-36 Physical Composite:
Quality Rating: Fair	Gender (% Male): 43		SMD 0.11 (CI -0.53, 0.76)
		Co-interventions: NA	
	Inclusion Criteria: (1) Were 65 years of age or older;		Adverse Events: None reported
	(2) had intact cognition (Mini-Mental Status Exam	Comparator: Passive (e.g., waitlist, no treatment)	
	P23); (3) had chronic low back pain, defined as		
	moderate pain occurring daily or almost every day	Primary Endpoint: Adherence	
	for at least the previous three months; and (4) spoke		
	English.	Power Calculation: Power insufficient (post hoc test by	
		authors)	
	Exclusion Criteria: Had previously participated in a		
	mindfulness meditation program and had "red flags"	Follow-Up Time: 8 weeks	
	suggestive of serious underlying illness (e.g.		
	malignancy, infection, unexplained fever, weight		
	loss, or recent trauma) causing their pain.		

Study Details	Participants	Intervention	Outcomes
Reference: Omidi and Zargar, 2014	Number of Patients: 66	Content of Intervention: Standard MBSR	Pain Measures: Pain Severity, 20 weeks: SMD
	Medical Condition/Type of Pain: Other headache	Setting: Unclear	1.23 (CI 0.68, 1.78)
Location: Middle East	Definition of Chronic Pain: Other definition	Dosage, Duration: 1–4 hours spent in session, homework,	Pain Severity, 8 weeks: SMD 1.21 (Cl 0.66, 1.76)
Purpose: Evaluating the efficacy		and other each week, for 8 weeks	
of MBSR in improving pain severity and mindful awareness in	Baseline Pain Score: Pain Severity Intervention Group: 7.36 (SD 1.25); Control Group:	Co-interventions: NA	Analgesic Use: No
patients with tension headache	7.5 (SD 1.35)	O and a start the start and af and	Adverse Events: No mention
Quality Rating: Poor	Mean Age: Intervention: 34.5 (SD 2.41); Control: 32	Comparator: TAU or standard of care	
	(SD 3.2)	Primary Endpoint: Pain Severity	
	Gender (% Male): 20	Power Calculation: No	
	Inclusion Criteria: Having a tension headache according to the International Headache Classification Subcommittee, and tending to participate in the study.	Follow-Up Time: 20 weeks	
	Exclusion Criteria: A medical diagnosis of organic brain disorder or psychotic disorder, and a history of psychologic treatment during the preceding six months.		

Study Details	Participants	Intervention	Outcomes
Reference: Parra-Delgado and	Number of Patients: 33	Content of Intervention: MBCT: Different practical	Pain Measures:
Latorre-Postigo, 2013		mindfulness exercises were conducted at each of the	VAS average score, 12 weeks:
	Medical Condition/Type of Pain: Fibromyalgia	sessions, with special focus on pain-related stimuli. The	SMD 0.19 (CI -0.51, 0.9)
Location: Europe	Definition of Chronic Pain: No definition	main aim was for patients to learn mindfulness techniques	VAS average score, 24 weeks:
Purpose: To examine whether	Definition of Chronic Pain. No definition	in order to relate to their experience of pain and the thoughts and feelings it provokes in a different way,	SMD 0.44 (CI -0.27, 1.15)
MBCT is successful in reducing	Baseline Pain Score: VAS average score	responding in a compassionate and nonjudgmental way.	Depression Measures:
the impact of the illness, as well	Intervention Group: 1.88 (SD 0.55); Control Group:	The participants were invited to reflect on the transitory	BDI: SMD 0.36 (CI -0.35, 1.07)
as the depressive symptoms and	1.83 (SD 0.47)	nature of the different painful stimuli and were invited to	
the pain perceived in different		experience their thoughts as passing events of the mind	Analgesic Use: No
parts of the body in fibromyalgia	Mean Age: 52.67 (SD 10.08)	rather than absolute truths. The modifications to the	5
patients		MBCT for the women with fibromyalgia were taking a	Adverse Events: No mention
	Gender (% Male): 0	closer look at the acceptance of the experience of pain in	
Quality Rating: Good		the different meditation practices of mindfulness,	
	Inclusion Criteria: Being diagnosed with fibromyalgia	encouraging participants to be aware of the automatic	
	syndrome in accordance with the diagnostic criteria	thoughts related to the response to pain and their	
	proposed by the American College of	relationship to the feelings and behaviors it caused,	
	Rheumatology, and committing to the daily practice	providing information on anxiety and its causes	
	of mindfulness.	(requested by the patients), and explaining the importance of not forcing their body into yoga postures	
	Exclusion Criteria: Being diagnosed with alcohol or	and of feeling comfortable by using appropriate clothes	
	substance dependence or abuse, and receiving	and postures during the practice of mindfulness.	
	psychological therapy from the Castillo-La Mancha	and posteres during the produce of mindraness.	
	Health Service fibromyalgia team.	Setting: Unclear	
		Dosage, Duration: Dosage is unclear, for 12 weeks	
		Co-interventions: TAU or standard of care	
		Comparator: TAU or standard of care; all participants	
		continued with their usual medication treatment, medical	
		visits, rehabilitation sessions, and activities proposed by	
		the Fibromyalgia Association	
		Primary Endpoint: VAS	
		Power Calculation: No	
		Follow-Up Time: 24 weeks	

Study Details	Participants	Intervention	Outcomes
Reference: Plews-Ogan et al.,	Number of Patients: 30	Content of Intervention: Standard MBSR: Meditation and	Pain Measures:
2005		yoga techniques were practiced to foster mindfulness	Pain Unpleasantness vs. TAU,
	Medical Condition/Type of Pain: Musculoskeletal	(present moment, nonjudgmental awareness)	12 weeks: SMD 0.02 (CI -1.04,
Location: United States or Canada	pain		1.07)
		Setting: Unclear	Pain Unpleasantness vs.
Purpose: To evaluate the	Definition of Chronic Pain: Musculoskeletal pain for		Massage, 12 weeks:
feasibility of studying MBSR and	greater than 3 months	Dosage, Duration: Dosage is unclear, for 8 weeks	SMD -0.16 (CI -1.19, 0.88)
massage for the management of			Pain Unpleasantness, vs TAU,
chronic pain, and estimate their	Baseline Pain Score: Pain Unpleasantness	Co-interventions: NA	4 weeks: SMD 0.07 (CI -0.99,
effects on pain and mood	Intervention Group: 6.7 (SD 2.69); Control Group:		1.13)
	6.9 (SD 2.55)	Comparator: Massage, TAU	Pain Unpleasantness vs.
Quality Rating: Poor			Massage, 4 weeks: SMD 0.11
	Mean Age: 46.5	Primary Endpoint: Pain unpleasantness	(CI -0.92, 1.14)
		Device Option Ma	Pain Unpleasantness vs. TAU,
	Gender (% Male): 23	Power Calculation: No	8 weeks: SMD 0.17 (CI -0.89,
	Indución Critoria: Musculaskalatal pain for gractar	Follow Lin Time: 12 weeks	1.23)
	Inclusion Criteria: Musculoskeletal pain for greater than 3 months.	Follow-Up Time: 12 weeks	Pain Unpleasantness vs.
	than 3 months.		Massage, 8 weeks: SMD -0.3
	Evolucion Critorio: Driconor status, cognitivo		(CI -1.34, 0.74)
	Exclusion Criteria: Prisoner status, cognitive impairment, lack of reliable transportation, or being pregnant.		Analgesic Use: No
			Mental Health-Related QoL
			Measure:
			SF-12 Mental Health:
			SMD 0.67 (CI -0.42, 1.75)
			Adverse Events: No mention

Study Details	Participants	Intervention	Outcomes
Reference: Rahmani and	Number of Patients: 24	Content of Intervention: MBSR with group conscious	Pain Measures:
Talepasand, 2015		yoga; MBSR was based on Kabat-Zinn (2005)	Global Quality Symptoms –
-	Medical Condition/Type of Pain: Cancer		Pain, 16 weeks: SMD 1.85 (CI
Location: Middle East		Setting: Other outpatient	0.89, 2.8)
	Definition of Chronic Pain: No definition	5	Global Quality Symptoms –
Purpose: To examine the		Dosage, Duration: 1–4 hours spent in session, homework,	Pain, 8 weeks: SMD 3.24 (CI
effectiveness of the MBSR	Baseline Pain Score: Global Quality	and other each week. for 8 weeks	2.02, 4.46)
program and conscious yoga on	Symptoms – Pain		,,
the mental fatigue severity and life	Intervention Group: 68.05 (SD 4.81); Control Group:	Co-interventions: Group conscious yoga	Analgesic Use: No
quality of women with breast	75 (SD 15.08)	oo merventions. Group conscious yoga	
cancer	13 (30 13.00)	Comparator: Passive (e.g., waitlist, no treatment)	General QoL Measure:
cancer	Maan Age: Treatment: 42.25 (SD.2.07); Central:		
Quality Dating: Dear	Mean Age: Treatment: 43.25 (SD 3.07); Control:	Primany Endnainty Clabal Quality	Global Quality Total Score:
Quality Rating: Poor	44.8 (SD 3.28)	Primary Endpoint: Global Quality	SMD 1.18 (CI 0.32, 2.05)
	Condex (% Male): 0	Device Coloulation, Unclose (connet tell for outcomes of	Adverse Events: No mention
	Gender (% Male): 0	Power Calculation: Unclear (cannot tell for outcomes of	Adverse Events: No mention
		interest)	
	Inclusion Criteria: Diagnosis of stages I, II, or III of		
	breast cancer based on the clinical findings,	Follow-Up Time: 16 weeks	
	cytological studies, and diagnosis of a physician;		
	fatigue severity score higher than 4; duration of		
	breast cancer greater than a month; no anemia; no		
	other cancer diagnosis; age between 30 and 55		
	years; no other psychological treatment from the		
	time of diagnosis; minimum of secondary school		
	education; consent to participate; and ability to take		
	part in the desired courses.		
	Exclusion Criteria: Absence of more than two		
	intervention sessions, not wanting to continue to		
	participate in the intervention, and disease		
	recurrence or development of metastasis elsewhere		
	in the body during the study.		

Study Details	Participants	Intervention	Outcomes
Reference: Schmidt et al., 2011	Number of Patients: 177	Content of Intervention: Modified MBSR: Each session covered specific exercises and topics within the context of	Pain Measures: Pain Perception Scale –
Location: Europe	Medical Condition/Type of Pain: Fibromyalgia	mindfulness practice and training. These included various types of formal mindfulness practice, mindful awareness	affective vs. waitlist, 16 weeks: SMD 0.17 (CI -0.2, 0.55)
Purpose: To investigate the efficacy of MBSR for enhanced	Definition of Chronic Pain: No definition	of dynamic yoga postures, and mindfulness during stressful situations and social interactions. The all-day	Pain Perception Scale – affective vs. active, 16 weeks:
well-being of fibromyalgia patients in a three-armed trial, which was a	Baseline Pain Score: Pain Perception Scale – affective	retreat included a combination of previously used and newly introduced mindfulness exercises.	SMD 0.15 (CI -0.22, 0.53) Pain Perception Scale –
follow-up to an earlier quasi- randomized investigation	Intervention Group: 35.47 (SD 9.38); Control Group: 34.78 (SD 7.66)	Setting: Unclear	affective vs. waitlist, 8 weeks : SMD 0.08 (CI -0.3, 0.45)
-			Pain Perception Scale –
Quality Rating: Fair	Mean Age: 52.5 (SD 9.6)	Dosage, Duration: >4 hours spent in session, homework, and other each week, for 8 weeks	affective vs. active, 8 weeks: SMD 0.22 (CI -0.16, 0.6)
	Gender (% Male): 0		
	Inclusion Criteria: Women 18–70 years of age who	Co-interventions: NA	Depression Measures: Center for Epidemiologic
	currently had fibromyalgia, as defined by the American College of Rheumatology criteria; command of the German language and motivation to	Comparator: Passive (e.g., waitlist, no treatment); Active control: muscle relaxation and stretching	Studies Depression Scale score: SMD 0.1 (CI -0.27, 0.48)
	participate.	Primary Endpoint: Pain Perception Scale	0.40)
			Analgesic Use: No
	Exclusion Criteria: Life-threatening diseases,	Power Calculation: Yes (sufficient power)	
	evidence of suppressed immune functioning, or		General QoL Measure:
	participation in other clinical trials.	Follow-Up Time: 16 weeks	QoL Profile for Chronically III:
			SMD 0.26 (CI -0.12, 0.63)
			Adverse Events: No mention

Study Details	Participants	Intervention	Outcomes
Reference: Teixeira, 2010	Number of Patients: 22	Content of Intervention: Received instruction in	Pain Measures:
		mindfulness meditation and was instructed to listen to a	Neuro QoL Pain: SMD 0.14
Location: United States or Canada	Medical Condition/Type of Pain: Diabetic peripheral	guided compact disc 5 days per week over a 4-week	(CI -0.74, 1.01)
	neuropathy	period	
Purpose: To explore the effect of			Analgesic Use: No
mindfulness meditation on quality	Definition of Chronic Pain: No definition	Setting: Remote (e.g., telephone Internet app)	
of life for adults with diabetic			General QoL Measure:
neuropathy	Mean Age: 74.6 (SD 10.8)	Dosage, Duration: Dosage is unclear, for 4 weeks	Neuro QoL Overall: SMD 0.79 (CI -0.12, 1.7)
Quality Rating: Poor	Gender (% Male): 25	Co-interventions: NA	
			Adverse Events: No mention
	Inclusion Criteria: Type 1 or Type 2 diabetes for at least 1 year, diabetic neuropathy symptoms of pain	Comparator: Nutritional information and food diary	
	and/or numbness for at least 6 months, male or female between the ages of 50 and 92 years, able to	Primary Endpoint: Europol Pain	
	provide informed consent, and not currently	Power Calculation: Power insufficient (post hoc test by	
	practicing formal meditation.	authors)	
	Exclusion Criteria: NA	Follow-Up Time: 4 weeks	

Study Details	Participants	Intervention	Outcomes
Reference: Wells et al., 2014	Number of Patients: 19	Content of Intervention: Standard MBSR	Pain Measures:
	Madia di Osadikian (Tura sef Daias Minasia s	O atting on Others and acting the	Headache severity, 12 weeks:
Location: United States or Canada	Medical Condition/Type of Pain: Migraine	Setting: Other outpatient	SMD 0.99 (CI 0.04, 1.95) Headache severity, 8 weeks:
Purpose: To assess the safety,	Definition of Chronic Pain: Other definition	Dosage, Duration: >4 hours spent in session, homework,	SMD 1.5 (CI 0.48, 2.51)
feasibility, and effects of the		and other each week, for 8 weeks	
standardized 8-week MBSR	Baseline Pain Score: Headache severity		Depression Measures:
course in adults with migraines	Intervention Group: 4.4 (SD 1.11); Control Group:	Co-interventions: TAU or standard of care; participants	Patient Health Questionnaire
Quality Rating: Fair	4.8 (SD 1.33)	were allowed to continue taking their prophylactic and abortive medications as usual	Depression: SMD 0.59 (CI −0.33, 1.51)
Quality Rating. Fail	Mean Age: Intervention: 45.9 (SD 17); Control: 45.2	abortive medications as usual	(CI = 0.33, 1.51)
	(SD 12)	Comparator: Passive (e.g., waitlist, no treatment), TAU or	Analgesic Use: No
		standard of care; participants were allowed to continue	5
	Gender (% Male): 10.5	taking their prophylactic and abortive medications as	General QoL Measure:
	Inclusion Criteric, Discussion of microine with en	usual	Migraine-Specific QoL:
	Inclusion Criteria: Diagnosis of migraine with or without aura (according to the International	Primary Endpoint: Headache severity	SMD -0.43 (CI -1.34, 0.48)
	Classification of Headache Disorders-II); 4–14		Adverse Events: No mention
	migraine days per month; one-year history of	Power Calculation: Power insufficient (post hoc test by	
	migraines; at least 18 years old; able and willing to	authors)	
	attend weekly sessions and willing to participate in		
	daily mindfulness assignments of up to 30–45 minutes per day; agreeable to participate and to be	Follow-Up Time: 8 weeks	
	randomized to either group; fluent in English; and in		
	good general health with no additional diseases		
	expected to interfere with the study.		
	Exclusion Criteria: Current regular meditation/yoga practice; major systemic illness or unstable		
	medical/psychiatric condition (e.g., suicide risk)		
	requiring immediate treatment or that could		
	compromise protocol adherence; medication		
	overuse headache (according to the International		
	Classification of Headache Disorders-II); current or planned pregnancy or breastfeeding; new		
	prophylactic migraine medicine started within 4		
	weeks of the screening visit; unwilling to maintain		
	stable migraine medication dosages; and failure to		
	complete baseline headache logs.		

Study Details	Participants	Intervention	Outcomes
Reference: Wong et al., 2011	Number of Patients: 100	Content of Intervention: Standard MBSR: Included three	Pain: No significant effect, data
		primary elements: (1) theoretical material related to	not usable
Location: Asia	Medical Condition/Type of Pain: Unspecified	mindfulness, relaxation, meditation, yoga, and the body-	Analysis Llass No.
Purpose: To compare the clinical	Definition of Chronic Pain: 3 months minimum or	mind connection; (2) experimental practice of meditation and yoga; and (3) group activities that focused on	Analgesic Use: No
effectiveness of the MBSR	"past normal time for tissue healing"	removing impediments to effective practice, practical day-	Adverse Events: No mention
program with a multidisciplinary		to-day applications of mindfulness, and supportive	
pain intervention program in terms of pain intensity, pain-related	Mean Age: 47.9 (SD 7.84)	intervention between group members	
distress, quality of life, and mood	Gender (% Male): Not Reported	Setting: Unclear	
in patients with chronic pain	Inclusion Criteria: Age between 19 and 65 years, the	Desage Duration 1.4 hours anont in appoint homowork	
Quality Rating: Good	Inclusion Criteria: Age between 18 and 65 years; the presence of chronic pain, which had persisted for at	Dosage, Duration: 1–4 hours spent in session, homework, and other each week, for 8 weeks	
Quality Mating: Coold	least 3 months at the moderate-to-severe level (i.e.,		
	at least 4 of 10 on an 11-point Numerical Rating	Co-interventions: TAU or standard of care:	
	Scale pain score); agreement by the participant not	acetaminophen, rheumatic painkiller, and opioids	
	to receive other new treatments during the		
	intervention, including the use of new medication, topical treatment, medication or other over-the-	Comparator: Multidisciplinary pain intervention	
	counter medication, or other nonpharmacological treatment; ability to give a written consent.	Primary Endpoint: Pain Intensity	
	a calment, ability to give a written consent.	Power Calculation: Yes (sufficient power)	
	Exclusion Criteria: Receiving concurrent treatment	· · · · · · · · · · · · · · · · · · ·	
	with therapies other than medications for pain or		
	psychological symptoms; having a known,		
	concurrent doctor-diagnosed Diagnostic and		
	Statistical Manual of Mental Disorders-IV Axis I		
	disorder; having previously participated in an MBSR program; having been engaged, currently or		
	previously, in the practice of meditation or relaxation		
	techniques, including an MBSR program; being		
	illiterate, as the participant would not be able to		
	complete the meditation diary.		

Study Details	Participants	Intervention	Outcomes
Reference: Wong, 2009	Number of Patients: 100	Content of Intervention: Standard MBSR	Pain: Decrease in pain intensity significant (no usable data)
Location: Asia	Medical Condition/Type of Pain: Unspecified	Setting: Unclear	Analgesic Use: No
Purpose: To compare the effectiveness of MBSR with an education program in terms of reduction of pain and improvement in quality of life for chronic pain patients Quality Rating: Poor	Definition of Chronic Pain: 3 months minimum or "past normal time for tissue healing" Mean Age: Not reported Gender (% Male): Not Reported Inclusion Criteria: Aged 18 to 65 years, with any chronic pain for at least 3 months. The pain had to be moderate to severe (scoring at least 4 out of 10 in an 11-point Numeric Rating Scale) verified by a trained research assistant and confirmed by a family physician.	Dosage, Duration: Dosage is unclear, for 8 weeks Co-interventions: NA Comparator: Multidisciplinary education program Primary Endpoint: Pain reduction Power Calculation: No	Analgesic Use: No Adverse Events: No mention
	other than medications for pain or psychological symptoms; had a concurrent Diagnostic and Statistical Manual of Mental Disorders Axis-I diagnosis; participated in an MBSR group, engaged in current or prior practice of meditation or relaxation techniques, including MBSR; were illiterate and unable to complete the meditation diary.		

Study Details	Participants	Intervention	Outcomes
Reference: Zautra et al., 2008	Number of Patients: 144	Content of Intervention: Mindfulness meditation and	Pain Measures:
		emotion regulation therapy: Designed to develop two	Pain vs. Education, 8 weeks:
Location: United States or Canada	Medical Condition/Type of Pain: Rheumatoid arthritis	distinct sets of skills—one to reduce the negative impact	SMD 0.22 (CI -0.2, 0.63)
		of stressful life events and illness burdens, and the other	Pain vs. Cognitive Behavior
Purpose: To investigate whether	Definition of Chronic Pain: No definition	to enhance the ability to sustain positive social	Therapy, 8 weeks: SMD 0.56
cognitive behavioral therapy and		engagements despite pain and stress. The treatment	(CI 0.16, 0.96)
mindfulness interventions that	Baseline Pain Score: Pain	modules included (1) mindfulness and the bidimensional	
target responses to chronic stress,	Intervention Group: 28.19 (SD 19.43); Control	model of emotion; (2) mindfulness and awareness; (3)	Depression Measures:
pain, and depression reduce pain	Group: 34.31 (SD 18.07)	emotional clarity and well-being; (4) acceptance, negative	Depressive Symptoms:
and improve the quality of		thoughts, and reframing; (5) positive emotions and	SMD 0.28 (CI -0.13, 0.7)
everyday life for adults with	Mean Age: Men: 62.11; Women: 50.62	pleasant event scheduling; (6) enhanced social relations;	
rheumatoid arthritis		(7) intimacy, stress, and mindfulness; and (8)	Analgesic Use: No
	Gender (% Male): 32	maintenance and generalization.	
Quality Rating: Good			Adverse Events: No mention
	Inclusion Criteria: Described themselves as having	Setting: Unclear	
	rheumatoid arthritis at screening and could obtain a	Desers Duration 4.4 hours anost in session homework	
	written confirmation of rheumatoid arthritis from their	Dosage, Duration: 1–4 hours spent in session, homework,	
	rheumatologist.	and other each week, for 8 weeks	
	Exclusion Criteria: Taking any cyclical estrogen	Co-interventions: NA	
	replacement therapies; have Lupus.		
		Comparator: Cognitive behavioral therapy for pain,	
		education	
		Primary Endpoint: Pain	
		Power Calculation: Yes (sufficient power)	
		Follow-Up Time: 8 weeks	

NOTE: NA = not applicable.

Appendix D: Studies Included in the Most Recent Systematic Review

The studies listed in Table D.1 were included in the most recent systematic review on mindfulness meditation for chronic pain (Bawa et al., 2015). We note whether each study was included in the present review, and if not, the reason for exclusion.

Reference	Status in Current Report	If Excluded, Reason
Astin, J. A., B. M. Berman, B. Bausell, W. L. Lee, M. Hochberg, and K. L. Forys, "The Efficacy of Mindfulness Meditation Plus Qigong Movement Therapy in the Treatment of Fibromyalgia: A Randomized Controlled Trial," <i>Journal of Rheumatology</i> , Vol. 30, No. 10, October 2003, pp. 2257–2262.	Included	
Brown, C. A., and A. K. Jones, "Psychobiological Correlates of Improved Mental Health in Patients with Musculoskeletal Pain After a Mindfulness-Based Pain Management Program," <i>Clinical</i> <i>Journal of Pain</i> , Vol. 29, No. 3, March 2013, pp. 233–244.	Included	
Esmer, G., J. Blum, J. Rulf, and J. Pier, "Mindfulness-Based Stress Reduction for Failed Back Surgery Syndrome: A Randomized Controlled Trial," <i>Journal of the American Osteopathic Association</i> , Vol. 110, No. 11, November 2010, pp. 646–652.	Included	
Morone, N. E., B. L. Rollman, C. G. Moore, Q. Li, and D. K. Weiner, "A Mind-Body Program for Older Adults with Chronic Low Back Pain: Results of a Pilot Study," <i>Pain Medicine</i> , Vol. 10, No. 8, November 2009, pp. 1395–1407.	Included	
Plews-Ogan, M., J. E. Owens, M. Goodman, P. Wolfe, and J. Schorling, "A Pilot Study Evaluating Mindfulness-Based Stress Reduction and Massage for the Management of Chronic Pain," <i>Journal of General Internal Medicine</i> , Vol. 20, No. 12, December 2005, pp. 1136–1138.	Included	
Pradhan, E. K., M. Baumgarten, P. Langenberg, B. Handwerger, A. K. Gilpin, T. Magyari, M. C. Hochberg, and B. M. Berman, "Effect of Mindfulness-Based Stress Reduction in Rheumatoid Arthritis Patients," <i>Arthritis and Rheumatism</i> , Vol. 57, 2007, pp. 1134–1142.	Excluded	Our review required pain outcome. This study focuses on depressive symptoms, psychological distress, well-being, and mindfulness.
Schmidt, S., P. Grossman, B. Schwarzer, S. Jena, J. Naumann, and H. Walach, "Treating Fibromyalgia with Mindfulness-Based Stress Reduction: Results from a 3-Armed Randomized Controlled Trial," <i>Pain</i> , Vol. 152, No. 2, February 2011, pp. 361–369.	Included	
Sephton, S. E., P. Salmon, I. "Weissbecker, C. Ulmer, A. Floyd, K. Hoover, and J. L. Studts, "Mindfulness Meditation Alleviates Depressive Symptoms in Women with Fibromyalgia: Results of a Randomized Clinical Trial," <i>Arthritis and Rheumatism</i> , Vol. 57, 2007, pp. 77–85.	Excluded	Our review required pain outcome. This study reported depressive symptoms.

Table D.1. Studies Included in the Most Recent Systematic Review

Reference	Status in Current Report	If Excluded, Reason
Weissbecker, I., P. Salmon, J. L. Studts, A. R. Floyd, E. A. Dedert, and S. E. Sephton, "Mindfulness-Based Stress Reduction and Sense of Coherence Among Women with Fibromyalgia," <i>Journal of</i> <i>Clinical Psychology in Medical Settings</i> , Vol. 9, No. 4, 2002, pp. 297–307.	Excluded	Design was not randomized.
Wong, S. Y., F. W. Chan, R. L. Wong, M. C. Chu, Y. Y. Kitty Lam, S. W. Mercer, and S. H. Ma, "Comparing the Effectiveness of Mindfulness-Based Stress Reduction and Multidisciplinary Intervention Programs for Chronic Pain: A Randomized Comparative Trial," <i>Clinical Journal of Pain</i> , Vol. 27, No. 8, October 2011, pp. 724–734.	Included	
Zautra, A. J., M. C. Davis, J. W. Reich, P. Nicassario, H. Tennen, P. Finan, A. Kratz, B. Parrish, and M. R. Irwin, "Comparison of Cognitive Behavioral and Mindfulness Meditation Interventions on Adaptation to Rheumatoid Arthritis for Patients With and Without History of Recurrent Depression," <i>Journal of Consulting and</i> <i>Clinical Psychology</i> , Vol. 76, No. 3, June 2008, pp. 408–421.	Included	

- Astin, J. A., B. M. Berman, B. Bausell, W. L. Lee, M. Hochberg, and K. L. Forys, "The Efficacy of Mindfulness Meditation Plus Qigong Movement Therapy in the Treatment of Fibromyalgia: A Randomized Controlled Trial," *Journal of Rheumatology*, Vol. 30, No. 10, October 2003, pp. 2257–2262.
- Balshem, H., M. Helfand, H. J. Schunemann, A. D. Oxman, R. Kunz, J. Brozek, G. E. Vist, Y. Falck-Ytter, J. Meerpohl, S. Norris, and G. H. Guyatt, "GRADE Guidelines: 3. Rating the Quality of Evidence," *Journal of Clinical Epidemiology*, Vol. 64, No. 4, April 2011, pp. 401–406.
- Bawa, F. L., S. W. Mercer, R. J. Atherton, F. Clague, A. Keen, N. W. Scott, and C. M. Bond, "Does Mindfulness Improve Outcomes in Patients with Chronic Pain? Systematic Review and Meta-Analysis," *British Journal of General Practice*, Vol. 65, No. 635, June 2015, pp. e387–400.
- Brown, C. A., and A. K. Jones, "Psychobiological Correlates of Improved Mental Health in Patients with Musculoskeletal Pain After a Mindfulness-Based Pain Management Program," *Clinical Journal of Pain*, Vol. 29, No. 3, March 2013, pp. 233–244.
- Cash, E., P. Salmon, I. Weissbecker, W. N. Rebholz, R. Bayley-Veloso, L. A. Zimmaro, A. Floyd, E. Dedert, and S. E. Sephton, "Mindfulness Meditation Alleviates Fibromyalgia Symptoms in Women: Results of a Randomized Clinical Trial," *Annals of Behavioral Medicine*, Vol. 49, No. 3, June 2015, pp. 319–330.
- Cathcart, S., N. Galatis, M. Immink, M. Proeve, and J. Petkov, "Brief Mindfulness-Based Therapy for Chronic Tension-Type Headache: A Randomized Controlled Pilot Study," *Behavioural and Cognitive Psychotherapy*, Vol. 42, No. 1, January 2014, pp. 1–15.
- Chiesa, A., and A. Serretti, "Mindfulness-Based Interventions for Chronic Pain: A Systematic Review of the Evidence," *Journal of Alternative and Complementary Medicine*, Vol. 17, No. 1, January 2011, pp. 83–93.
 - , "Are Mindfulness-Based Interventions Effective for Substance Use Disorders? A Systematic Review of the Evidence," *Substance Use and Misuse*, Vol. 49, No. 5, April 2014, pp. 492–512.
- Chou, R., J. A. Turner, E. B. Devine, R. N. Hansen, S. D. Sullivan, I. Blazina, T. Dana, C. Bougatsos, and R. A. Deyo, "The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to

Prevention Workshop," *Annals of Internal Medicine*, Vol. 162, No. 4, February 17, 2015, pp. 276–286.

- Cramer, H., H. Haller, R. Lauche, and G. Dobos, "Mindfulness-Based Stress Reduction for Low Back Pain: A Systematic Review," *BMC Complementary and Alternative Medicine*, Vol. 12, 2012, p. 162.
- Davis, M. C., and A. J. Zautra, "An Online Mindfulness Intervention Targeting Socioemotional Regulation in Fibromyalgia: Results of a Randomized Controlled Trial," *Annals of Behavioral Medicine*, Vol. 46, No. 3, December 2013, pp. 273–284.
- Day, M. A., B. E. Thorn, L. C. Ward, N. Rubin, S. D. Hickman, F. Scogin, and G. R. Kilgo, "Mindfulness-Based Cognitive Therapy for the Treatment of Headache Pain: A Pilot Study," *Clinical Journal of Pain*, Vol. 30, No. 2, February 2014, pp. 152–161.
- de Souza, I. C., V. V. de Barros, H. P. Gomide, T. C. Miranda, P. Menezes Vde, E. H. Kozasa, and A. R. Noto, "Mindfulness-Based Interventions for the Treatment of Smoking: A Systematic Literature Review," *Journal of Alternative and Complementary Medicine*, Vol. 21, No. 3, March 2015, pp. 129–140.
- Dowd, H., M. J. Hogan, B. E. McGuire, M. C. Davis, K. M. Sarma, R. A. Fish, and A. J. Zautra, "Comparison of an Online Mindfulness-Based Cognitive Therapy Intervention with Online Pain Management Psychoeducation: A Randomized Controlled Study," *Clinical Journal of Pain*, Vol. 31, No. 6, June 2015, pp. 517–527.
- Egger, M., G. Davey Smith, M. Schneider, and C. Minder, "Bias in Meta-Analysis Detected by a Simple, Graphical Test," *BMJ*, Vol. 315, No. 7109, September 13, 1997, pp. 629–634.
- Esmer, G., J. Blum, J. Rulf, and J. Pier, "Mindfulness-Based Stress Reduction for Failed Back Surgery Syndrome: A Randomized Controlled Trial," *Journal of the American Osteopathic Association*, Vol. 110, No. 11, November 2010, pp. 646–652.
- Fjorback, L. O., M. Arendt, E. Ornbol, H. Walach, E. Rehfeld, A. Schroder, and P. Fink,
 "Mindfulness Therapy for Somatization Disorder and Functional Somatic Syndromes: Randomized Trial with One-Year Follow-Up," *Journal of Psychosomatic Research*, Vol. 74, No. 1, January 2013, pp. 31–40.
- Fogarty, F. A., R. J. Booth, G. D. Gamble, N. Dalbeth, and N. S. Consedine, "The Effect of Mindfulness-Based Stress Reduction on Disease Activity in People with Rheumatoid Arthritis: A Randomised Controlled Trial," *Annals of the Rheumatic Diseases*, Vol. 74, No. 2, February 2015, pp. 472–474.
- Garland, E. L., E. G. Manusov, B. Froeliger, A. Kelly, J. M. Williams, and M. O. Howard, "Mindfulness-Oriented Recovery Enhancement for Chronic Pain and Prescription Opioid

Misuse: Results from an Early-Stage Randomized Controlled Trial," *Journal of Consulting and Clinical Psychology*, Vol. 82, No. 3, June 2014, pp. 448–459.

- Gaylord, S. A., O. S. Palsson, E. L. Garland, K. R. Faurot, R. S. Coble, J. D. Mann, W. Frey, K. Leniek, and W. E. Whitehead, "Mindfulness Training Reduces the Severity of Irritable Bowel Syndrome in Women: Results of a Randomized Controlled Trial," *American Journal of Gastroenterology*, Vol. 106, No. 9, September 2011, pp. 1678–1688.
- Goleman, D. J., and G. E. Schwartz, "Meditation as an Intervention in Stress Reactivity," *Journal of Consulting and Clinical Psychology*, Vol. 44, No. 3, June 1976, pp. 456–466.
- Goyal, M., S. Singh, E. M. Sibinga, N. F. Gould, A. Rowland-Seymour, R. Sharma, Z. Berger, D. Sleicher, D. D. Maron, H. M. Shihab, P. D. Ranasinghe, S. Linn, S. Saha, E. B. Bass, and J. A. Haythornthwaite, "Meditation Programs for Psychological Stress and Well-Being: A Systematic Review and Meta-Analysis," *JAMA Internal Medicine*, Vol. 174, No. 3, Mar, 2014, pp. 357–368.
- Hamling, J., P. Lee, R. Weitkunat, and M. Ambuhl, "Facilitating Meta-Analyses by Deriving Relative Effect and Precision Estimates for Alternative Comparisons from a Set of Estimates Presented by Exposure Level or Disease Category," *Statistics in Medicine*, Vol. 27, No. 7, March 30, 2008, pp. 954–970.
- Hartung, J., and G. Knapp, "A Refined Method for the Meta-Analysis of Controlled Clinical Trials with Binary Outcome," *Statistics in Medicine*, Vol. 20, No. 24, December 30, 2001, pp. 3875–3889.
- Hartung, Joachim, "An Alternative Method for Meta-Analysis," *Biometrical Journal*, Vol. 41, No. 8, 1999, pp. 901–916.
- Higgins, J., and S. Green, eds. *Cochrane Handbook for Systematic Reviews of Interventions*, Version 5.1.0, The Cochrane Collaboration, March 2011.
- IntHout, Joanna, John Ioannidis, and George Borm, "The Hartung-Knapp-Sidik-Jonkman Method for Random Effects Meta-Analysis Is Straightforward and Considerably Outperforms the Standard DerSimonian-Laird Method," *BMC Medical Research Methodology*, Vol. 14, No. 1, 2014, p. 25.
- Kabat-Zinn, J., *Coming to Our Senses: Healing Ourselves and the World Through Mindfulness*, New York: Hyperion, 2005.
- Kabat-Zinn, J., L. Lipworth, and R. Burney, "The Clinical Use of Mindfulness Meditation for the Self-Regulation of Chronic Pain," *Journal of Behavioral Medicine*, Vol. 8, No. 2, June 1985, pp. 163–190.

- Kozasa, E. H., L. H. Tanaka, C. Monson, S. Little, F. C. Leao, and M. P. Peres, "The Effects of Meditation-Based Interventions on the Treatment of Fibromyalgia," *Current Pain and Headache Reports*, Vol. 16, No. 5, October 2012, pp. 383–387.
- Kuijpers, H. J., F. M. van der Heijden, S. Tuinier, and W. M. Verhoeven, "Meditation-Induced Psychosis," *Psychopathology*, Vol. 40, No. 6, 2007, pp. 461–464.
- la Cour, P., and M. Petersen, "Effects of Mindfulness Meditation on Chronic Pain: A Randomized Controlled Trial," *Pain Medicine*, Vol. 16, No. 4, April 2015, pp. 641–652.
- Lakhan, S. E., and K. L. Schofield, "Mindfulness-Based Therapies in the Treatment of Somatization Disorders: A Systematic Review and Meta-Analysis," *PloS One*, Vol. 8, No. 8, 2013, p. e71834.
- Lauche, R., H. Cramer, G. Dobos, J. Langhorst, and S. Schmidt, "A Systematic Review and Meta-Analysis of Mindfulness-Based Stress Reduction for the Fibromyalgia Syndrome," *Journal of Psychosomatic Research*, Vol. 75, No. 6, December 2013, pp. 500–510.
- Lee, C., C. Crawford, and A. Hickey, "Mind-Body Therapies for the Self-Management of Chronic Pain Symptoms," *Pain Medicine*, Vol. 15, Suppl. 1, April 2014, pp. S21–S39.
- Lewin Group and ECRI Institute, *Management of Dyslipidemia: Evidence Synthesis Report. Clinical Practice Guideline*, Washington, D.C.: Veterans Health Administration, U.S. Department of Veterans Affairs and U.S. Department of Defense, 2014.
- Ljotsson, B., L. Falk, A. W. Vesterlund, E. Hedman, P. Lindfors, C. Ruck, T. Hursti, S. Andreewitch, L. Jansson, N. Lindefors, and G. Andersson, "Internet-Delivered Exposure and Mindfulness Based Therapy for Irritable Bowel Syndrome: A Randomized Controlled Trial," *Behaviour Research and Therapy*, Vol. 48, No. 6, June 2010, pp. 531–539.
- Ljotsson, B., E. Hedman, E. Andersson, H. Hesser, P. Lindfors, T. Hursti, S. Rydh, C. Ruck, N. Lindefors, and G. Andersson, "Internet-Delivered Exposure-Based Treatment Vs. Stress Management for Irritable Bowel Syndrome: A Randomized Trial," *American Journal of Gastroenterology*, Vol. 106, No. 8, August 2011, pp. 1481–1491.
- Management of Opioid Therapy for Chronic Pain Working Group, *VA/DoD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain*, Washington, D.C.: Department of Veterans Affairs and Department of Defense, May 2010.
- Meize-Grochowski, R., G. Shuster, B. Boursaw, M. DuVal, C. Murray-Krezan, R. Schrader, B. W. Smith, C. J. Herman, and A. Prasad, "Mindfulness Meditation in Older Adults with Postherpetic Neuralgia: A Randomized Controlled Pilot Study," *Geriatric Nursing*, Vol. 36, No. 2, March–April 2015, pp. 154–160.
- Merkes, M., "Mindfulness-Based Stress Reduction for People with Chronic Diseases," *Australian Journal of Primary Health*, Vol. 16, No. 3, 2010, pp. 200–210.

- Mindfulness Awareness Research Center, "UCLA Mindfulness Awareness Research Center," web page, undated. As of May 29, 2015: http://marc.ucla.edu
- Morone, N. E., C. M. Greco, and D. K. Weiner, "Mindfulness Meditation for the Treatment of Chronic Low Back Pain in Older Adults: A Randomized Controlled Pilot Study," *Pain*, Vol. 134, No. 3, February 2008, pp. 310–319.
- Morone, N. E., B. L. Rollman, C. G. Moore, Q. Li, and D. K. Weiner, "A Mind-Body Program for Older Adults with Chronic Low Back Pain: Results of a Pilot Study," *Pain Medicine*, Vol. 10, No. 8, November 2009, pp. 1395–1407.
- Office of the Army Surgeon General, *Providing a Standardized DoD and VHA Vision and Approach to Pain Management to Optimize the Care for Warriors and Their Families*, Pain Management Task Force, May 29, 2010.
- Omidi, A., and F. Zargar, "Effect of Mindfulness-Based Stress Reduction on Pain Severity and Mindful Awareness in Patients with Tension Headache: A Randomized Controlled Clinical Trial," *Nursing and Midwifery Studies*, Vol. 3, No. 3, September 2014, p. e21136.
- Parra-Delgado, M., and J. M. Latorre-Postigo, "Effectiveness of Mindfulness-Based Cognitive Therapy in the Treatment of Fibromyalgia: A Randomised Trial," *Cognitive Therapy and Research*, Vol. 37, No. 5, October 2013, 2013, pp. 1015–1026.
- Plews-Ogan, M., J. E. Owens, M. Goodman, P. Wolfe, and J. Schorling, "A Pilot Study Evaluating Mindfulness-Based Stress Reduction and Massage for the Management of Chronic Pain," *Journal of General Internal Medicine*, Vol. 20, No. 12, December 2005, pp. 1136–1138.
- Rahmani, S., and S. Talepasand, "The Effect of Group Mindfulness-Based Stress Reduction Program and Conscious Yoga on the Fatigue Severity and Global and Specific Life Quality in Women with Breast Cancer," *Medical Journal of the Islamic Republic of Iran*, Vol. 29, 2015, p. 175.
- Reiner, K., L. Tibi, and J. D. Lipsitz, "Do Mindfulness-Based Interventions Reduce Pain Intensity? A Critical Review of the Literature," *Pain Medicine*, Vol. 14, No. 2, February 2013, pp. 230–242.
- Sanchez-Meca, J., and F. Marin-Martinez, "Confidence Intervals for the Overall Effect Size in Random-Effects Meta-Analysis," *Psychological Methods*, Vol. 13, No. 1, March 2008, pp. 31-48.
- Schmidt, S., P. Grossman, B. Schwarzer, S. Jena, J. Naumann, and H. Walach, "Treating Fibromyalgia with Mindfulness-Based Stress Reduction: Results from a 3-Armed Randomized Controlled Trial," *Pain*, Vol. 152, No. 2, February 2011, pp. 361–369.

- Sidik, K., and J. N. Jonkman, "Robust Variance Estimation for Random Effects Meta-Analysis," *Computational Statistics & Data Analysis*, Vol. 50, No. 12, 2006, pp. 3681–3701.
- Teixeira, E., "The effect of Mindfulness Meditation on Painful Diabetic Peripheral Neuropathy in Adults Older Than 50 Years," *Holistic Nursing Practice*, Vol. 24, No. 5, September– October 2010, pp. 277–283.
- Toblin, R. L., P. J. Quartana, L. A. Riviere, K. C. Walper, and C. W. Hoge, "Chronic Pain and Opioid Use in US Soldiers After Combat Deployment," *JAMA Internal Medicine*, Vol. 174, No. 8, August 2014, pp. 1400–1401.
- U.S. Preventive Services Task Force, U.S. Preventive Services Task Force Procedure Manual, Rockville, Md.: Agency for Healthcare Research and Quality, 2008.
- Wells, R. E., R. Burch, R. H. Paulsen, P. M. Wayne, T. T. Houle, and E. Loder, "Meditation for Migraines: A Pilot Randomized Controlled Trial," *Headache*, Vol. 54, No. 9, October 2014, pp. 1484–1495.
- Wong, S. Y., "Effect of Mindfulness-Based Stress Reduction Programme on Pain and Quality of Life in Chronic Pain Patients: A Randomised Controlled Clinical Trial," *Hong Kong Medical Journal. Xianggang Yi Xue Za Zhi*, Vol. 15, Suppl. 6, October 2009, pp. 13–14.
- Wong, S. Y., F. W. Chan, R. L. Wong, M. C. Chu, Y. Y. Kitty Lam, S. W. Mercer, and S. H. Ma, "Comparing the Effectiveness of Mindfulness-Based Stress Reduction and Multidisciplinary Intervention Programs for Chronic Pain: A Randomized Comparative Trial," *Clinical Journal of Pain*, Vol. 27, No. 8, October 2011, pp. 724–734.
- Zautra, A. J., M. C. Davis, J. W. Reich, P. Nicassario, H. Tennen, P. Finan, A. Kratz, B. Parrish, and M. R. Irwin, "Comparison of Cognitive Behavioral and Mindfulness Meditation Interventions on Adaptation to Rheumatoid Arthritis for Patients With and Without History of Recurrent Depression," *Journal of Consulting and Clinical Psychology*, Vol. 76, No. 3, June 2008, pp. 408–421.